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ABSTRACT 
Fibronectin (FN) is a multidomain glycoprotein found in plasma and tissue extracellular 
matrices (ECM). Plasma FN (pFN) is produced and secreted into the bloodstream by the 
liver. Liver ECM-FN and pFN are characterized by the absence of the EDA domain, one of 
the three FN exons undergoing alternative splicing. However, in pathological situations 
such as wound healing, the liver produces and accumulates huge amounts of EDA +FN in 
sinusoidal ECM. In order to study the functions of the FN isoforms produced by the liver, 
we used two mouse strains devoid of EDA-exon alternative splicing, which constitutively 
include (EDA+1+ strain) or exclude (EDA-1- strain) the EDA domain. 
The EDA+1+ strain is characterized by an important decrease of FN levels both in plasma 
and tissues. Here, we show that the atypical presence of the EDA domain in hepatocytes 
affects pFN secretion into the bloodstream and we demonstrate that a high proportion of 
tissue ECM-FN is supplied by plasma. In fact, removal of the EDA exon only from the 
liver, by hepatocyte-specific deletion of the EDA exon, restores normal levels of FN in 
both plasma and tissues of the EDA +1+ animals. This finding not only suggests that plasma 
behaves as a sort of FN reservoir for tissue maintenance but also shows for the first time 
that the pFN contribution to the ECM of tissues is roughly equal to that produced locally. 
The EDA-1- strain was used to study the role of the EDA domain in the onset of liver 
fibrosis. In two different liver fibrosis models, we observed that EDA/- animals develop 
attenuated fibrosis in comparison to control mice. The important role of the EDA domain 
in the activation and proliferation of the hepatic stellate cells (HSCs), these are the key 
cells responsible for the ECM protein overproduction in the fibrotic processes, is 
demonstrated for the first time in vivo. EDA/- livers treated to induce fibrosis, present a 
striking reduction in the number of myofibroblasts or activated HSCs, suggesting that the 
EDA domain could be a potential target for the treatment of liver fibrosis. 
13 
1. INTRODUCTION 
1.1 FIBRONECTINS. 
Fibronectins (FNs) are a large family of multifunctional and multidomain 
glycoproteins mainly found in the extracellular matrix (ECM) of tissues and in plasma. FN 
is organized in functional domains as "beads on a string" that are arranged in a "modular 
fashion" and used by the protein to fulfill diverse interactions (Hynes and Yamada, 1982; 
Yamada, 1983). FNs have been implicated in a wide variety of cellular processes, 
particularly those involving the interactions of cells with other ECM proteins. These 
processes include cell-adhesion, -migration and -differentiation, ECM and cytoskeletal 
organization, wound healing, embryogenesis, oncogenic transformation, and hemostasis 
(Hynes, 1990). The basic role of FN in these processes is that of a ligand between various 
intracellular and extracellular molecules for the regulation and maintenance of the normal 
cell and tissue functions. The interaction of FN with specific transmembrane receptors 
called integrins is considered fundamental for cell regulation and signal transduction (Plow 
et aI., 2000). 
1.1.1 Fibronectin functional domains. 
The FN functional molecule consists of two similar or identical subunits of 220-250 
kDa that are held together by two disulfide-bonds near their carboxyl-termini and forming 
a dimer. Each monomer is made of several compact globular domains separated by short, 
flexible and extendable connecting regions (Figure 1 ). Three different types of 
homologous and repeating domains, termed Type I, II, and III, exist (Hynes, 1990). Each 
of the twelve Type I modules is made of - 40 amino acids (aa) forming five anti-parallel 13-
strands, originating two anti-parallel j3-sheets stabilized by two disulfide bonds (Baron et 
aI., 1990). There are only two Type II modules that are made of - 60 aa forming four anti-
14 
parallel ~-strands and stabil ized by two disulfide bonds (Constantine et aI. , 1991 ; Petersen 
et aI. , 1983). 
Fibronectin Scheme 
~ la l rlx n'~mb l ' 
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Figure 1. Schematic representation of the fibronectin protein and its 
interactions. 
Upper part. Type I (vio let), Type II (red boxes) and Type III (yellow boxes) are the 
repeating homologous domains present in the FN polypeptide. DB, EDA, and 
IlleS are the alternatively spliced domains. EDA and EDB are Type III domains, 
whereas IIICS does not fa ll into any of the homology category. Type I, Type II , 
EDB, EDA and JIlCS domains are each encoded by a sing le exon. Mo t of the type 
III domains are instead encoded by two exons. Interaction of FN functiona l domains 
with other extracellular matrix proteins, ce ll s and itself is shown in the top . 
Lower part. Representat ion of the FN splicing pattern. While EDA and EDB exons 
can be simply spliced in or out from the FN mRNA, IlICS undergoes a much more 
complex splicing pattern, lead ing to the generat ion of two, three and five splicing 
variants in chickens, rodents and human, respectively. 
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The fifteen Type III modules constitute the largest part of the FN polypeptide (Figure 1). 
The 90 aa are organized in seven ~-strands forming a sandwich of two anti-parallel ~­
sheets (Baron et aI., 1992). There are no disulfide bonds present. One of the most 
intriguing features of the Type III modules in fibronectin is that their number is modulated 
through the alternative splicing of the single FN pre-mRNA (Figure 1). Besides the 
constitutive fifteen type III domains, two extra Type III domains can be incorporated into 
the FN molecule by means of the alternative splicing mechanism (Gutman and Kornblihtt, 
1987; Kornblihtt et aI., 1984a; Kornblihtt et aI., 1984b; Schwarzbauer et aI., 1987a; 
Schwarzbauer et aI., 1987b). These domains are termed Extra-Domain A (EDA, also called 
EIIIA or EDI) and B (EDB, also called EIIIB or EDII). In addition, a third element that 
undergoes alternative splicing, called Type III homology Connecting Segment (lnCS or V 
for Variable) is present, but it does not fall into any of the three categories of homology 
(Schwarzbauer et aI., 1983). The EDA (90 aa) (Kornblihtt et aI., 1984a) and EDB (91 aa) 
(Gutman and Kornblihtt, 1987) domains are located between repeats 1111 tlIII 12 and IIhlIIlg, 
respectively, whereas IIICS (120 aa) (Schwarzbauer et aI., 1983) is in between repeats 
III 141111 15 (Figure 1). 
1.1.2 A single FN gene for multiple protein variants. 
It has already been established that all FNs variants are encoded by a single gene 
(George et aI., 1993; Kornhlihtt et aI., 1983; Schwarzhauer et aI., 1983). The FN gene has 
been mapped to chromosome 1 and 2, in mouse (Skow et aI., 1987) and human (Prowse et 
aI., 1986), respectively. However, multiple FN mRNAs, and consequently multiple protein 
isoforms, can arise due to the alternative splicing mechanism of the FN pre-mRNA 
(ffrench-Constant, 1995; Kornblihtt et aI., 1996). Whereas EDA and EDB exons can be 
simply included or excluded from FN mRNA by the splicing machinery, the IIICS element 
undergoes a more complicated splicing pattern (Pankov and Yamada, 2002). In fact, it can 
be completely included (VI20) or excluded (VO), or partially included, according to the 
16 
species (Figure 1). Two variants are present in chicken (Norton and Hynes, 1987), three in 
both rat and mouse (Schwarzbauer et aI., 1983), and five in human (Hershberger and Culp, 
1990). As the single splicing events in the three regions of variability are independent from 
each other (Caputi et aI., 1995a; Chauhan et aI., 2004), at least 8 different polypeptides 
could be generated from the FN gene in chicken, 12 in rat and mouse and up to 20 in 
human (Pankov and Yamada, 2002). Even though the mechanism by which the FN gene 
produces protein variants has been known for a long time, the different properties of the 
single isoforms in different processes such as ligand-binding, cell-adhesion, -activation or-
differentiation, solubility, composition of the ECM are poorly understood especially in 
vivo. 
1.1.3 Plasma and cellular flbronectins. 
In vivo analyses have shown that FNs are found in most body fluids such as plasma, 
bile and amniotic fluids, in the ECM of all connective tissues, and on the cell surfaces and 
most basement membranes (Hynes, 1990). In vitro experiments have revealed that FNs are 
synthesized by a wide variety of cell types such as fibroblasts, endothelial cells and 
hepatocytes that are the most important producers, and by macrophages, platelets, 
myoblasts, epithelial-, amniotic- and glial-cells that synthesize FNs at lower levels (Hynes 
and Yamada, 1982). Overall, FNs can be subdivided in two major forms: the plasma (pFN) 
and the cellular (cFN) fibronectin. pFN is soluble and secreted by the hepatocytes (Owens 
and Cimino, 1982; Tamkun and Hynes, 1983a) into the bloodstream at a concentration of 
300 !!g/ml and 580 ~g/ml in human (Yamada, 1983) and mice (George et aI., 1993), 
respectively. On the contrary, cFN is insoluble; it is assumed that it is locally produced by 
fibroblasts and other cell types, and assembled into the ECM of the tissues (Hayashi and 
Yamada, 1981 ; Yamada and Kennedy, 1979) even though hepatocytes are also able to 
produce and incorporate cFN (lacking both the EDA and EDB domains) into the ECM of 
liver (Marceau et aI., 1980; Voss et aI., 1979). Plasma and cellular FNs are structurally and 
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functionally very similar but they are not identical. Whereas pFN remains as a soluble, 
compact heterodimer lacking both the EDA and EDB domains, although VO and V+ 
splicing variants are present, cFN is deposited as insoluble polymers, forming a three-
dimensional fibrillar matrix embedding all the cells forming a tissue. Furthermore, cFN 
contains EDA and EDB domains at variable proportions depending on the specific tissue 
(ffrench-Constant, 1995; Hynes, 1990; Kornblihtt et aI., 1996). FNs are also characterized 
by different levels of glycosylation (Tajiri et aI., 2005; Zhu and Laine, 1985), 
phosphorylation (Ali and Hunter, 1981; Teng and Rifkin, 1979) and sulfation (Dunham 
and Hynes, 1978). The structural differences in the FN polypeptide chains due to 
alternative splicing and post-translation modifications may explain the diverse biochemical 
behavior of the two types of FN, such as solubility and electrophoretic mobility (Hayashi 
and Yamada, 1981; Olden et aI., 1979; Tamkun and Hynes, 1983a; Yamada and Kennedy, 
1979). The exclusive presence of EDA and/or EDB in cFN may be responsible for its 
lower solubility and its higher tendency to aggregate and form fibrils. 
1.1.4 Interaction of fibronectin with other molecules. 
The most important characteristic of fibronectins [fibre = fiber + nectere = to bind, 
to connect] is their capablility of interacting specifically with cells and with a wide variety 
of other macromolecules present in the ECM (Hynes, 1990; Yamada, 1983). Due to the 
organization of its functional domains in a modular fashion, FN appears to mediate or 
modify cell adhesion and several other complex biological events by mechanisms that are 
being intensively investigated. Expression of recombinant FN fragments or limited 
digestion of FN with a variety of proteases generate a collection of fragments that are 
sometimes referred to as functional domains due to their ability to interact with other 
macromolecules. The best-established interactions, for which evidence exists both for their 
occurrence in vivo and for their specificity in vitro, are those with collagens and gelatin 
(denatured collagen), fibrin, fibrinogen, glycosaminoglycans and proteoglycans, integrins 
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and FN itself (Hynes, 1990; Pankov and Yamada, 2002; Yamada, 1983) (Figure 1). A 
region of 30-40 kDa in size, including repeats 16-9 and II 1.2, near the amino-terminus of FN 
is retained to interact with collagens. It has been suggested that the physiological function 
of the collagen/gelatin-binding domain is related to both the binding and clearance of 
denatured collagenous materials from blood and tissues, and mediation of cell-attachment 
to collagen (Leikina et aI., 2002; Pankov and Yamada, 2002). Two major heparin-binding 
domains, located at the C-terminal and N-terminal ends of the protein, interact with widely 
distributed glycosaminoglycans such as heparin, heparan and chondroitin sulfate, 
hyaluronic acid, and also bacteria. It seems that interactions between FN and 
glycosaminoglycans may provide structural organization to the extracellular matrix where 
FN functions as a cross-linking molecule stabilizing the matrix around cells (Mostafavi-
Pour et aI., 2001; Pankov and Yamada, 2002). 
FN binds to fibrin and fibrinogen through two major fibrin-binding sites localized at the N-
and C-terminals. The interaction of FN with fibrin is important for cell adhesion or cell 
migration into fibrin clots during hemostasis. FN-fibrin interaction is also important during 
wound healing, providing a substrate for fibroblasts migrating into the wounds to initiate 
the repair process (Yamada, 1983). 
A striking feature of cFN is its ability to arrange into fibrils as a result of FN-FN 
associations. Although pFN circulating in blood is in a closed, reportedly non-active form, 
most of the FN activities in the body have been ascribed to the insoluble form of FN that 
exists as an important part of the tissue ECM. The creation and deposit of insoluble FN 
fibrils into the ECM is a tightly regulated, cell-mediated process termed FN matrix 
assembly or fibrillogenesis (Geiger et aI., 2001; Pankov and Yamada, 2002). A critical step 
in this process is the self-association of FN into aggregates and fibrils that is directed by 
multiple binding sites that have been identified along the molecule. An example is the first 
Type III domain (111 1, Figure 1). Some of these self-interaction sites are exposed and 
available for binding, while others are cryptic and become accessible only after 
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conformational changes, for example, by cell-driven mechanical stretching of the FN 
molecule. In comparison to cFN, pFN has a minor tendency to undergo self-aggregation 
(Yamada, 1983). 
The binding of FN to the cell surface requires a specific region of the molecule termed 
cell-binding domain (Figure 1). The cell-binding site lies in the central part of the molecule 
and binds transmembrane receptors termed integrins (Yamada, 1983). Integrins are 
structurally and functionally related transmembrane heterodimeric (uj3) receptors that link 
the ECM with the intracellular cytoskeleton (Pankov and Yamada, 2002; Plow et aI., 2000) 
(Figure 2). In particular, integrins serve as FN receptors at the cell surface, and this 
interaction is crucial for the ability of FNs to affect cellular activity (Giancotti and 
Ruoslahti, 1999; Hynes, 1992; Yamada, 2000). The well-known tripeptides Arg-Gly-Asp 
(RGD), located close to the C-terminus of repeat III 10 and its synergic site PHSRN in the 
repeat III9 are retained to promote specific binding of u5j31 integrin to FN (Hynes, 1992; 
Pierschbacher and Ruoslahti, 1984) (Figure 1). The stability of individual modules is often 
affected by interactions with neighboring modules and such interactions have important 
implications for the overall shape of the protein. However, binding of USj31 integrin to FN 
is not restricted only to repeats III9 and III 10. It can also interact with an N-terminal 
fragment containing repeats 11-9 and Bu, which also promotes USj31 integrin-mediated cell-
adhesion (Pankov and Yamada, 2002). It is possible that interaction with this N-terminal 
region triggers integrin-mediated intracellular signals that are distinct from those generated 
in response to ligation with the RGD sequence. On the other hand, the tripeptide RGD also 
interacts with other integrins such as Ullbj33 and u v j33, that seem to playa central role in the 
platelet adhesive reactions (Plow et aI., 2000). Recently, binding of U4j31 as well as U9f31 
integrins to the EDGIHEL sequence located within the alternatively spliced EDA segment 
has been reported (Liao et aI., 2002), suggesting a possible role of EDA domain in cell-
adhesion and gene expression. Two other cell-recognition sequences, LDV and REDV, 
were also identified in the alternatively spliced segments CS-l and CS-4 of the IIICS 
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region. Both of them are recognized by a4 ~ 1 as well as a4~7 integrins (Komoriya et aI. , 
199 1; Pankov and Yamada, 2002). By means of the cell-binding region, FN can mediate 
the attachment and spreading of many cell types such as fibroblasts, phagocytes neurons, 
glial cell s and bacteri a and affect their cellular activities. Moreover, the ob ervation that 
some integrins bind specific sequences within alt rnati ve ly spliced s gments indicates the 
existence of a novel mechani sm by which cell adhesion to fibronectin is regul ated by the 
alternative splicing process. 
Integrln 
o 
Matrix 
Actin 
Cytoskeleton 
Figure 2. Schematic representation of the extracellular matrix. 
Fibronectins along with other extracellular macromolecules form a ort of fibrill ar 
network or matrix surrounding the cell surface , involved in th cell and ti ssue 
morphology organization and maintenance. ell-activation, -migration and -
adhesion are processes that normally need speci fi e interaction of FN with ce ll-
surface receptors called integrins. Integrins are tran membrane receptor , made of 
two subunits termed a and ~, which integrate the extra-cellular matrix with the 
intra-cellular cyto keleton. 
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1.2 THE ALTERNATIVE SPLICING OF EDA EXON. 
The splicing reaction that assembles eukaryotic mRNAs from their much longer 
precursors provides a uniquely versatile means of genetic regulation. Alterations in the 
splice site choice can have many different effects on the mRNA and protein products of a 
gene. Commonly, alternative splicing patterns determine the inclusion or exclusion of an 
exon in the mRNA eventually giving rise to protein isoforms that differ in their peptide 
sequence and hence chemical and biological activity (Black, 2003). Alternative splicing is 
a major contributor to protein diversity in eukaryotic organisms. Most of the gene exons 
are constitutive, always being included in the final mRNA. Instead, several exons undergo 
alternative splicing as they are sometimes included and excluded from the final mRNA. 
Such regulated exons, like the FN EDA and EDB, are called "cassette exons". Exons can 
also be lengthened or shortened by the selective use of alternative 5' and 3' splice 
junctions as indeed occurs to the FN V segment (I1ICS). Changes in the splice site choice 
can have different effects on the encoded protein. Small changes in the peptide sequence 
can alter ligand binding, enzymatic activity, allosteric regulation, or protein localization. 
Genetic switches based on alternative splicing are also important in many cellular and 
developmental processes such as sex determination, apoptosis, axon guidance, cell-
excitation and -contraction and many others. Errors in splicing regulation have also been 
implicated in a number of different disease states (Grabowski and Black, 2001). 
1.2.1 The splicing reaction. 
The splicing reaction consists of excision of the introns from a pre-mRNA and 
joining of the exons. It is directed by special sequences at the intronlexon boundaries 
called "splice sites" (Gesteland, 1999) (Figure 3). The 5' splice site marks the exonlintron 
junction at the 5'-end of the intron. This includes a GU dinucleotide at the intron end 
encompassed within a larger, less conserved consensus sequence. At the other end of the 
intron, the 3' splice site region has three conserved sequence elements: the branch point, 
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Figure 3. Schematic representation of the splicing reaction. 
plicing takes place in two transesterification steps. The first tep re ult in two 
reaction intermediates: the detached 5 ' -exon and an intronl3 -exon fragment in a 
lariat structure. The second step ligates the two exons and releases the intron 
lariat. See text for detail s. X and Ware joined exons; 5'ss, 5'splice site; 3 ' ss, 
3'splice site; A, branch point; (Py)n, poly-pyrimidine tract (Black, 2003). 
followed by a polypyrimidine tract, and subsequently a terminal AG at the ex treme 3' -end 
of the intron. In the first tep of the spl icing reaction , thc 2-hydroxyl group of a sp ci fic 
residue at the branch point attacks the phosphate at the 5' splice site. This tep produce 
two reaction intermediates: a detached 5' exon and an intronl3' -exon fragment in a lariat 
configuration containing a branched A nucleotide at the branch point. 1n the second step, 
the phosphate at the 3' -end of the intron is attacked by the 3-hydroxyl of the detached 5' 
exon. This reaction ligates the two exons and releases the intron , that i till in the form of 
a lariat (Black, 2003). A large macromo lecular complex called " pliceosome", made-up of 
a set of five small nuclear ribonucleoprotein (nRNP) and numerOl! acces ory proteins 
(splicing factors) , is a sembled on each intronlexon boundary and catalyze the two steps 
of the splicing reaction (Brow, 2002 ' Gesteland, 1999). Th information contained in the 
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splice site sequences is generally not sufficient to determine whether a site will assemble a 
functional spliceosome complex. Other information and interactions are necessary to 
activate their use. Indeed, there are many non-splice site regulatory sequences that strongly 
affect spliceosome assembly (Berget, 1995; Black, 2003). RNA elements that act 
positively to stimulate spliceosome assembly are called splicing "enhancers". On the 
contrary, those RNA sequences that block spliceosome assembly and certain splicing 
choices are called splicing "silencers". Consequencely, exons often contain exonic splicing 
enhancer (ESEs) or silencer (ESSs) elements that affect their ability to be defined and 
spliced in or out. Some regulatory sequences create an RNA secondary structure that 
affects splice site recognition (Libri et aI., 1991) but most seem to be protein-binding sites. 
The ESE elements are normally recognized by specific splicing regulatory proteins called 
Serine/Arginine proteins (SR proteins) facilitating the binding of snRNPs and other 
splicing factors at the 3' and 5' splice sites ofa regulated exon (Graveley, 2000). The ESS 
elements are instead retained to interact with the heterogeneous nuclear ribonucleoproteins 
(hnRNPs), a large group of molecules identified in splicing as factors that counteract SR 
protein activity (Krecic and Swanson, 1999). 
1.2.2 Regulation of EDA exon alternative splicing. 
Interesting studies of the regulatory sequences involved in the recognition of the 
EDA exon by the splicing machinery have been performed during the last two decades. It 
is now clear that an 8 I-nucleotide regulatory-region, bearing two brief sequences with the 
function of splicing enhancer (ESE) and silencer (ESS) and located in the centre of EDA 
exon (Figure 4A), is involved in the regulation of EDA exon alternative splicing (Caputi et 
aI., 1994; Mardon et aI., 1987). Indeed, it seems that the ESE and ESS sequences regulate 
the inclusion/exclusion process of the EDA exon from the FN mRNA, determining the 
relative proportion of the EDA+ and EDA- mRNAs that are present in the diverse cell 
types or tissues. The accurate exon definition in the pre-mRNA by the splicing machinery 
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Figure 4. Mouse splicing cis-acting elements (Panel A) and trails-acting factors 
(Panel B) that controls alternative splicing of the EDA exon. 
A. A schematic representation of the EDA reg ion of FN gene and its regulatory 
cassette. The sequences of the mouse and human 3' and 5' splicing sites (ss) are 
compared with the consensus sequence, and the exonic region sequences involved in 
EDA splicing regulation are indicated. Enhancer (E ) and sil encer (E S) 
sequences are underlined. Individual base frequencies are a lso indicated (Muro et aI. , 
1998). B. Interaction of the E E element with R proteins fac ilitates the binding of 
snRNP and other splicing factors (BBP, U2AF) on the 5' and 3 ' spli cing site , 
respectively, enhancing the EDA exon inclusion in the FN mRNA. Exons and 
introns are shown as boxes and lines, respectively ; Y, pyrimidine; n, generi c base; 
SP, branch point; PPT, po ly-pyrimidine tract. 
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requires a good base-pairing interaction between the 3' and 5' splice sites and the snRNPs 
of the spliceosomal complex and a high affinity with the splicing factors (Black, 2003). 
However, both the 5' and 3' splice sites of the EOA exon have a poor homology with the 
consensus sequences and consequently, have a lower affinity with both the snRNPs and 
splicing factors (Muro et al., 1998) (Figure 4A). The presence of weak splicing sites may 
render the EDA exon definition process less efficient during the spliceosome complex 
formation. It is also possible that all the ambiguities are overcome by the presence of the 
ESE sequence, which, interacting with specific SR proteins, promotes an accurate exon 
definition and recognition by the splicing machinery. It has been shown that some 
members of the SR-protein family, such as the ASF/SF2 splicing factors, specifically 
recognize the EDA enhancer and mediate the selection of the 3' and 5' splicing sites, 
facilitating the interaction of the U2-snRNP and the splicing factor U2AF to the 3' splice 
site and of the U I-snRNP to the 5' splice site (Lavigueur et al., 1993) (Figure 4B). 
The EDA exon sequence folds into a secondary structure, made of several stem-loop 
domains, that localizes the ESE element in a terminal, single-stranded loop-region of one 
of these stem-loop domains, thus the ESE element is well exposed to the environment 
(Buratti et al., 2004; Muro et al., 1999) (Figure 4B). The cis-acting elements of an exon 
must be exposed to the milieu in order to be recognized by the trans-acting cellular factors, 
such as SR proteins. On the contrary, the ESS element exclusively ensures the proper RNA 
conformation, since it lies in a double-stranded stem-region of the same stem-loop domain 
(Muro et al., 1999). Although it has been demonstrated that the ESE within the EDA exon 
specifically interacts with the ASF/SF2 splicing factor (Buratti et al., 2004), it is not yet 
known if any of the trans-acting factors interacts with the ESS. However, we can 
hypothesize that a possible competition between the EDA-ESE linking SR proteins and 
antagonistic splicing factors such as the hnRNPs, can positively or negatively affect the 
formation of the RNA secondary structure and determine the EDA +/EDA- mRNA ratio. 
The EOA exon inclusion/exclusion ratio is strictly regulated in a developmentally-, age-
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and ti ssue-specific manner (Caputi et aI., 1995a' hauhan et aI. , 2004' Magnuson et a!. 
1991; Pagani et aI. , 199 1) (Figure 5). RT -P R analysis of total RNA, prepared from 
various embryo organs, showed a high inclusion percentage of the DA exon in the FN 
mRNA. The EDA exon is completely excluded from the FN mRNA in adult liver and skin, 
but in other tissues its inclusion gradually d crease with the age ( hauhan et aI. , 2004) 
(Figure 5). We can envision several parallel splicing regulatory circuits interacting with 
various regulatory Irans-acling factors, to explain the peculiar spectrum of DA exon 
inclusion observed in different tissues, at different dev lopmental stage and under 
different experimental conditions. 
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Figure 5. Splicing pattern variation of the EDA exon in the FN pre-mRNA 
at different ages and at the various tissues. 
The graphs shows the percentage of each alternatively spliced form as a function 
of the age. The different ages are indicated a numbers from 1 to 7 ( 13.5 1-
day-old, 14-day-old 2-month-old, 6-month-old, 15-month-old and 24-month-
old, respectively). Spleen analysis in the 13.5 stage was not performed due to 
low amount of material recovered from the embryo. (+), DA + isoform ' (- ) 
DA- isoform (Chauhan et a!. 2004). 
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1.3 GENE TARGETING STRATEGY. 
Gene targeting, defined as the introduction of site-specific modifications into the 
mouse genome by homologous recombination, is generally used for the production of 
mutant animals to study gene function in vivo (Torres, 1997). The only efficient gene 
targeting method presently established utilizes pluripotent murine embryonic stem (ES) 
cell lines. Using these cells, the identification of the rare, homologous recombinant ES cell 
clones can be easily accomplished in vitro by both the positive and negative selection. As a 
substrate for homologous recombination, vectors of the replacement type are most 
frequently used for gene targeting in ES cells and usually to simply inactivate gene 
function (Figure 6A and B). A typical replacement vector consists of two regions of DNA 
homologous to the genomic target locus interrupted by a positive selection marker such as 
the bacterial aminog/ycoside phosphotransJerase (neo) gene (Torres, 1997). This marker is 
either inserted into the homology region or alternatively replaces the genomic sequence 
located between the homology arms. A viral thymidine kinase (tk) gene is often included at 
the end of the long homology arm of the vector and serves as an additional negative 
selection marker against ES clones that have randomly integrated the targeting vector. 
Such genetically modified ES cells, when introduced into a blastocyst, contribute to all cell 
lineages, including the germ line of the resulting chimeric animals (Torres, 1997). 
1.3.1 Conventional gene targeting. 
The positive selection marker (neo) is primarily used to enrich rare, stably 
transfected ES cell clones. It frequently serves in the generation of site-specific 
mutagenesis by insertion of the marker gene into a coding exon or the replacement of 
coding exons of the target gene by the marker (Figure 6A). In any case, the end product of 
a targeting experiment using a replacement type vector, that includes a positive selection 
marker, is the presence of the selection marker gene in the targeted locus which cannot be 
further modified. 
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Thus, this gene targeting strategy is only suitable for the generation of a nonfunctional 
(knock-out) allele of a target gene. This type of gene inactivation is called "conventional 
gene targeting" (Torres, 1997). 
1.3.2 CRE/loxP recombination system. 
The use of a recombination system, and in particular the CRE/loxP system, has 
considerably improved the gene targeting technique (Torres, 1997). CRE/loxP-based gene 
targeting allows the introduction of mutations into target loci with the subsequent removal 
of the selection marker gene (Figure 6B and C). Moreover, the use of the CRE/loxP system 
allows a greater versatility in gene targeting experiments offering the opportunity for 
"conditional gene modifications" in vivo (Figure 60). The PI bacteriophage CRE 
recombinase recognizes and mediates site-specific recombination between two 34 bp 
sequences referred to as loxP (Sauer and Henderson, 1988) (Figure 7 A). When two loxP 
sites are placed in the same orientation on a linear DNA molecule, aCRE-mediated 
intramolecular recombination event results in the excision of the loxP-flanked, or "floxed", 
sequence as circular molecule with one loxP site left on each reaction product (Figure 7B). 
Figure 6. Gene targeting strategy. 
A. Conventional gene targeting. B. Conditional gene targeting based on the 
introduction of three loxP sites in the genome (flox-and-delete). C. Transient 
expression of the CRE recombinase in the recombinant ES cells generates the floxed 
version of the targeted allele, necessary for the conditional gene targeting. If 
recombination occurs between the outer 10xP sites (Type I deletion) a large deletion 
is created that should inactivate or modify the gene. Recombination between the 
loxP sites flanking the neo gene (Type II deletion) leaves one loxP site in the 
genome that generates, together with the isolated (outer) 10xP site, the floxed version 
of the gene. The third recombination product, the deletion between the isolated loxP 
site and the inner loxP site flanking the neo gene (Type III deletion), is usually not 
of practical use and will not be found if ES colonies are screened for 0418 
sensitivity after eRE expression since such colonies retain the neo gene. D. 
Crossbreeding of the floxed mouse with a mouse expressing the CRE recombinase 
under the control of a tissue-specific or inducible promoter allows deletion of the 
floxed DNA segment in a temporal or spatial manner. TO, targeting vector; TL, 
target locus; exons, neomycin cassette (neo) and thymidine kinase (tk) are 
represented as blue, red and green boxes, respectively. LoxP sites and promoters are 
represented as black triangle and dots, respectively. 
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Figure 7. CRElloxP site-specific recombination system. 
A. LoxP sites (locus of crossover (~) in £. 1; black triangles) are compo ed of two 
13-bp inverted repeated sequences separated by an 8-bp non-palindromic sequence 
which dictates the orientation of the overall sequence (spacer). B. By inserting two 
directed 10xP sites it is possible to delete the floxed DNA stretch following tran ient 
in vitro or in vivo expression of the eRE recombinase. eRE recombina e C~au ses 
recombination; red stars) specifically recognizes and recombines two consecuti ve 
10xP sequences, generating both a linear and a circle subproduct, each with a single 
10xP site (flox-and-delete-strategy). ach of the two repeats within a 10xP site is 
bound by one molecule of eRE and a staggered 6-bp cut is generated. In the li fe-
cycle of the PI phage, eRE recombinase serves to ensure the segregation of the 
cyclic unit-copy PI plasmid prophage and the cyclization of the linear viral genome 
after infection of bacteria. 
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If the two 10xP sites are placed in opposing orientations the floxed sequence will be 
inverted. An alternative recombination system can be used for gene manipulation not only 
of the mammalian cells but also of yeast, Drosophila and plants (Torres, 1997). Indeed, the 
FLP/FRT recombinase system of the yeast 2-micron plasmid has been successfully used 
for the removal of FRT sequence-flanked selection markers by expression of FLP 
recombinase (Veit and Fangman, 1988). 
1.3.3 Conditional gene targeting. 
The term "conditional gene targeting" indicates a restricted gene modification in 
the mouse, limited either to certain cell types (tissue-specific) or to a portion of its lifetime 
(temporally-specific) or to both (Torres, 1997) (Figure 6). This contrasts with the 
conventional gene targeting strategy that creates a permanently modified allele in all cells 
of an animal from the onset of development (Figure 6A). The use of the CRE/loxP 
recombination system (Figure 7) for conditional gene targeting requires the generation of 
both a mouse strain harboring a 10xP-flanked segment of a target gene (Figure 6C) and a 
second transgene strain expressing CRE recombinase in specific cell types, due to the 
control of a constitutive or inducible cell type-specific promoter (Figure 6D). Therefore, 
the modification introduced in the target gene is restricted in a spatial and temporal manner 
according to the pattern of CRE expression in the particular murine strain used. The 
regional specificity of conditional gene targeting allows both to test the function of widely 
expressed molecules in a particular cell lineage and to investigate gene function post-
natally. The latter point is particularly usefull in the case the conventional (complete) gene 
inactivation leads to a severe or lethal phenotype during embryonic development, 
preventing a more detailed in vivo analysis (Torres, 1997). The use of an inducible or 
tissue-specific promoter for CRE expression has the important additional advantage that 
the wild-type gene product is present throughout ontogeny until the time of induction. 
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1.3.4 Flox-and-delete strategy. 
The "flox-and-delete" strategy can be used for conditional gene inactivation and is 
especially useful if lethality is anticipated in conventional mutants (Torres, 1997). A 
minimal flox-and-delete gene-targeting vector contains three 10xP sites in the same 
orientation, two sites flanking a selection marker gene and an isolated site within one arm 
of homology (Figure 68). After identification of homologous recombinant ES clones, that 
have cointegrated the isolated 10xP site, transient in vitro CRE expression leads to three 
different recombination products (Figure 6C). The ES cell clones with deletion of the 
marker gene are used to produce a strain with the floxed allele for conditional gene 
inactivation, while clones with deletion of the fragment flanked by the external 10xP sites 
can be used to generate mice harboring the inactivated version (knock-out) of the gene of 
interest (Figure 60). 
1.3.5 Site-specific recombination in hepatocytes. 
In order to obtain an hepatocyte-specific recombination of a DNA segment flanked 
by 10xP sites, a transgenic mouse has been generated that expresses the CRE recombinase 
open reading frame under the control of both the mouse albumin regulatory elements and 
the a-fetoprotein enhancer (Alf-p-CRE Trangene, Figure 8) (Kellendonk et aI., 2000). This 
configuration has been chosen to mimic the genomic organization of the mouse albumin 
gene, which is specifically activated in hepatocytes. In mammals, the albumin gene is 
located upstream of the a-fetoprotein (AFP) gene and its expression is thought to be 
influenced by the AFP enhancers located between both genes. In mice, the albumin gene 
starts its expression during embryogenesis shortly after the appearance of the liver bud 
(day 9.5 pc) and mRNA levels increase following liver development. CRE is active before 
day 10.5 pc but not before day 9.5 pc. Thus, the Alf-p-CRE expression vector seems to 
allow the expression of CRE recombinase in mice at the time, during embryogenesis, 
coincident with activation of the endogenous albumin gene. 
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Figure 8. Schematic representation of CRE recombinase transgene (TG Alf-p-
CRE). 
When the eRE recombinase gene is expressed under the control of specific 
promoter/enhancer sequences is possible to condition the removal of a floxed DNA 
stretch from the genome either temporally or spatially. A eRE recombinase transgene, 
that under the control of the mouse albumin enhancer and promoter and alpha-
fetoprotein enhancer is specifically expressed in the hepatocytes, is represented. hGH 
polyA is a human polyadenylation site (Kellendonk et aI. , 2000). 
1.4 GENETICALLY MODIFIED-FN GENE-MURINE MODELS. 
In order to study in vivo the biological role of FN and its alternative spliced 
segments, different genetic manipulations have been introduced in the gene. onventional 
and conditional knock-out mice, and specific alternative splicing modifications of the FN 
gene have been generated and are briefly described below: 
1.4.1 Conventional fibronectin knock-out mouse. 
The importance of FN in embryonic development was shown for the first time by 
George et al. (George et a\., 1993) through the generation of a conventional FN knock-out 
(KO) mouse strain, constitutively devoid of the protein. The promoter region and the first 
exon of the mouse FN gene were replaced with a selection marker (neo), thus preventing 
FN gene transcription. Mice homozygous for the targeted FN allele (FN-1-) die during early 
gastrulation (ES.O) due to severe defects in mesodermally-derived tissues such as 
notochord and somites that are absent. Mutant embryos also display a shortened anterior-
posterior axis, deformed neural tube, heart and embryonic vasculature, and defective yolk 
sac, extra-embryonic vasculature and amnion. All of these abnormalities can be interpreted 
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as a consequence of severe deficits in mesodermal adhesion, differentiation, proliferation, 
and migration to its correct location as a result of the absence of fibronectin. Thus, the 
early embryonic lethality of the FN KO mice proves that deposition of FN is required for 
successful completion of embryogenesis and normal development. On the contrary, mice 
heterozygous for the targeted FN allele (FNwtJ-) are viable, healthy, fertile and of the same 
size of wild-type mice, even though the concentration of FN in the blood plasma is one 
half (- 233 f.1g/ml) of that found in wild-type mice (- 580 f.1g/ml). This finding indicates 
that the wild-type allele does not up-regulate to compensate for the null-allele. 
1.4.2 Conditional pFN-null mouse. 
Due to the early embryonic lethality, the conventional KO mouse of the FN gene 
could not be used to address the role of FNs in adult physiology and pathology. To 
examine the functions of FN in adult tissues, and in particular the role of pFN in 
hemostasis and tissue repair, Sakai et al. (Sakai et aI., 2001) generated a conditional liver-
specific FN-null mouse using the CRE/loxP system. CRE-mediated recombination at the 
two inserted 10xP sites removed the start codon (ATG). the signal sequence and the 
exonlintron border of exon 1, thus generating the null allele. To induce the conditional 
deletion of the floxed DNA segment in the adult liver, mice bearing the floxed FN alleles 
were crossed with two transgenic strains expressing CRE recombinase under the control of 
the interferon-/polyinosinic-polycytidic acid (pI-pC)-inducible Mx promoter and the 
tissue-specific albumin promoter, respectively. An important role of pFN in hemostasis is 
demonstrated by several evidences such as i) the high concentration of pFN in blood, ii) 
the abundant amount of platelet-derived FN that becomes secreted upon platelet activation, 
iii) the ability of pFN to crosslink with fibrin or fibrinogen and to bind to the FN receptors 
(integrins) on the platelet surface during the formation of the blood clots. However, the 
initial data obtained performing experiments using pFN-deficient mice (both in plasma and 
in platelets) did not confirm this hypothesis. Indeed, in vitro and in vivo measurements of 
35 
the clotting and bleeding time, respectively, or in vitro platelet-aggregation tests carried on 
the Sakai's conditional pFN-null mice (Sakai et aI., 2001), on the George's FN 
heterozygous (FNwtJ-) mice (Matuskova et aI., 2006) and on the Muro's EDA+1+ mice 
(unpublished data, see next paragraph) showed that the differences with the respective 
control mice were not significant. An explanation for this unexpected finding could be the 
presence of cFN in platelets derived from pFN-deficient mice or, alternatively, several 
other blood coagulation factors compensating for the absence of pFN. Conditional pFN-
null mice were also used to study tissue-repair processes such as skin wound healing and 
brain injury after focal cerebral ischemia. No differences in skin reepithelization process 
were observed in pFN-null mice in comparison with control mice. The abundant deposition 
of cFn on the surface of the wounds made by platelets, keratinocytes, macrophages and 
fibroblasts, that transmigrate to close the wound (Clark, 1990; Ffrench-Constant et aI., 
1989) is a likely explanation for the normal cutaneous wound healing in pFN-null mice 
(Sakai et aI., 2001). Thus, this model initially did not show a direct involvement of pFN 
either in blood clotting or in skin wound healing. However pFN was found to fulfill an 
important role in the brain wound healing after induction of an injury by focal ischemia. 
Ischemia leads to a blood-brain barrier damage resulting in the extravasation of plasma but 
not of blood cells in brain (Garcia et aI., 1994). As expected, pFn was found throughout the 
infarcts in normal mice but no pFN was found in the infarcts of pFn-null mice that were 
also larger than those of the control animals. Several factors could contribute to the 
increase in infarct size of pFn-null mice. pFn could provide a matrix for adherence, 
migration and proliferation of those blood cells necessary to repair the tissue damage. This 
is not possible in the pFn-null mice. 
1.4.3 EDA exon knock-in and knock-out mice. 
The study of the function of the different FN protein isoforms is difficult in vivo 
due to the simultaneous presence of more than one variant at a given specific 
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developmental time and tissue. To address this issue a novel genetic approach was 
previously designed in our lab (Muro et aI., 2003) without modifying the coding sequence 
of the FN gene. Taking advantage of the detailed knowledge of the elements involved in 
EDA splicing regulation (Caputi et aI., 1994; Mardon et aI., 1987; Muro et aI., 1999; Muro 
et aI., 1998) (Figure 4) and the gene targeting technique (Figure 6 and 7), knock-in 
(EDA +1+) and knock-out (EDA-1-) murine strains for the FN EDA exon (Figure 9) were 
generated. In brief, the 5' splice site was mutated to that of the consensus sequences and 
the 3' splice site was replaced by that of the constitutively spliced-in second exon of the 
apolipoprotein AI gene that exactly matches the 3' splice site consensus (Figure 4A). The 
targeting construct consisted of 11.5 kb of mouse genomic DNA (Figure 9A and B). Three 
10xP sites were included in the targeting vector flanking the neo-tk marker cassette and the 
EDA exon, and an additional marker gene, the diphtheria toxin (DT A) gene, was linked at 
the end of the long arm of homology. The homologous recombinant clones obtained 
underwent a second step of recombination by transient expression of the CRE recombinase 
in vitro (Figure 9C and D). The recombinant clones, containing the deleted neo-tk cassette 
and the 10xP flanked EDA in one of the FN alleles, were used to obtain chimeras. 
Heterozygous offsprings (EDA wt/+) were then mated to each other to produce the EDA +/+ 
mice that include the modified EDA exon in both the FN alleles. EDA wt/+ mice were also 
mated with CRE-recombinase transgenic mice (Deleter-CRE, Figure 6D) to obtain 
EDA wt/- progeny that were subsequently mated to each other to obtain EDA/- animals 
(Figure 9E). The EDA exon, that is normally spatially and temporally regulated during 
development and ageing (Figure 5), is now constitutively either present or absent from the 
FN mRNA of the EDA+1+ and EDA-1- strains, respectively (Figure 10). Radioactive RT-
PCR analysis of total RNA extracts of various organs from EDA wt/w" EDA +1+ and EDA-1-
adult mice 
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Figure 9. Strategy fo r the generation of mouse strains lacking regulated 
splicing at the EDA exon of the FN gene. 
A. Partial map of the wild-type FN allele. B. The targeting vector. C. The 
targeted allele. D. The EDA-floxed allele. E. The EDA-null alleles. xons neo-
tk, and diphtheria toxin (DT A) are shown as light-blue, red and green boxes, 
respectively. The EDA exon and its internal splicing regulatory elements, E E 
and ESS, are indicated as grey, blue and red boxes, respectively. Lox P ites and 
optimized 3' and 5' splice sites are indicated as black triangles and dots, 
respectively. The recombinant ES cells were transiently transfected with a RE-
recombinase expressing plasmid, to remove the neo-tk cassette (Panel C and D). 
EDA +/\\t heterozygote cells were used for blastocyst microinjection. EDA +/wt mice 
were mated with a eRE-expressing transgenic mouse strain to obtain the DA -/\\1 
mIce. 
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confirmed the lack of regulated splicing of the EDA exon in both mutant mouse strains. In 
the mutant tissues, the EOA +FN isoform is never present in the samples from EOA/- mice 
but is constitutively present in all tissues from EOA +1+ mice (Figure 10). The evidence that 
both homozygous murine strains were viable and developed normally showed that 
alternative splicing regulation of the EOA exon is not necessary during embryonic 
development or that it may be compensated by other gene products. However, adult EOA-1-
mice displayed abnormal skin wound healing, whereas EOA +1+ mice showed a clear 
reduction in the plasma and tissue FN levels. This abnormal reepithelization could be 
explained by the lack of EOA +FN isoform upregulation, which is thought to participate 
actively in the reepithelization process (Clark et al., 1983; Ffrench-Constant et al., 1989) 
due to its essential role in the organization of the granulation tissue and probably in 
epidermal cell migration, either directly or by interaction with other ECM components. 
Furthermore, both mutant mouse strains have a significant shorter lifespan than the control 
mice, suggesting that EDA splicing regulation is necessary for efficient long-term 
maintenance of biological functions. 
1.4.4 pFN-deficient mice and thromboembolism. 
The conditional inactivation of the FN gene in liver reduced pFN levels to less than 
2% and the platelet FN levels to about 20% of the levels of the control mice (Ni et al., 
2003; Sakai et al., 2001). Heterozygous mice for FN (FNwtI-) were found to have 55% of 
reduction in pFN levels and 21 % of reduction in platelet FN content, when compared to 
the levels of control animals (George et al., 1993; Matuskova et al., 2006). EOA +1+ are 
instead characterized by a reduction of about 70-80% in the pFN content (Muro et al., 
2003) and a reduction of about 50-60% in the platelet FN content (unpublished data). All 
these pFN-deficient mice were tested in a model of thromboembolism to evaluate their 
capacity to form thrombi, following induction of arterial injuries by topical application of 
ferric chloride. Interestingly, both the partial and the total pFN deficiency of the FNwtl-
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Figura 10. RT-PCR analysis of the splicing pattern of adult mutant and 
control mice. 
A. Radioactive RT-PCR analysis of total RNA prepared from different organs from 
4-month-old adult EDA wt/W\ EDA+/ + and EDA-1- mice for the EDA alternatively 
spliced region. The inclusion of the EDA exon within the wt FN mRNA is subjected 
to a tight tissue-specific regulation. The most dramatic example is seen in liver, 
where EDA exon is completely excluded from the mRNA. On the oth r hand, the 
highest inclusion of EDA exon is seen in testis, where the EDA +FN [oml 
outnumbers the EDA rN form . In all other ti sues the inclusion is lower but always 
present. In the mutant mice is always present only one of the two variants, DA + or 
EDA - mRNA. B. Quantification of the radioacti e PCR products. The p rcentage of 
EDA inclusion for each genotype is indicated by the coloured graph-bars ( hauhan 
et al. 2004). 
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(Matuskova et aI., 2006) and conditional pFN-null mice (Ni et aI., 2003), respectively, 
resulted in an evident delay in the formation of thrombi after vessel wall injury. Moreover, 
even though the thrombi formed in both models were stably anchored to the vessel wall, 
they continuously shed platelets or small platelet clumps, thus slowing their growth 
significantly. Due to the reduced pFN levels, the platelet/platelet cohesion was apparently 
diminished and consequently the occlusion of the vessels was delayed. Contrary to the 
other two pFN-deficiency models and in spite of the striking pFN decrease, we found that 
thrombi grew faster and were more stable in our EDA +1+ mice, using the same ferric 
chloride injury model (unpublished data). Moreover, the mean vessel occlusion time was 
also shorter in comparison to the control mice. Overall, these data seem to demonstrate a 
clear involvement of pFN in the process of formation, growth and stability of the arterial 
thrombus, where FN seems to function as a sort of glue for sticking platelets together. 
pFN' s ability in promoting platelet aggregation/cohesion in the growing thrombus seems 
also to be dramatically enhanced by the inclusion of the EDA domain in the FN protein, 
revealing a prothrombotic role of the EDA +FN isoform. 
1.4.5 Role of EDA domain in atherosclerosis. 
An EDA-1- ko mouse was generated by Tan et al. (Tan et aI., 2004) similarly but 
independently to that generated by Muro et al. (see above). EDA/- mice were then mated 
to apolipoprotein E (ApoE)-null mice (ApoE-1-) to generate EDA/-ApoE-1- double KO 
mice. ApoE-1- mice are animals that develop hypercholesterolemia and atherosclerotic 
lesions in arterial wall, following a high-fat, high-cholesterol diet (Plump et aI., 1992). 
Immunohistochemistry with monoclonal antibodies revealed that EDA +FN variant is 
prominent in atherosclerotic lesions of the ApoE-1- mice. Morphometric measurement of 
the extent of the atherosclerotic plaques both in EDA-1-ApoE-1- and control ApoE-1- mice 
revealed that the EDA-1-ApoE"/- mice have reduced, thinner lesions, containing less 
quantity of lipids. Additionally, cholesterol concentrations in EDA-1-ApoE-1- plasma were 
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slighty lower than the ApoE"/- controls. These studies provide an in vivo evidence for a role 
of the alternatively spliced EDA segment of FN in atherogenesis, suggesting a pro-
atherogenic function in the pathophysiology of the disease. However, our EDA +1+ and 
EDA-1- mouse strains (Muro et aI., 2003) revealed a 40% reduction in atherosclerotic 
lesions after a fat-diet treatment, in comparison to control mice (EDA wtlwt) (Babaev et aI., 
2007. In press in Atherosclerosis). These results seem to rule out a pro-atherogenic role of 
the EDA domain and suggest that the observed reduction of atherosclerosis in both the 
EDA +1+ and EDA/- strains might be associated with the impossibility to modify the steady 
state levels of the EDA domain due to the absence of regulated splicing in both mutant 
strains. 
1.4.6 EDD exon knock-out mice. 
A first attempt to study the in vivo role of the FN-EDB domain by gene targeting 
was made by Georges-Labouesse et al. (Georges-Labouesse et aI., 1996). The EDB exon 
and part of the flanking intronic sequences were deleted and replaced by a marker cassette 
(neo) in order to generate a constitutive EDB-null strain. On the other hand, the EDB exon 
and the two flanking exons (III7b and IIISa) were replaced by the corresponding III7b-
EDB-IIISa cDNA segment in an attempt to generate a constitutive EDB+ strain. The neo 
cassette was inserted into the intron downstream of the exon IIISa. Although the 
heterozygous animals from both strains (EDBwtI+ and EDBwtl-) appeared normal in size and 
fecundity and presented no obvious defects after more than 2 years of age, it was found 
that the pFN levels were about half of the levels of control littermates. Furthermore, none 
of the homozygous mutant embryos (EDB-1-) survived over the tenth day of gestation 
(E I 0). Both mutations resulted to be recessive embryonic lethal as already observed in the 
conventional FN KO animals (George et aI., 1993). The reason for the non-functionality of 
the FN alleles containing the deletion of the EDB exon or its replacement with a 
corresponding cDNA segment is not clear. However, the presence of the marker cassette 
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inside the FN gene or the presence of a long artificial exon (III7b-EDB-III8a) may have 
altered its expression, generating a defective phenotype similar to that obtained by George 
et al. (George et aI., 1993). It is noteworthy that also Fukuda et al. (Fukuda et aI., 2002) 
examined the function of the FN-EDB exon by generating mice lacking the EDB exon 
(EDB-I-) in which the neo marker was deleted in vivo. The EDB domain is prominently 
expressed during embryonic development, wound healing and malignant transformation 
although it is mostly eliminated from FN in normal adult tissues (Ffrench-Constant and 
Hynes, 1989; Oyama et aI., 1993; Oyama et aI., 1989a; Oyama et aI., 1989b), similarly to 
what occurs in the EDA domain. Analysis of the EDB-null mice revealed the absence of 
any significant abnormal phenotypes in vivo, upon anatomical inspection of major organs. 
Mice developed normally and were fertile, even though embryonic fibroblasts grew slower 
in vitro and deposited less FN in the pericellular matrix than fibroblasts from wild-type 
mice. These results indicate that expression of EDB+ isoforms is dispensable during 
embryonic development, even though it may play a regulatory role in the FN matrix 
assembly and growth of the connective tissue cells. Given that matrix-assembled FNs is 
supposed to transduce signals that stimulate cell cycle progression via interaction with 
integrins (Assoian and Schwartz, 2001), decreased FN matrix assembly may well explain 
the reduced proliferative potential ofEDB-null fibroblasts in vitro. 
1.5 PLASMA AS A RESERVOIR OF PROTEINS FOR THE TISSUES. 
Previous experiments have shown that the bloodstream could behave as an 
important reservoir of FN and other plasma proteins to supply to the tissues for the 
formation and/or maintenance of the extracellular matrixes and the regulation of many 
other cell activities. Initial evidences supporting this hypothesis came from in vivo studies 
where purified human pFN was intravenously injected into mice. By immunostaining, 
human FN was detected in the tissues of mice and its distribution was found 
indistinguishable from the mouse endogenous cFN (Dh et aI., 1981). In vitro experiments 
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performed with human fibroblast cultures showed that exogenous pFN added to the 
cultures was incorporated into the culture ECM to form fibrils on the fibroblast cell surface 
along with the endogenous cFN (Bae et aI., 2004; McKeown-Longo and Mosher, 1983; 
Peters et aI., 1990). These data indicate that soluble FN may be insolubilized and 
assembled into the multimeric, insoluble matrices characteristic of connective tissues, most 
likely via specific cell-surface receptors, but quantification of the FN incorporated has 
never been assessed. 
1.6 ROLE OF EDA+FN VARIANT IN WOUND HEALING. 
The ability of repairing damaged tissues represents an important response to injury 
that is common to all complex organisms. Just as in embryonic development, the repair 
process involves proliferation, migration, and differentiation of a number of different cell 
types. Therefore, it is likely that wound healing might share many of the molecular 
mechanisms used during development. For example, the EDA +FN variant is highly 
expressed in early embryonic tissues where proliferation, migration, and an 
undifferentiated state of cells are prevalent. Similarly, the EDA +FN isoform is highly 
expressed in many pathological situations characterized by dedifferentiation, cell 
proliferation, and migration such as wound healing (Ffrench-Constant and Hynes, 1988; 
Ffrench-Constant et aI., 1989) (Ffrench-Constant and Hynes, 1989; Norton and Hynes, 
1987; Oyama et aI., 1989a; Oyama et aI., 1989b; Pagani et aI., 1991; Peters and Hynes, 
1996). The experimentally induced injury in both liver and skin represents an excellent 
procedure to study the role of the EDA +FN variant in the wound healing process. This is 
due to the fact that those tissues do not synthesize EDA +FN mRNA in normal conditions. 
It has been shown that EDA -FN mRNA comprises - 70% and 100% of the total FN 
mRNA in fetal and adult liver, respectively, both in human (Oyama et aI., 1 989b) and in 
mice (Chauhan et aI., 2004). However, in situations such as fibro-pathologies, 
tumorigenesis or other pathological circumstances, the EDA segment is again included at 
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high levels (Brown et aI., 1993; Ffrench-Constant et aI., 1989; Glukhova et aI., 1990; 
G1ukhova et aI., 1989; Jarnagin et aI., 1994; Knowlton et aI., 1992; Oyama et aI., 1993). 
This deregulation of the EOA exon alternative splicing mechanism that resembles an 
embryonic condition is one of the main features of the liver during the processes of 
regeneration, fibrosis and malignancy, and of the skin during wound healing. 
1.6.1 Liver regeneration. 
An example of up-regulation of the EOA exon in pathological situations comes 
from the analysis of the splicing pattern of regenerating liver after partial hepatectomy. 
After partial resection of the liver, normally quiescent hepatic cells are stimulated to 
reenter the cell cycle and proliferate in order to restore the original liver mass in 7-10 days. 
This means that during the regeneration process, a significant reprogramming of the 
cellular activities (Arai et aI., 2003; Su et aI., 2002), including the alternative splicing 
process (Caputi et aI., 1995b; Ou et aI., 1997), occurs. It has been reported that in rat 
regenerating liver, 24 hrs after 70% organ resection, there is an abnormal over-production 
ofFN mRNAs (up to three fold) including an up-regulation of the EOA+FN isoforms. The 
EOA +FN mRNA arises from almost 0% up to 20% of the total amount of FN mRNA 
(Caputi et aI., 1995b). This finding is consistent with the observation that hepatocytes start 
producing EOA +FN after being 3 days in culture, suggesting that the EOA domain has a 
role in cell-proliferation and tissue modeling (Odenthal et aI., 1992). Interestingly, an 
increased inclusion of the EOB exon but not of the EOA exon is observed in the FN 
transcript within the first few hours posthepatectomy (Ou et aI., 1997). We can speculate 
that the changes in both the EOA and EOB splicing patterns, generating increased 
EOA +FN EOB+FN/total FN mRNA ratios, serve to provide a more adequate extracellular 
matrix facilitating tissue repair by promoting cell-activation, -proliferation and -migration. 
However, the fact that EOA exon does not appear in the early phases of normal liver 
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regeneration lends support to the idea that the EDA and EDB alternative splicing are 
regulated by different mechanism and may have different functions. 
1.6.2 Liver fibrosis. 
The fibroproliferative disorders are not well understood, even though major efforts 
are being made to elucidate the pathogenic mechanisms. These disorders are characterized 
by three important events: i) a tissue injury, ii) an abnormal activation and differentiation 
of fibroblasts or other cell types such as the hepatic stellate cells (HSCs) into 
myofibroblasts; they are indeed the key cells of the fibrotic process in most organs, and iii) 
a dramatic increase in the production and deposition of ECM proteins in injured tissues 
(Bataller and Brenner, 2005; Bissell, 2001). It has been reported that collagen is the 
predominant ECM protein identified in fibrotic lesions and is the hallmark of 
fibroproliferative diseases. EDA +FN variant is also present in abnormally large quantities 
and localized in areas of active fibrogenesis where it seems to participate in the activation 
of fibroblasts (Jarnagin et aI., 1994). In a rat model in which liver fibrosis was 
experimentally induced by ligation of the bile duct, the most conspicuous event in FN 
expression is the sharp increase of the synthesis of both total FN mRNAs (up to 7-fold) 
and EDA +FN mRNAs. The EDA +FN variant is almost undetectable in the whole normal 
liver extract. The in vitro analysis of FN synthesis of each cell type constituting the liver, 
before and after the injury, revealed that two types of non-parenchymal cells are 
principally involved in the overproduction of EDA +FN mRNA: firstly, the sinusoidal 
endothelial cells (SECs) that line blood capillaries and secondly the HSCs that are fat-
storing cells (also called Ito cells or lipocytes) present in the liver space of Disse (Figure 
11). Both of the SECs and HSCs normally express very little FN mRNA, but after the 
injury the EDA +FN/total FN mRNA ratio is dramatically increased (Jarnagin et aI., 1994). 
Indeed, the EDA+ mRNAs in the SECs increase rapidly and constitute most (> 80%) of the 
total FN mRNA within 24 hrs, while in the HSCs increase from -7% to 42% within 7 days 
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after the liver injury. On the contrary, in the hepatocytes, the level of total FN mRNA 
remains constant and the EDA exon is almost undetectable up to 14 days after the bile duct 
ligation. The appearance of the EDA domain during development (Ffrench-Constant and 
Hynes, 1989; Oyama et aI., 1989b; Pagani et aI., 1991), its nearly total disappearance in the 
adult liver and reappearance in a context of wound healing clearly suggest a specific 
biological role for the EDA +FN variant. The fibrotic process that follows a liver injury is 
characterized by the appearance and proliferation of myofibroblast-like cells (Bissell, 
1990; Friedman, 2000; Serini and Gabbiani, 1999). These cells seem to arise in part from 
the HSCs through a conversion process called "activation" (Jarnagin et aI., 1994; 
Lotersztajn et aI., 2005; Magness et aI., 2004). In normal liver, HSCs are synthetically 
quiescent, notable mainly for their abundant stores of retinoid esters. Once they are active, 
the HSCs start proliferation, synthesis of cytokine receptors and secretion of ECM 
proteins. It is thought that HSCs activation is regulated by soluble products of 
inflammation such as cytokines and growth factors, and by the ECM itself (Friedman et aI., 
1989; George et aI., 2000). Studies performed in vitro by plating HSCs on substrata with 
various FN matrixes, containing or not containing the EDA domain, revealed that the 
presence of the EDA domain in the matrix is an important factor for the activation of the 
HSCs (Jarnagin et al., 1994). The activation of HSCs was monitored by quantitation of one 
of the protein markers for the activated HSCs such as the smooth muscle a-actin (aSMA). 
The fresh isolates contained no detectable aSMA, but in culture on a collagen substrate, 
they underwent spontaneous activation that was detectable after 2-3 days and increased 
progressively. HSCs plated for the same period of time on a matrix containing EOA +FN 
(cFN) or EDA -FN (pFN) expressed substantially higher levels of aSMA, but strikingly the 
aSMA level in the HSCs incubated on EOA +FN matrix was twice the level of aSMA of 
the HSCs incubated on EDA-FN matrix. Moreover, the activation effect of the EOA+FN 
matrix was completely blocked by the use of anti-EDA antibodies, confirming that the 
activation of the HSCs was related to the presence of the EOA segment (Jarnagin et aI., 
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1994}. During wound healing, it has been shown that non-parenchymal cells have a 
predominant role in respect to parenchymal cells, due to their increased production of both 
the EDA +PN and collagen mRNAs (Jarnagin et aI., 1994; Maher and McGuire, 1990). 
However the role played by the non-parenchymal cells in the pathophysiology of the liver 
fibrosis has never been firmly established in vivo. 
1.6.3 Liver tumorigenesis. 
Many studies have been performed in order to investigate the splicing pattern of PN 
in human liver diseases such as chronic hepatitis, cirrhosis and hepatocellular carcinoma. 
The scenario looks to be very similar to that of animal models for wound healing. It has 
been shown that EDA +PN mRNA expression is upregulated in human liver malignant and 
fibrotic tissues, as occurs during development. The physiological significance of the 
increased expression of the EDA +PN variant in tumorigenesis has not yet been well 
understood. It is possible that the EDA +PN variant is involved in the manifestation of the 
invasive properties such as migration and proliferation of the malignant tumor cells 
(Matsui et aI., 1997; Oyama et aI., 1993; Oyama et aI., 1989a; Tavian et aI., 1994). 
1.6.4 Skin wound healing. 
Similarly to liver, skin of adult animals does not contain the EDA domain in the FN 
protein. However, the EDA +PN variant is thought to participate actively in the 
reepithelization process (Clark et aI., 1983; Pfrench-Constant et aI., 1989). It has been 
observed that after skin wounding, PN gene is highly expressed in the cells at the base and 
edge of the wound and in the subjacent uninjured muscle and dermis. Interestingly, the 
splicing pattern of FN mRNA is different in these areas. In adjacent dermis and muscle, the 
splicing pattern remains identical to that of normal adult skin with exclusion of EDA exon 
from the PN mRNA. On the contrary, EDA exon is included in the PN mRNA present in 
the cells at the base and edge of the wound (Pfrench-Constant et aI., 1989). These data are 
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in agreement with the abnormal skin wound healing of adult EDA-1- mice, following full 
thickness excision of skin (Muro et aI., 2003). A factor that promotes the EDA domain 
inclusion into FN is the transforming growth factor-j3 (TGF-j3). TGF-j3 is a multifunctional 
cytokine that is implicated in a broad range of processes such as tissue development and 
repaIr, including the pathogenesis of fibroproliferative disorders (Ellingsworth et aI., 
1986). It has been shown that the treatment of cultured human skin fibroblasts with 
picomolar quantities ofTGF-j3 results in two- to three-fold increase in the relative amount 
of EDA +FN (BaIza et al., 1988; Borsi et aI., 1990). Additionally, EDA +FN variant over-
production exerts a sort of synergic effect on the initial TGF -j3-mediated stimulation of 
fibroblasts (Serini et aI., 1998). Following the early EDA +FN deposit and the EDA-
dependent auto-stimulation, fibroblasts start the intracitoplasmatic accumulation of aSMA 
and the secretion of collagen. TGF-j3 stimulation of fibroblasts plated on gelatin substrata 
containing a specific anti-EDA antibody showed a dramatic inhibition of aSMA and 
collagen induction. Conversion of fibroblasts to a myofibroblast-like phenotype mediated 
by both the EDA domain and cytokines such as TGF-j3, is an important event to generate 
contraction and closure of the skin wounds (Montesano and Orci, 1988; Serini and 
Gabbiani, 1999). The expression of smooth muscle a-actin (aSMA) in stress fibers 
increases the contractile activity of cultured fibroblasts and this perfectly correlates with 
wound contraction efficiency in vivo (Hinz and Gabbiani, 2003). 
1. 7 EXPERIMENTAL MODELS FOR LIVER FIBROSIS 
Liver fibrosis results from chronic damage to the liver in conjunction with the 
accumulation of ECM proteins, which is a characteristic of most types of chronic liver 
diseases. The main causes of liver fibrosis in industrialized countries include chronic 
hepatitis C virus (HCV) infection, alcohol abuse and nonalcoholic steatohepatitis (diabetes 
mellitus, obesity and hypertriglyceridemia) (Bataller and Brenner, 2005; Friedman, 2003). 
Animal models of chronic hepatic fibrosis are excellent tools to study cells and molecular 
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mediators involved in the onset of fibrosis, in a serial manner during both progression 
and/or recovery. Several approaches towards induction of fibrosis have been described. Of 
these, carbon tetrachloride (CCI4) intoxication and bile duct ligation (BDL) in rodents are 
the most widely studied and applied. However, the importance of studying human diseases 
using animal models should not be overemphasized as, at best, only a snapshot of a disease 
process which may develop over months or few years can be provided. Nevertheless, 
mechanistic studies combining knock-out or transgenic animals with CCl4 or BDL 
experimental models have provided unparalleled insight into mechanism underlying 
hepatic fibrosis (Constandinou et aI., 2005). The hepatotoxicity of CCl4 involves two main 
phases. Firstly, CCl4 is metabolized to trichloromethyl radical by the cytochrome P450 that 
is highly expressed in centrilobular hepatocytes. Trichloromethyl radicals are responsible 
for lipid peroxidation and membrane damage. The second phase is an inflammatory 
response that is launched by resident hepatic macrophages or Kupffer cells. After 
activation, these cells secrete cytokines such as TGF-~, chemokines, and other 
proinflammatory factors (Novobrantseva et aI., 2005). In addition to their direct cytotoxic 
effects, these factors attract and activate other monocytes as well as neutrophils and 
lymphocytes, all of which contribute to tissue damage. Initial damage is followed by a 
phase of repair that includes a TGF-~-induced increase in the production of ECM proteins 
such as fibronectins and collagens. Repeated cycles of injury, inflammation and repair 
attempts lead to fibrosis. The accumulation of ECM proteins occurs in the space between 
hepatocytes and endothelial cells that is called space of Disse (Figure 11). 
Bile duct ligation is as efficient as CCl4 administration in the induction of liver fibrosis 
even though the two models are mechanically different. In both cases, damage to 
hepatocyte plasma membrane is the starting point of liver fibrosis. Bile secretion normally 
depends on the function of a number of membrane transport systems in hepatocytes and 
cholangiocytes (epithelial cells of the bile duct), and on the structural and functional 
integrity of the bile-secretory apparatus. Ligation of the extra-hepatic bile duct provokes 
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blocking of the free bile flow excretory pathway between liver and duodenum, generating 
stagnation of the bile constituents within hepatocytes (Rodriguez-Garay, 2003). Alterations 
in membrane functionality are rapidly produced. Since the hydrophobic bile acids are 
strong detergents, they damage the plasma membrane proteins and the cell tight-junctions, 
provoking impairment of membrane functions (Rodriguez-Garay, 2003). 
Normal liver 
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Figure 11. Changes in the hepatic architecture (Panel A) associated with 
advanced hepatic fibrosis (panel B). 
Following chronic liver injury, inflammatory lymphocytes infiltrate the hepatic 
parenchyma. Some hepatocytes undergo apoptosis, and Kupffer cells activate, 
releasing fibrogenic mediators. Hepatic stellate cells (H Cs) proliferate and 
undergo a dramatic phenotypical act ivation, secreting large amounts of 
extracellular matrix proteins such as EDA +FN and collagens. inusoidal 
endothelial cells lose their fenestrations, and the tonic contraction of H Cs causes 
increased resistance to blood flow in the hepatic sinusoid (Bataller and Brenner, 
2005). 
51 
The presence of damaged or apoptotic hepatocytes trigger both the inflammatory and 
repair response leading to fibrosis. In both models, accumulation of ECM proteins in the 
space of Disse distorts the hepatic architecture due to the formation of a fibrous scar. The 
subsequent development of nodules of regenerating hepatocytes leads to cirrhosis. If the 
hepatic injury persists and the liver regeneration fails, the necrotic or apoptotic cells are 
substituted with abundant ECM, including fibrillar collagen. Cirrhosis produces 
hepatocellular dysfunction and increased intrahepatic resistance to blood flow that result in 
hepatic insufficiency and portal hypertension, respectively (Bataller and Brenner, 2005). 
Following chronic injury, HSCs or perisinusoidallipocytes activate and transdifferentiate 
into myofibroblast-like cells, acquiring contractile, pro inflammatory, and fibrogenic 
properties (Friedman et aI., 1985; Geerts, 200}; Jarnagin et aI., 1994) (Figure 11). 
Activated HSCs proliferate, migrate and accumulate at the sites of tissue repair, secreting 
large amounts of ECM and regulating ECM degradation (Bataller and Brenner, 2005). 
Several different molecules are involved in the modulation of the HCSs 
transdifferentiation: i) TGF -~ and the EDA +FN variant mainly produced by the SECs 
(George et aI., 2000) are responsible for the activation of the quiescent HSCs and their 
subsequent synthesis of ECM proteins, cytokine and growth factor receptors and aSMA; 
ii) PDGF and EGF, mainly produced by Kupffer cells, are the predominant mitogens for 
the activated HSCs; iii) Chemotactic signals as well as specialized cell-ECM interactions 
modulate the migration of the myofibroblasts to the injured areas, instead iv) Endothelins 
modulate their contraction (Bissell, 2001). Quiescent HSCs express markers that are 
characteristic of adipocytes (PPARy, SREBP-}c, and leptin), while the activated HSCs 
express myogenic markers (aSMA, c-myb, and myocyte enhancer factor-2) (Bataller and 
Brenner, 2005). Hepatocytes are the target for most hepatotoxic agents such as carbon 
tetrachloride, diamethylnitrosamine and thioacetamide (Constandinou et aI., 2005), 
including alcohol metabolites, bile acids and hepatitis viruses (Higuchi and Gores, 2003). 
Damaged hepatocytes release reactive oxygen species (ROS) and fibrogenic mediators and 
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induce the recruitment of white blood cells and inflammatory cells such as leucocytes, 
lymphocytes, macrophages, polymorphonuclear cells and platelets. Apoptosis of damaged 
hepatocytes and the recruited inflammatory cells stimulates the fibrogenic actions of the 
myofibroblasts. Activated HSCs secrete inflammatory chemokines, express cell adhesion 
molecules, and modulate the activation of the inflammatory cells. Therefore, a sort of 
"vicious circle" or "synergic effect" in which inflammatory and fibrogenic cells stimulate 
each other is likely to occur (Bataller and Brenner, 2005). 
The identification of activated HSCs or myofibroblasts as the major fibrogenic cell types 
as well as the recognition of the key cytokines and growth factors involved in the liver 
fibrosis process is facilitating the design of promising new antifibrotic therapies. These 
therapies are aimed at inhibiting the accumulation of activated HCSs at the sites of liver 
injury and preventing the deposit of extracellular matrix and scar formation. To date, 
removal of the causative agent is the only effective therapy to stop or even reverse liver 
fibrosis. The development of effective antifibrotic therapies represents a challenge for 
modem hepatology. Experimental antifibrotic strategies tested in rodents involve the use of 
antagonist of cytokines or cytokine receptors, specific inhibitors of the HSC activation and 
anti-collagen agents (Bataller and Brenner, 2001; Bissell, 2001). Antibodies like anti-TGF-
P or "soluble TGF-p receptors" that consist of the extracellular portion of the TGF-p 
receptor, may function as competitive binders of TGF-p, preventing interaction of the 
cytokine with its receptor (George et aI., 1999). Antioxidant compounds such as vitamine 
E, sylimarin, phosphatidylcoline, S-adenosyl-L-methionine, inhibit HSC activation, protect 
hepatocytes from apoptosis, and attenuate experimental liver fibrosis (Bataller and 
Brenner, 2005). The use of modifiers of collagen cross-linking as well as inhibitors of 
collagen synthesis or promotion of its degradation (Bataller and Brenner, 2001) can be a 
valid alternative approach. Moreover, the finding of a direct participation of EDA domain 
in the activation of the HSCs opens a novel pathway towards the identification of new 
anti fibrotic therapies having as a potential target the EDA domain itself or its receptors. 
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1.8 AIM OF THE THESIS. 
As previously described, the FN-EDA exon undergoes alternative splicing and its 
inclusion/exclusion pattern is strictly regulated in a developmental and tissue specific 
manner (Chauhan et aI., 2004). The adult liver tissue is characterized by the total absence 
of EDA domain from the FN polypeptide. Both embryonic and pathologic livers are 
instead characterized by an upregulation of EDA +FN mRNA (Jarnagin et aI., 1994; Oyama 
et aI., 1989b). The main objective of this thesis is to address the functions of the FN 
isoforms produced by the liver, containing or not the EDA domain, during physiological 
and pathological situations such as i) the supply of pFN to tissues and ii) tissue 
repair/progressive fibrosis, respectively. 
To address these issues we have used two mouse strains devoid of EDA-exon alternative 
splicing (Muro et aI., 2003). The strain called EDA +1+ modified to constitutively include 
the EDA exon into the FN mRNA was used to address the contribution of liver to the 
formation of the tissue FN matrix. The strain called EDA/- bearing a deletion of the EDA 
exon from the genome was used to study the involvement of EDA domain in the activation 
of the hepatic stellate cells, the key cells of the fibrotic process in liver. 
To demonstrate the first issue, we generated and characterized a liver-specific EDA-null 
mouse (EDA+1+CRE ) bearing an EDA-1-liver inside an EDA+1+ body. That mouse was simply 
obtained by crossbreeding our EDA +1+ strain with a transgenic mouse expressing the CRE 
recombinase only in the hepatocytes (Kellendonk et aI., 2000). 
To demonstrate the in vivo role of the EDA domain in liver fibrosis, we challenged our 
EDA-1- and control mice with two well-established experimental models of liver fibrosis: 
carbon tetrachloride (CCI4) intoxication and the bile duct ligation (BDL) models 
(Constandinou et aI., 2005). 
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2. MATERIALS AND METHODS 
2.1 CHEMICAL REAGENTS. 
General chemicals were purchased from Sigma-Aldrich, Merck, Gibco BRL, Life 
Technologies and Analar, BOH Laboratory Supplies, Fluka, Riedel-de-Hael, BO 
Bioscience, Amersham Biosciences, Pharmacia, Analyticals and Invitrogen. 
2.1.1 Standard solutions. 
All solutions are identified in the text where used, except for the following: 
a) 5X ONA Loading Buffer: 500 grlL Sucrose, 240 gr/L Urea, 500 mIlL lOX TBE, 
1 % 10-20 mllL 1 % wlv Bromophenolo blue in H20. 
b) 50X Oenhardts Solution: 5 gr Ficoll (Type 400, Pharmacia), 5 gr 
Polyvinylpyrrolidone, 5 gr Bovine Serum Albumin (BSA) and H20 to 500 ml. 
Filtered and stored at -20°C. 
c) 20X SSPE: 3M NaCl, 0.2M NaH2P04, 0.02M EDT A. pH adjusted to 7.4 with 
NaOH. 
d) 20X SSC: 3M NaCl, 0.3M Na3Citrate. pH adjusted to 7.0 with HC!. 
e) lOX TBE: 108 grlL Tris, 55 grlL Boric acid, 9.5 gr/L EOT A. 
t) IX PBS: 137 mM NaCl, 2.7 mM KCI, 10 mM Na2HP04, 1.8 mM KH2P04 (pH7.4). 
g) lOX Protein Loading Buffer: 20% w/v SOS, 1M OTT, 0.63 M Tris pH 7,0.2% wlv 
Bromophenol blue, 12% w/v sucrose, 10 mM EOT A pH 7. 
h) 5X Running Buffer for SOS-PAGE: 30 grlL Tris base, 144 gr/L Glycine, 5 gr/L 
SOS. 
i) lOX Protein Blotting Buffer: 30 grlL Tris base, 144 gr/L Glycine. 
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2.1.2 Radioactive isotopes. 
[a)2P]-dCTP isotope was purchased from Amersham Biosciences and used to label 
the probe for the Southern blot experiments. 35S-Methionine and 35S-Cysteine isotopes 
(ProMix, Amersham Biosciences) were used for the in vivo labeling of cultured 
hepatocytes. 
2.2 GENERATION OF THE GENETICALLY MODIFIED MICE. 
The generation and genetic background of the mice devoid of regulated splicing at 
the EOA exon (EOA +1+ and EOA-I-) has been previously described by Muro at al. (Muro et 
al., 2003), see also the introduction section of this thesis. EOA-I- and EOA +1+ mice have 
been backcrossed > 6 generations onto a C57BlI6 background. The liver-specific EOA-null 
mice (EOA +I+CRE) were generated by crossbreeding the floxed EOA +1+ mice, which have 
two 10xP sites in the introns flanking the EOA exon, with the transgenic strain Tg Alf 
pCRE, which has the CRE recombinase gene under the control of the albumin promoter 
and enhancer (Kellendonk et al., 2000). The heterozygous mice having the CRE 
recombinase (EOA wtl+CRE) were mated with EOA +1+ animals in order to obtain the 
homozygous EOA +1+ strain with the CRE transgene (EOA +I+CRE). These strains express the 
CRE recombinase exclusively in hepatocytes. All murine strains (C57BLl6 control mice, 
EOA+I+, EOA/-, EOA wtI+, EOA wtI+CRE, EOA+I+cRE and Tg AlfpCRE mice) were bred at the 
International Centre for Genetic Engineering and Biotechnology animal house, and housed 
in rooms at 25°C with 12 hr light/dark cycles. Mice were fed with standard food and water 
ad libitum. In all experiments, mice were males and age-matched (2/4-month-old), except 
in the CCl4 mortality experiment in which both males and females were used, or 
specifically indicated in the text. 
2.3 PREPARATION OF HEPATOCYTE PRIMARY CULTURE. 
f EOAwtlwt EOA+I+ E -1- +I+CRE Hepatocytes rom , ,OA and EOA whole livers were 
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purified by the two-step collagenase perfusion method (Seglen, 1976) using Liver Digest 
Medium (Gibco) as described by manufacturers. About 1.3 x 106 hepatocytes per each 
genotype were plated in 1% rat-tail collagen-containing 60 mm Petri's dishes and 
incubated at 37°C with 5 ml of culture medium (Dulbecco's Modified Eagle Medium 
supplemented with 10% fetal bovine serum, Gibco) until use for RNA and protein 
extraction or in vivo labelling. 
2.4 NUCLEIC ACID ANALYSIS. 
2.4.1 Genomic DNA extraction from organs. 
Organ biopsies were digested overnight (OIN) with 600 ~l of Lysis Buffer (50 mM 
Tris pH S.O, 100 mM EDT A pHS, 0.5% SDS, 200 ~g/ml Proteinase K by Boehringer 
Mannheim), in a water bath at 58°C (Laird et aI., 1991). The mix was then centrifuged for 
15 min at 14000 rpm. 500 ~l of supernatants were recovered and added to 500 ~l of 
isopropanol to allow DNA precipitation, by tube invertion. The DNA pellets were washed 
with SO% ethanol, resuspended in 200 ~l ofTE Buffer (10 mM Tris pH 7.4, 0.1 mM pH 8) 
prewarmed at 65°C, left OIN at 37°C to facilitate the dissolution, and quantitated by 
measuring the absorbance at 260 nm and 2S0 run with a spectrophotometer (Jenway 
Genova). The DNA integrity was checked by electrophoresis on 1 % w/v agarose gel and 
stored at 4°C until use either for PCRs or Southern blot analysis. 
2.4.2 Polymerase Chain Reaction (PCR) for genotyping. 
The genotype of mice was determined by PCR analysis of DNA samples from tail 
biopsies (0.5-0.S cm). The reaction was performed in a final volume of 50 ~l with 250-500 
ng of genomic DNA, IX Taq Buffer, dNTP mix (200 ~M each, final concentration), 
appropriate sense and anti-sense oligonucleotide primers (15 ~M each, final concentration) 
and 2.5-5 U of Taq DNA polymerase (BioLabs). For the amplification of the CRE-
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transgene the following pnmers were used: Forward pnmer 5' -
CGAGTGATGAGGTTCGCAAG-3 ' ; Reverse pnmer 5' -
TGAGTGAACGAACCTGGTCG-3 ' . Conditions for PCR were: cycle (initial 
denaturation step at 95°C for 2 min), 45 cycles (denaturation step at 95°C for 30 sec; 
annealing step at 58°C for 30 sec; extension step at n oc for I min), 1 cycle (final 
extension step at n oc for 10 min). The amplified fragment was 390 bp long. To amplify 
the EDA exon, primers pairing into the EOA-flanking introns were used : Forward primer 
5'_CTTCAGGGTGTCTACATAC-3'; Reverse primer 5'-ACCGAGGTGTCT A TT G-
3'. Conditions for PCR were: 1 cycle (initial denaturation step at 95° for 2 min), 30 
cycles (denaturation at 95°C for 30 sec; annealing step at 54°C for 30 ec' extension t pat 
720C for I min), I cycle (final extension step at n oc for 10 min). The amplified fragm nts 
were: EOA \\1 band 860 bp; EDA + band, 1152 bp; EDA - band, 350 bp (Figure 12). All P R 
products (115 of the PCR volume) were separated in a 1 % w/v agarose gel prestained with 
ethidium bromide and verification of the correct size was done by visualization of their 
migration relative to the molecular weight standards. 
1152 bp ~ 
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350 bp ~ 
EDA~ ' allele 
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Lox P Loxr 
---c:D _. • _ [±IJI---
• • 
11 52 bp 
EDA- allfJ e 
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Figure 12. PCR-genotyping for the EDA exon. 
PCR analysis was performed using DNA samples from tail biopsis. To amplified the 
EDA exon, primers (green arrows) pairing into the ED -flanking introns were used. 
1152 bp-band, EOA-floxed allele' 860 bp-band, WT allele; 350 bp-band, EDA-null 
allele. 
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2.4.3 Southern blot analysis. 
DNA was extracted from tissues as described above. IS-20 J.lg of DNA were 
digested OIN at 37°C in a final volume of 400 ~l with 1 X NEBuffer 2 and 200 U of the 
restriction enzyme Hind III (BioLabs). The DNA was than precipitated (111 0 volume of 
3M Sodium Acetate pH S.3, 2 volumes of 100% Ethanol) washed in 70% Ethanol, 
resuspended in 40-S0 ~l of IX DNA Loading Buffer, and run OIN at 20 V in a 0.8% (w/v) 
agarose gel. The gel was then soaked in the Denaturing Solution (O.SM NaOH, I.SM 
NaCl) for IS min with slight agitation (two times) at room temperature (RT). The DNA 
was blotted for 16 hrs onto a Z-Probe nylon membrane (Bio-Rad) by capillary blotting 
using the denaturing solution. Next, the membrane was neutralized with 1 M Tris pH 8.0 
and I.5M NaCI by incubating at RT for IS min (two times), dried, UV crosslinked, and 
prehybridized in a minimum amount of Hybridization Solution (6X SSPE, lOX Denhardt's 
Solution, 2% SDS, 200 ~g/ml of denatured Salmon Sperm) for 2-3 hrs at 6SoC. The 
radioactive labeled DNA probe (see below) was denatured at 9SoC for S min, quickly 
chilled on ice, and then added to the hybridization solution. The hybridization reaction was 
performed OIN at 6S°C. The membrane was then subjected to successive washes of 10-IS 
min each, each wash repeated two times: at RT in 2X SSC, O.S% SDS; at 6SOC in IX SSC, 
0.2% SDS, then in O.SX SSC 0.1% SDS, and in O.IX SSC, 0.1 SDS. The membrane was 
next covered with a plastic wrap and exposed OIN at -80°C using BIOMAX MS films 
with the help of the BIOMAX MS intensifying screen (Kodak). Digestion with HindIII 
generated in heterozygous EDA wt/+CRE three fragments: a EDA wI band of 4.0 kb, a EDA + 
band of 2.7 kb and, only in liver, an additional EDA- band of 2 kb (Figure 19A); in 
homozygous EDA+1+ two fragments: the EDA+ band of 2.7 kb and, only in liver, the 
additional EDA - band of 2 kb (Figure 19B). 
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2.4.4 Hybridization probe. 
A DNA fragment corresponding to the exon downstream to the EDA exon was 
used as a probe for the Southern blot analysis (Muro et aI., 2003). 50 ng of DNA were 
radioactive labeled with [a)2p] dCTP isotope by the random priming method using the 
oligolabelling kit (Amersham Biosciences) and then purified from unincorporated 
nucleotides by passing the probe mixture through a Nick column (Amersham Biosciences). 
Both the labeling and the probe purification were carried out according to the 
manufacturers' instructions. 
2.4.5 Isolation of total RNA from organs. 
Total RNA was prepared from tissues by the Guanidinium Thiocyanate method 
(Chomczynski and Sacchi, 1987). Organs were removed, quickly frozen in liquid nitrogen 
and stored at -80DC until use. Then, 8 ml of ice-cold Solution D (4M Guanidine 
Thiocynate, 25 mM Sodium Citrate, 100 mM (3-Mercaptoethanol, 0.5% w/v 
Lauroylsarcosine) was added to organs and completely homogenized in series of 20 sec by 
using the UTRA-TURRAX T-25 Basic homogenizer (Ika-Werke). To the homogenate, 0.8 
ml of 2M Sodium Acetate pH 4, 8 ml of Phenol (saturated with water) and 1.6 ml of 
Chloroform were then added. The whole mix was vortexed, kept on ice for 15 min and 
centrifuged in a 581O-R rotor (Eppendorf) at 3500 rpm for 20 min (4DC). The aqueous 
phase was then separated and subjected to a second phenol-chloroform extraction to 
improve the sample purification from proteins and fatty acids. The RNA was precipitated 
by addition of one volume of Isopropanol, kept for one hour at _20DC and centrifuged in a 
5415-D rotor (Eppendorf) at 14000 rpm for 15 min (4DC). RNA pellets were washed once 
in ice-cold 70% Ethanol, resuspended in 200-400 III of DE PC-treated ddH20, separated in 
aliquots frozen immediately in dry-ice, and kept at -80DC until use. RNA integrity was 
confirmed by running the samples on 1 % w/v agarose gel with 7% formaldehyde and 
quantitated by measuring absorbance at 260 run and 280 run with a spectrophotometer 
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(Jenway Genova). 
2.4.6 Isolation of total RNA from cultured hepatocytes. 
To a 60 mm Petri dish containing -1.3 x 106 cells was added 1.6 ml of Solution D 
(4M Guanidine Thiocynate, 25 mM Sodium Citrate, 100 mM f3-Mercaptoethanol, 0.5% 
w/v Lauroylsarcosine), 1.6 ml of Phenol (saturated in H20) and 160 III of 2M Sodium 
Acetate pH 4, following removal of the culture medium and two washes in cold 1 X PBS. 
Lysis was carried out by shaking for 15 min at 4°C. To the lysate was added 1110 volume 
of Chloroform, and the mix was then vortexed, incubated for 15 min on ice, and 
centrifuged at 14000 rpm for 15 min (4°C). The aqueous phase was separated, added of 
one volume of Phenol (saturated in H20) and Y4 volume of Chloroform, reincubated on ice 
and recentrifuged. The supernatant was added of one volume of ice-cold Isopropanol, left 
for one hour at -20°C and centrifuged. The pellet was then washed with 70% Ethanol and 
resuspended in 50-100 III of DEPC-treated ddH20. RNA integrity was confirmed by 
running the samples on 1 % agarose gel with 7% formaldehyde and quantitated by 
measuring absorbance at 260 nm and 280 nm with a spectrophotometer (Jenway Genova). 
2.4.7 FN cDNA synthesis and RT -peR for the EDA exon. 
To synthesize FN eDNA, 1-2 Ilg of total RNA were used in the following 20 III 
reaction: 1 III of random primers (hexanucleotides, 200 ng/IlI), 1 III of dNTP mix (100 
mM), 4 III of RT buffer (5X), 2 III of 0.1 M DTT (10X), 1 III of RNAsin (40 U/Ill) and 50 
units of M-ML V reverse transcriptase (RT) (Invitrogen). The reaction was incubated for 
one hour at 37°C. Following RT reaction, the PCR reaction was carried out in a final 
volume of 50 III with 1-2 III of the RT reaction (cDNA), IX Taq buffer, dNTP mix (200 
IlM each, final concentration), FN-EDA forward (5'-
ACCATCACCCTGTATGCTGTCACT3') and reverse (5'-
ATGAGTCCTGACACAATCAC-3') oligonucleotide primers (2 ng/Ill each, final 
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concentration) pairing in the two exons flanking the EDA, and 2.5 U of Taq DNA 
polymerase (Eppendorf). Conditions for PCR were: I cycle (initial denaturation step at 
95°C for 2 min), 35 cycles (denaturation step at 95°C for 30 sec; annealing step at 58°C for 
30 sec; extension step at 68°C for I min), I cycle (final extension step at 68°C for 10 min). 
The amplified fragments were: EDA+ band, 805 bp; EDA- band, 535 bp (Figure 20A and 
29). The PCR products (115 of the PCR volume) were separated in a 1 % w/v agarose gel 
prestained with ethidium bromide and verification of the correct size was done by 
visualization of their migration relative to the molecular weight standards. 
2.4.8 Agarose gel for nucleic acid routine screening electrophoresis. 
All agarose gels were prepared dissolving the right weight of agarose (EuroClone) 
in I X TBE Buffer and heating in a microwave oven (DeLonghi). All DNA samples were 
diluted in IX DNA Loading Buffer, loaded into the gels prestained with ethidium bromide 
(1:20000) and run in IX TBE Buffer at 80-100V according to the gel size. The DNA bands 
were sized by confront to the molecular weight standards (1 kb DNA ladder, Invitrogen). 
2.S PROTEIN ANALYSIS. 
2.S.1 Plasma and bile fluid preparation. 
Blood was drawn by puncture of the internal maxillary artery from EDA wtlwt, 
EDA +/+, EDA-1-, EDA wtI+, EDA wtI+CRE, EDA +/+CRE mice of different ages, from 6 day- to 30 
month-old. A quantity of 200-300 ~l of blood was mix with 2-3 ~l of 0.5M EDT A pH 8, 
centrifuged at 4000 rpm for 15 min (RT), to separate the cell component from plasma. 
Plasma was then recovered, recentrifugated and stored at -80°C until use. The I8.5-day 
post-coitus (PC) and I-day blood was pooled from 6-7 EDA wtlwt and EDA +1+ embryos and 
newborns, respectively. Bile fluid was drawn directly from the gallbladder of EDA wtlwt and 
EDA +/+ mice, following laparatomy. The whole content of bile was recovered by means of 
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a 0.5 ml insulin syringe (BO MICRO-FINE +), holding the gallbladder with forceps. 
2.5.2 In vivo labelling of cultured hepatocytes. 
About 1.3 x 106 EOA wtlw., EOA +1+ and EOA-I- hepatocytes were plated in 60 mm 
1 % rat-tail collagen-containing Petri dishes and incubated for 1 h at 37°C with 5 ml of 
culture medium (Dulbecco' s Modified Eagle Medium supplemented with 10% fetal bovine 
serum, Gibco). Next, cells were incubated immediately, after 24 and 48 hrs with 1.5 ml 
Methionine/Cysteine free culture medium (DMEM -Met/-Cys, Gibco) supplemented with 
300 "",Ci/ml of 35S-Methionine/35S-Cysteine (ProMix, Amersham) for additional 24 hrs, 
following removal of the former medium. The conditional media were then collected and a 
fraction of 500 "",I was affinity-purified with Gelatin-Sepharose as described (Owens and 
Baralle, 1986) (Ruoslahti et aI., 1982). Next, 40 "",I of the conditional media and 25 "",I of 
the affinity-purified eluted of each sample were run in a 6% SOS-PAGE. Gels were then 
fixed in 10% glacial acetic acid, 25% methanol, 65% H20, dried by the use of a gel-dryer 
(Bio-Rad) and autoradiographed OIN using BIOMAX MR films (Kodak) at RT. 
2.5.3 Total protein extract from cultured hepatocytes. 
To a 60 mm Petri dish containing - 1.3 x 106 hepatocytes was added 100 "",I of 
Protein Lysis Buffer (150 mM NaCl, 50 mM Tris pH 8, 1 % NP-40, protease inhibitors by 
Roche). The lysate, after mild shaking, was collected by the use of a cell scraper, sonicated 
three times for 10 sec by the Soniprep-150 sonicator (Cellai) at the maximum power, and 
centrifuged for 15 min at 14000 rpm at 4°C. The supernatant was then separated, aliquoted 
and stored at -80°C until use. 
2.5.4 Total protein extracts from tissues. 
Mice used for the study of the origin of the tissue FN (EDA Wtlw" EOA +1+, 
EDA+I+CRE) were firstly perfused with 25 ml of cold IX PBS through the left ventricle of 
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the heart, following anesthetizing with 2.5% Avertin (15 III per gram of body weight). 
Normally, all organs were immediately dissected from animals and snap-frozen in liquid 
nitrogen until use. All tissues were homogenized in 2 ml of Protein Lysis Buffer (150 mM 
NaCl, 50 mM Tris pH 8, 1 % NP-40, protease inhibitors by Roche), whereas fibrotic livers 
and controls were homogenized in 0.5% Sodium Deoxycholate, 0.1 % SDS, and protease 
inhibitors by Roche. Homogenization was carried out in series of 20 sec by using the 
UTRA-TURRAX T-25 basic homogenizer (lka-Werke) and the homogenates were next 
sonicated two times for 15 sec by the Soniprep-150 sonicator (Cellai) at the maximum 
power, and centrifuged in a 5415-D rotor (Eppendorf) at 14000 rpm for 15 min. The liquid 
phase was separated and recentrifiged always at 4°C. Samples were then ali quoted and 
stored at -80°C until use. Protein sample concentration was determined by Bradford assay 
(Bio-Rad Protein Assay). 
2.5.5 Sodium Dodecyl Sulfate-PolyAcrylamide Gel Electrophoresis (SDS-P AG E). 
Proteins were separated running 20 to 150 Ilg of tissue or cellular samples or 0.2 III 
of plasma or 2 III of bile on a polyacrylamide gels. Proteins were mixed with 2X Protein 
Loading Buffer, denatured for 5 min at 95°C, ice-cooled and then loaded into the gels. The 
electrophoretic run was performed at 25-30 rnA for 4-5 hrs using IX Running Buffer for 
SDS-PAGE. 6% SDS-PAGEs were performed to visualize both pFN and cFN (- 220 kDa). 
10 % SDS-PAGEs were done to visualize vitronectin (VN, - 75 kDa), and 12 % SDS-
PAGEs for p-Tubulin (- 55 kDa), smooth muscle a-actin (aSMA, 45 kDa) and IgG 
(heavy chain - 58 kDa, light chain - 28 kDa). Solutions used for preparing the 5% 
stacking gels were: 30% acrylamide mix (Ultra pure Protogel, National Diagnostics) 
diluted 1 :6, 12 volume of 0.5M Tris pH 6.8, 0.1 % SDS, 0.1 % Ammonium persulfate, 
IIll/ml TEMED. Solutions used for preparing the running gels were: the right volume of 
30% acrylamide mix, 12 volume of 1.5M Tris pH 8.8, 0.1 % SDS, 0.1 % Ammonium 
persulfate, 11l1/ml TEMED. 
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2.5.6 Western blot analysis. 
Following electrophoresis, separated proteins were Coomassie-blue stained (see 
below) or blotted onto nitrocellulose membranes (Hybond-C Extra, Amersham Bioscience) 
at 200 rnA for 2 hrs using IX Protein Blotting Buffer supplemented with Methanol at 5, 10 
or 20%. Next, membranes were blocked in 5-10% milk in IX PBS for 1 hr at RT or OIN at 
4°C, stained with the primary antibody, washed 3 times for 5 min in 0.2-0.5% Tween-20 
or Triton X-IOO (Sigma) in IX PBS, stained with a polyclonal horseradish-peroxidase-
conjugated (HRP)-antibody (Dako Cytomation, 1 :2000) directed against mouse, rabbit or 
goat Immunoglobulins (lgG) for 1 hr at RT, and washed again. A chemiluminescent 
reaction, generated by adding 3-4 ml of a chemiluminescent ECL-substrate (PIERCE) to 
the membrane, was used to impress films (Hyperfilm-ECL, Amersham Biosciences). Serial 
ECL expositions of the membranes were performed to determine the optimum linear range 
to quantify the signals. Films were then scanned with the Versadoc scanner (Bio-Rad) and 
quantified with the help of the Quantity One software package (Bio-Rad). Normally, two 
or three animals per genotype (EDA wtlw., EDA +1+ EDA-1- EOA wtl+, EDA wtl+CRE and 
EDA +I+CRE) were analyzed. 
2.5.7 Western blot conditions for the total FN detection in tissues, plasma and bile 
fluid. 
To perform the 6% SOS-PAGE, 50 !-,g of tissue or cellular protein extract, 0.2 !-,l of 
plasma and 2 !-,l of bile were used. The gel blotting was done in presence of 5% methanol 
and the membrane blocking was done in 5% milk. The primary antibody was an anti-total 
FN polyclonal antibody developed in goat (Sigma), used diluted 1 :2000 in 1 % BSA, 0.2% 
Tween-20, IX PBS for one hour at RT. The secondary antibody was an anti-goat IgG 
HRP-antibody (Oako), used diluted 1 :2000 in 1 % BSA, 0.2% Tween-20, 1 X PBS for one 
hour at RT. Washes were performed in 0.2% Tween-20. The tissues analyzed were 
perfused liver, brain, lung, heart and testis. 
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2.5.8 Western blot conditions for EDA+FN detection in plasma and tissues. 
To perform the 6% SDS-PAOE, 150 ~g of tissue protein extract and 2.5 1-1-1 of 
plasma were used. The gel blotting was done in presence of 5% methanol. The membrane 
blocking was done in 5% milk, followed by antigen unmasking by soaking the membrane 
in 6 M urea for 2 min in a microwave oven at half power. The primary antibody was an 
anti FN-EDA monoclonal antibody developed in mouse (Clone FN-3E2, Sigma), used 
diluted 1 :300 in IX PBS OIN at 4°C. The secondary antibody was an anti-mouse IgO 
HRP-antibody (Dako), used diluted 1 :2000 in IX PBS for one hour at RT. Washes were 
performed in IX PBS. The tissues analyzed were perfused liver, brain, lung and testis. 
2.5.9 Western blot conditions for VN detection in plasma and liver. 
To perform the 10% SDS-PAOE, 50 ~g of liver protein extract and 0.2 IAI of 
plasma were used. The gel blotting was done in presence of 10% methanol; the membrane 
blocking was done in 5% milk. The primary antibody was an anti-total VN polyclonal 
antibody developed in rabbit (kindly provided by D. Seiffert, Scripps Research Institute, 
(Zheng et aI., 1995)), used diluted 1:2000 in 0.5% Tween-20, IX PBS for one hour at RT. 
The secondary antibody was an anti-rabbit IgO HRP-antibody (Dako), used diluted 1 :2000 
in 0.5% Tween-20, IX PBS for one hour at RT. Washes were performed in 0.5% Tween-
20. Membrane was then stripped and analyzed for the ~-Tubulin (see below). 
2.5.10 Western blot conditions for aSMA detection in liver. 
To perform the 12% SDS-PAOE, 60 I-I-g of tissue protein extract were used. The gel 
blotting was done in presence of 20% methanol; the membrane blocking was done in 10% 
milk. The primary antibody was an anti-aSMA monoclonal antibody developed in mouse 
(clone lA4, Dako), used diluted 1:500 in 5% BSA, 0.2% Triton X-IOO, IX PBS for 6 hrs 
at RT. The secondary antibody was an anti-mouse IgO HRP-antibody (Dako), used diluted 
1:2000 in 5% BSA, 0.2% Triton X-IOO, IX PBS for one hour at RT. Washes were 
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performed in 0.2% Triton X-I00. 
2.5.11 Western blot condition for IgG detection in liver and brain. 
To determine the efficiency of perfusion and elimination of plasma proteins in each 
of the organs analyzed, a Western blot analysis of protein extract from liver and brain was 
performed using an anti-mouse IgG polyclonal HRP-antibody (Dako) as unique antibody. 
50 ~g of protein were run in a 12% SDS-PAGE. The gel blotting was done in presence of 
20% methanol; the membrane blocking was done in 5% milk. The antibody was used 
diluted 1 :2000 in 0.2% Tween-20, IX PBS for one hour at RT. Washes were performed in 
0.2% Tween-20. Membrane was then stripped and analyzed for the ~-Tubulin (see below). 
2.5.12 Western blot conditions for ~-Tubulin detection in tissues. 
To normalize the protein loads, 20 !lg of protein from the same tissue extracts were 
run in a 12% SDS-PAGE. The gel blotting was done in presence of 20% methanol; the 
membrane blocking was done in 10% milk. The primary antibody was an anti ~-Tubulin 
monoclonal antibody (Developmental Studies Hybridoma Bank, University of Iowa, E7), 
used diluted 1 :3000 in 5% BSA, 0.2% Triton X-IOO, IX PBS for one hour at RT. The 
secondary antibody was an anti-mouse IgG HRP-antibody (Dako), used diluted 1 :2000 in 
5% BSA, 0.2% Triton X-IOO, IX PBS for one hour at RT. Washes were performed in 
0.2% Triton X-I 00. The tissues analyzed were liver, brain, lung, heart and testis. When the 
~_ Tubulin analysis was done by stripping of the membrane, were used the same antibody 
dilution buffers and washes of the primary antibody. 
2.5.13 Stripping ofthe membranes. 
Stripping was performed by soaking membranes in 200 ml of 2% SDS, 65.5 mM 
Tris pH 6.8 supplemented with 1.4 ml of ~-Mercaptoethanol and incubation at 65°C for 45 
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min. After two washes in 1 X PBS for 15 min and blocking in milk, membranes were 
stained with a different antibody. 
2.5.14 Coomassie blue staining. 
Following 10% SDS-PAGE, gels were soaked O/N in Coomassie Staining Solution 
(0.2% w/v Coomassie brilliant blue R, 10% glacial acetic acid, 40% methanol, 50% H20) 
and destained in 10% glacial acetic acid, 25% methanol, 65% H20 until appearance of the 
bands. 
2.5.15 Hydroxyproline assay. 
Total collagen content was measured in fibrotic livers and controls via a 
conventional hydroxyproline assay (Bergman and Loxley, 1970). Briefly, the technique 
consists in the quantification of the hydroxyproline content of the collagen. 
Hydroxyproline is a very rare amino acid but it is particularly abundant in the collagen 
protein (14% of the total amino acid amount) and in a few other proteins. Experimental 
results were quantitated by comparison to a standard curve of known linear hydroxyproline 
(cis-4-Hydroxy-I-proline, Sigma) concentrations (from 200 I-lg/ml to 6.25 I-lg/ml) in 6N 
HCI solution. The whole liver was weighted, added to distilled H20 to a final 
concentration of 400 mg/ml and homogenized. One ml of the homogenate was then added 
to 1 ml of 12N HCI (37%). Two 1 ml glass-vials (Sigma) were filled up with 500 I-li of the 
acid mix, sealed with the help of a portable Bunsen's burner and baked at 120°C for 24 hrs 
in order to hydrolyze the proteins and release amino acids. Next, the amino acid mix was 
centrifuged in order to remove the burnt particles. In a 96 well plate, the following reaction 
was performed: to 5 I-li of each amino acid sample and standard (in triplicate) was added 5 
I-li of Citrate-Acetate Buffer pH 6 (5% Citric acid, 1.2% Glacial Acetic acid, 7.24% 
Sodium Acetate, 3.4% Sodium Hydroxide, in H20) and 100 I-li of Chloramine T solution 
(0.282 gr Chloramine T by Aldrich dissolved in 2 ml N-Propanol, 2 ml H20, 16 ml Citrate-
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Acetate Buffer, and heated in water bath at 37°C until completely clear) to oxidate the 
hydroxypolines to pyrroles. Following incubation at RT for 30 min, 100 fAI of hrlich's 
solution (2.5 gr Ehrlich 's reagent [4-(Dimethylamino) benzaldehyde] by igma di sso lved 
in 9.3 ml N-Propanol, 3.9 ml 70% Perchloric acid) was added to each well . The plate was 
next incubated at 65°C for 30 min to condensate the pyrroles to a red dye tuff. The 
concentration of the red dyestuff was evaluated by reading the plate at 540 nm in a plate-
reader (SpectraCount, PACKARD). 
2.6 EXPERIMENTAL MODELS FOR LIVER FIBROSIS. 
Liver injury was induced either by Carbon Tetrachloride ( 14) administration a 
described (Constandinou et aI., 2005) or by bile duct ligation (BDL) as described (Xia et 
al., 2006). At the indicated time (see below) animals were sacrificed, livers were exci ed 
and samples of the same portion of the left lobe were taken for RNA, protein and 
histological analysis (Figure 13). 
Gall bladder --f-i--- -r 
'T----F-~----.:;~-Left adrenal 
Righi kidney~--r-,.tf-
-t--~~------Infertor v no cava 
Figure 13. Schematic view of the mouse abdominal surface of the liver. 
The left lobe was excised and the upper part was used for RNA extraction the 
central part was fixed in 4% formaldehyde, the lower part was used for protein 
extraction. 
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2.6.1 Carbon Tetrachloride (Celt) intraperitoneal administration. 
A chronic liver injury was induced in mice by intraperitoneal (lP) administration of 
CCI4. All mice were 2/4-month-old male and age-mated. 8-10 animals were used for each 
genotype (EDA wtlwt, EDA +1+ and EDA"IO) in each experiment. CCl4 (Fluka) was diluted 1:4 
(v/v) in mineral oil (Sigma) used as toxin vehicle. The mix was IP injected by a 0.5 ml 
insulin syringe (BD MICRO-FINE +) twice a week. Control mice were treated with 
mineral oil alone. A low- and middle-CCl4 dose of 0.5 and 1.0 ,.d/gr of body weight, 
respectively, was administrated for a period of 5 weeks, whereas a high- and very high-
CCl4 dose of 1.5 and 2.0 f.ll/gr of body weight, respectively, was administrated for a period 
of 6 weeks. Following the intoxication period, mice were sacrificed three days after the last 
injection. For the CCl4 surviving curve a total number of 30 animals per genotype 
(EDA wtlwt and EDAOlo), 15 for each sex were IP injected with 2.0 ,.d/gr of body weight of 
CCI4. The number of survivors was daily graph reported. 
2.6.2 Bile duct ligation (BDL). 
Two-month-old male mice, 8-10 animals per genotype (EDA wtlwt and EDA"IO) and 
each BDL-period, were anesthetized with 15 illIg of body weight of 2.5% Avertin and the 
common bile duct was double ligated using 5-0 Ethicon surgical suture and cut in between 
the stitches, after laparotomy. Sham-operated mice had their common bile duct exposed 
and manipulated but not ligated. Animals were sacrificed 7, 14 and 18 days after ligation 
of the duct. In a trial experiment, we injected 0.5% Evan's blue through the gall bladder to 
detect the position of the bile duct (Figure 14). The bile duct is the one that connects the 
gall bladder to the duodenum, in which the bile fluid is poured. 
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A 
B 
-+- ---Gall bladder 
Cystic duct - --------->o.oc--H 
Cammon bile duct------~I-I 
r------Duodenum 
Figure 14. Mouse gall bladder and bile-duct. 
A. The whole bile duct was identified by injection of 0.5% Evan' s blue through the 
gall bladder. The common bile duct was double ligated with surgical suture and cut in 
between the stitches. B. chematic representation of the of the upper real image. The 
bile duct connects the gall bladder to the duodenum. L, liver lobes; GB, galJ bladder; 
CD, cystic duct; CBD, common bile duct ; D, duodenum. 
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2.7 HISTOLOGICAL ANALYSIS. 
2.7.1 Immunohistochemistry of tissue sections. 
Organs were fixed OIN in 4% formaldehyde, IX PBS and then paraffin embedded. 
Four 11m sections of each tissue (liver, brain and testis) were cut by the use of a microtome 
(MICROM HM 400) and dried at 37°C for 24 hrs on microscope slides (SuperFrostiPlus, 
Kaltek). Each section was then deparaffined by soaking of the slides in Xylene (Aldrich) 
for 15 min (two times) and hydrated by the following alcohol scale: 2 washes in 100% 
ethanol for 5 min, 1 wash in 95%, 80%, 70%, and 50% ethanol for 5 min, and 2 washes in 
ddH20 for 5 min. Hydrated sections were then stained for the following proteins: total FN, 
aSMA and collagen, accordingly the following protocols: 
2.7.2 Anti-total FN staining of the sections. 
Following an additional wash in IX PBS for 5 min, sections for FN staining were: 
i) permeabilized in 0.5% Triton X-IOO (Sigma) in IX PBS at RT for 10 min, and washed 
two times in IX PBS and one time in ddH20 for 5 min; ii) treated in 0.4% w/v Pepsin 
(Sigma) and O.OIN HCl in ddH20 at 37°C for 30 min, to unmask the epitopes, washed in 
cold running tap water for 10 min and in ddH20 for 5 min; iii) treated with 3% H202 in 
methanol at RT for 15 min, to block the endogenous peroxidases, washed in cold running 
tap water for 5 min and three times in IX PBS for 5 min; iiii} blocked with 3% BSA and 
1 % Normal Goat Serum (NGS, Dako) in 1 X PBS at RT for one hour (l00-200 III of mix 
for each section). Incubation with the primary antibody was performed OIN at 4°C using 
an affinity-purified anti-FN polyclonal antibody developed in rabbit (Sigma) diluted 1 :200 
in 3% BSA, 1 X PBS (100-200 III of mix for each section), following blocking-buffer 
removal by slide inversion. Slides were then washed in 0.05% Tween-20 (Sigma), 1 X PBS 
three times for 5 min. Incubation with the secondary antibody was performed for one hour 
at RT using a biotinylated anti-rabbit IgG developed in goat (Vector) diluted to a final 
72 
concentration of 5 ~g/ml in 3% BSA, 2% NGS in IX PBS (100-200 ~l of mix for each 
section). Slides were then washed in 0.05% Tween-20, IX PBS three times for 5 min. 
Incubation with the biotinylated secondary antibody was followed by incubation with a 
preformed Avidin and Biotinylated Horseradish Peroxidase macromolecular complex (1-2 
drops of R.T.U. ABC reagent for each section, Vector) for one hour at RT. Slides were 
then washed in 0.05% Tween-20, IX PBS three times for 5 min. As a peroxidase substrate 
the DAB substrate mix (Vector) was used. Incubation was done with 100-200 ~l of DAB 
mix for each section for 4 min, followed by one wash in cold running tap water and one in 
ddH20 for 5 min. Sections were then stained for 2 min in Gill's Hematoxylin (Vector), 
washed with cold running tap water and ddH20 for 5 min, dehydrated repeating the alcohol 
scale but up-side-down, up to the xilene. Each slide was mount with a micro cover glass 
(Prestige) using Eukitt quick-hardening mounting medium (Fluka). A Leica DM LA 
microscope was used to visualize and photograph the sections. 
2.7.3 Anti-a SMA staining of the liver sections. 
Hydrated sections were firstly subjected to antigen unmasking with 10 mM Sodium 
Citrate buffer pH 6 (18 mIlL 0.1 M Citric acid, 82 mIlL 0.1 M Sodium Citrate in H20) for 
20 min at a sub-boiling temperature on a hot stirrer. Slides were then cooled on the bench 
for 20 min. After washing with cold running tap water for 10 min, sections were treated 
with 3% H202 in methanol at RT for 30 min, to block the endogenous peroxidases. After 
washing in cold running tap water for 5 min and three times in 1 X PBS for 5 min, sections 
were blocked with 5% BSA and 5% Normal Goat Serum (NGS, Dako) in IX PBS at RT 
for 2 hrs (I 00-200 ~l of mix for each section). Incubation with the primary antibody was 
performed for one hour at RT using anti-a SMA monoclonal antibody developed in mouse 
(clone 1 A4, Dako) diluted I :80 in 5% BSA, I X PBS (100-200 I-li of mix for each section), 
following blocking buffer removal by slide inversion. Slides were then washed in 0.2% 
Tween-20 (Sigma), IX PBS three times for 5 min. Incubation with the secondary antibody 
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was performed for one hour at RT using a biotinylated anti-mouse IgG developed in goat 
(Vector) diluted to a final concentration of 2.5 Ilglml in 5% BSA, 5% NGS, 2% Normal 
Mouse Serum in IX PBS (100-200 III of mix for each section). Slides were then washed in 
0.2% Tween-20, IX PBS three times for 5 min. Incubation with the biotinylated secondary 
antibody was followed by incubation with a preformed A vidin and Biotinylated 
Horseradish Peroxidase macromolecular complex 0-2 drops of R.T.U. ABC reagent for 
each section, Vector) for 30 min at RT. Slides were then washed in 0.2% Tween-20, IX 
PBS three times for 5 min. As a peroxidase substrate, the DAB substrate mix (Vector) was 
used. Incubation was done with 100-200 III of DAB mix for each section for 10 min, 
followed by one wash in cold running tap water and one in ddH20 for 5 min. Sections 
were next dehydrated repeating the alcohol scale up to the xilene. Each slide was mount 
with a micro cover glass (Prestige) using Eukitt quick-hardening mounting medium 
(Fluka). A Leica DM LA microscope was used to visualize and photograph the sections. 
2.7.4 Trichrome staining of the liver sections. 
Liver sections were subjected to the Gomori's Trichrome staining for collagen 
fibers (Accustain Trichrome Stain Gomori, Sigma-Aldrich) accordingly to the 
manufacturers' protocol. Briefly, slides were soaked in Bouin's Solution (Sigma-
Diagnostics) for 15 min in a water bath at 56°C, to intensify the final coloration of the 
tissue. After cooling on the bench up to RT, slides were washed in cold running tap water 
until removal of the yellow color from the sections and in ddH20 for 5 min. Next, the 
slides were soaked in the working Weigert's Iron Hematoxylin solution for 1.5 min to stain 
nuclei blue-black. Working solution was prepared by mixing 1: 1 the solution A (1 % 
Certified Hematoxylin by Sigma, in ethanol) with the solution B (1.2% w/v Ferric Chloride 
and 1 % v/v Hydrochloric acid). After washing in cold running tap water and in ddH20 for 
5 min, sections were stained by socking the slides in Trichrome Stain AB Solution (Sigma-
Aldrich) for 5min, to stain collagen fibers blue. Next slides were briefly rinsed in ddH20 
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and in 0.5% Acetic acid for 1.5 min to remove the color in excess and to render the shades 
of color more delicate and transparent, respectively. Slides were again rinsed in ddHzO, 
dehydrated through alcohol, cleared in xilene, mounted and photographed as described 
above. 
2.7.5 Immunofluorescence of cultured hepatocytes. 
Purified hepatocytes from EDA wtlwt EDA +/+ livers were plated on 15 mm 1 % rat-tail 
collagen-containing glass disk in a 12 well plate and incubated at 37°C with I ml of culture 
medium (Dulbecco's Modified Eagle Medium supplemented with 10% fetal bovine serum, 
Gibco) for 24 and 48 hrs before staining for total FN. Each disk-containing well was 
emptied out of the culture medium, washed with 1 ml of cold 1 X PBS for two times and 
cells were fixed with I ml of 3% paraformaldeyde at RT for 20 min. After washing with 1 
ml of IX PBS for two times, cells were permeabilized with I ml of 0.5% Triton X-100 
(Sigma) for 5 min, washed, saturated with 1 ml of 0.2% BSA, 20 mM Glycine in IX PBS 
at RT for 30 min, and washed again. Next, each disk was incubated with 20 !AI of affinity-
purified anti-FN polyclonal antibody developed in rabbit (Sigma) diluted I :400 in 0.2% 
BSA, IX PBS at RT for one hour. After 2 washes with I ml of 0.05% Tween X-IOO, IX 
PBS, disks were incubated with 20 !AI of anti-rabbit fluorescein-conjugated 
immunoglobulins (FITC green, DAKOPATTS) diluted 1:80 in 0.2% BSA, IX PBS at RT 
for one hour. After washing, nuclei were stained with I ml of 4',6-diamidino-2-
phenylindole (DAPI blue, Invitrogen) diluted 1:10000 in IX PBS at RT for 5 min 
(Hoetscht staining). After 2 washes in 1 X PBS and one in ddHzO, disks were mounted up-
side-down on microscope slides (SuperFrostiPlus, Kaltek) with the Faramount aqueous 
mounting medium (Dako). A Leica DM LB fluorescent microscope was used to visualize 
and photograph the cells. 
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2.8 STATISTICAL ANALYSIS. 
All bar graphs, the Standard Deviation (SO) and the Student's T-test were drawn 
and calculated, respectively, with the help of Microsoft Excel software. A p-value of 0.05 
was chosen as the limit of statistical significance in the T -test. Quantification of the 
collagen-positive areas (trichrome staining) of liver sections was carried out by counting of 
the pixels of the fibrotic areas with the help of the Adobe Photoshop software. Log-rank 
test statistical analysis was used to evaluate the survival curves (Kaplan-Meier graph). 
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3. RESULTS 
3.1 ORIGIN OF TISSUE FIBRONECTIN. 
3.1.1 Plasma from EDA+/+ mice does not contain normal levels ofpFN. 
We have previously observed that the mouse strain that constitutively include the 
EDA exon of the FN gene (EDA +1+) have a significant decrease of FN in plasma and in 
most tissues (Chauhan et al., 2004; Muro et al., 2003). Further characterization of pFN 
levels of embryos, young and adult EDA +/+ mice showed very low amounts of FN 
compared to EDA wtlwt and EDA-/- mice (Figure 15). Same amounts of plasma proteins were 
run in a 6% SDS-PAGE and blotted onto nitrocellulose. The nitrocellulose membrane was 
subsequently stained with an antibody anti total FN (Figure 15A). Quantification of the 
Western blots revealed that embryos had 60% of the pFN levels of the control samples 
(Figure 158). A further decrease in pFN levels occurred in I-day-old newborns and 7-day-
old EDA +/+ pups. The pFN levels stabilized at 20% of control levels in mice older than 7 
days (Figure 15B). Western blot analysis of the same samples using an EDA-specific 
monoclonal antibody revealed the complete absence of EDA domain in pFN of the 
EDA wtlwt mice at all time points analyzed (Figure 15C). As expected, a positive signal was 
present only in the EDA +1+ samples, confirming the progressive decrease of the pFN levels 
in EDA +1+ blood (Figure 15C) associated with age. 
3.1.2 Liver from EDA +/+ mice contains normal levels of ECM-FN and other 
extracellular matrix (ECM) proteins. 
Next, we examined whether the depletion of pFN from EDA +/+ plasma could be 
correlated to variations of other ECM proteins or FN itself in liver. As previously shown, 
EDA +1+ animals revealed evident decreased levels of FN in almost all EDA +/+ tissues when 
compared to the control mice (Muro et al., 2003). 
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Figure 15. Plasma fro m EDA+/+ mice does not contain norm al levels of pFN. 
A. Western-blot analysis of pFN fro m 18 .5 pc embryos, 1, 6 and 14 day-old babies, 
I , 2.5 and 30 month-old young and adult mice from EDAwt/wt EDA +/+ and DA-/-
an imals. Equal quantities of plasma were separated in a 6% D -PAGE blotted 
onto nitrocellulosa and probed fo r FN with an anti-FN polyclonal antibody, fo llowed 
by chemi luminescence. B. Quantification of the chemiluminescent signal . erial 
EeL expositions of the membranes were p rfo rmed to determine the optimum linear 
range before quantifying the signal . pFN levels are relative to the w ild-type levels 
considered as 100%. C. Western-blot analysis of pFN fro m 18.5 pc embryos 1 6 
b b· f EDA\\ t/\\t +/+ . . ' , and 14 day-old a Ie rom and EDA anImals uSll1g an anti- · DA 
monoclonal antibody. 
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On the contrary, similar levels of ECM-FN in EDA +1+ liver samples were seen (Figure 
16A). No variation was observed in the FN levels of EDA"I- livers. Normalization of 
protein load was done measuring the 13-Tubulin levels in the same extracts. Like FN, 
vitronectin (VN) and fibrinogen are glycoproteins synthesized by hepatocytes and secreted 
into the bloodstream. VN is abundantly present both in plasma and the ECM of the tissues 
(Zheng et aI., 1995). Plasma (Figure 168) and liver (Figure 16C) Western blot analysis, 
using an ant i-VN antibody, revealed no difference in VN content among the three 
genotypes, either in young or old mice. In vitro measurement of fibrinogen concentration 
in plasma also revealed no variation among the three genotypes (Figure 160). Similarly, 
no variation was seen in the liver content of collagen, one of the most important proteins of 
extracellular matrixes, when analyzed by the hydroxyproline assay (Figure 16E). 
3.1.3 Hepatocytes of EDA +1+ mice have normal levels of ECM-FN but do not secrete 
pFN. 
The decrease in pFN was due neither to lower levels of mRNA in EOA +1+ tissues as 
shown by Northern-blot analysis, nor to a reduced FN production by EDA +/+ tissues. 
Fibronectin secreted by embryonic fibroblasts or adult heart fibroblasts was indeed similar 
to that produced by the EDA wt/wt fibroblasts, as shown by Western blot and 
immunofluorescence analyses (Muro et aI., 2003). These results seem to exclude a general 
defect in the FN production by the EDA +/+ tissues. Moreover, specific degradation of FN 
in the EOA +/+ mice by proteases was ruled out by a series of experiments. Matrix 
metalloproteinases (MMPs) are enzymes responsible for remodeling of the extracellular 
matrixes (Nagase et aI., 2006). Consequently, we evaluated the MMPs activity present in 
plasma and tissues. The same amount of plasma and tissue samples from EOA wtlwt, EOA +1+ 
and EOA/- mice was loaded in a gelatin-SOS polyacrylamide gel and the activity of 
metalloproteinases was determined by gelatin zymography analysis. 
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Figure 16. Liver from EDA+1+ mice contains normal levels of ECM-FN and 
other extracellular matrix (ECM) proteins. 
A. Western-blot analysis of ECM-FN of total liver extracts from EDA \v1J\vt ~ DA +1+ 
and EDA/- an imals. Equal quantities of protein were separated in a 6% 0 -PAG , 
blotted onto nitrocellulose and probed for FN with an anti-FN polycJonal antibody 
followed by chemiluminescence. B. and C. Western-blot analysis of vitronectin 
(VN) in plasma (Panel B) and total liver extracts (Panel C) from DAwtlw" DA +/+ 
and EDA-1- young and old animals. Equal quantities of protein were s para ted in a 
12% SDS-PAGE and probed for VN with an anti-VN polycJonal antibody. 
Normalization was done by measurement of the 13-Tubulin levels after tripping of 
the anti-FN and anti-VN membranes. D.ln vitro measurement of fibrinogen levels in 
plasma of the three geneotypes. E. Quantification of liver collagen by 
hydroxyproline (HP) assay. The content of HP is relative to the wild-type levels 
considered as 100%. N = 4 for each genotype. 
VN 
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No variation of the MMP activity was present among EDA wtlwt, EDA +/+ and EDA"/- mice 
(Supplementary Figure 1 in the attached paper). Moreover, recombinant FN fragments, 
containing or not the EDA exon, were in vitro translated in the presence of 3sS-MetlCys 
and incubated for different time (3 and 24 hr) with tissue extracts in the absence of protein 
inhibitors. The recombinant fragments were degraded at the same rate when incubated with 
EDA wtlwt or EDA +/+ liver and brain protein extracts in the absence of protease inhibitors 
(Supplementary Figure 1 in the attached paper). Additionally, no increase in FN 
degradation rate was observed after mixing protein extracts from EDA +/+ or EDA wI/wI liver 
with different organ extracts or plasma from EDA +/+ mice, in the absence of protease 
inhibitors (data not shown). Western blot analysis of tissue extracts utilizing different sets 
of anti-FN polyclonal antibodies, run on 5-17% gradient gel, did not show any specific 
degradation products in EDA +/+ mice (data not shown). Since hepatocytes are the source of 
pFN (Owens and Cimino, 1982; Tamkun and Hynes, 1983b), we performed metabolic 
labeling of hepatocyte primary cultures from EDA wtlW\ EDA +/+ and EDA"I- livers. FN-
affinity purification of the conditioned medium was performed to analyze the pFN 
production in a time-course experiment (Figure 17). Hepatocytes from EDA wtlw" EDA +1+ 
and EDA"/- animals were isolated, plated and metabolically labeled with 3sS-MetlCys for 
24 hrs at different timepoints (Figure 17A). Total conditioned media were then collected 
and run on a 6% SDS-PAGE (Figure 17C). Additionally, equal quantities of total 
conditional media from the three genotypes were affinity purified with a gelatin-agarose 
resin, eluted and separated through a SDS-PAGE (Figure 17D). Autoradiograph analysis 
(Figure 17C and D) revealed a clear decrease in soluble FN levels in the EDA +1+ mice, due 
to reduced secretion of pFN by the EDA +/+ hepatocytes. Cellular extracts prepared from 
equal number of cultured hepatocytes from EDA wtlW\ EDA +1+ and EDA"I- mice were 
analyzed by Western blot with a polyclonal anti-FN antibody. Similarly to what occurs in 
vivo (Figure 16A), the FN levels were similar in the three genotypes (Figure 17B). 
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Figure 17. Hepatocytes of EDA +1+ mice have normal levels of ECM-FN but do not 
secrete pFN. 
A. Hepatocytes from a primary culture. B. Cell extracts prepared with an equal 
number of hepatocytes from EDA " t/w" EDA +1+ and EDA-1- li vers were analyzed by 
Western blot using an anti-FN polyclonal antibody. C. Hepatocytes from EDAwt/"\ 
EOA +1+ and EOA/- Ii ers were isolated, plated and metabolically labeled w ith 35 -
Met/Cys for 24 hrs. An autoradiographic analysis of equal amount of the conditioned 
medium run on a 6% SOS-PAGE is shown. D. Equal quantities of samples prepared in 
C were affin ity purified with a gelatin-agarose resin, e luted, separated 1\1 an 0-
PAGE and autoradiographed . 
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These results showed that EDA +/+ hepatocytes were unable to secrete pFN in normal 
amounts. Consequently, we hypothesized that the reduced levels of tissue FN may be due 
to the decreased supply of FN from plasma to tissues. 
3.1.4 Generation of liver-specific EDA-null mice. 
The addition or injection of exogenous soluble FN into the culture medium of cells or into 
the plasma of mice, respectively, resulted in the incorporation of FN into the ECM (Bae et 
aI., 2004; McKeown-Longo and Mosher, 1983; Oh et aI., 1981; Peters et aI., 1990; Sottile 
et aI., 1998). However, it was not possible to address the magnitude of the contribution of 
pFN to the ECM with those models. In order to determine the extent of FN flow into 
tissues we restored the capacity of hepatocytes to produce pFN not containing the EDA 
exon: we crossbred our floxed EDA +/+ strain with a transgenic strain expressing CRE 
recombinase only in hepatocytes (Kellendonk et aI., 2000). The goal was to perform a 
liver-specific deletion of the EDA exon without modifying the EDA +FN allele in other cell 
types and tissues (Figure 18A-C). EDA +/+ mice were firstly bred with TG-Alf-p-CRE mice 
and the heterozygous mice positive for CRE recombinase (EDA wtl+CRE) were identified 
among the littermates by PCR genotyping. Secondly, EDAwtl+CRE mice were bred with 
EDA +/+ mice to generate homozygous EDA +/+CRE mice. In order to check the efficiency of 
recombination we performed Southern blot analysis of different tissues from EDA wtl+CRE 
and EDA +/+CRE, both strains carrying the liver-specific CRE recombinase (Figure 19). 
Hybridization of the membranes with a probe corresponding to the exon downstream of the 
EDA ex on (Figure 19C) showed CRE-mediated recombination only in the liver and not in 
other tissues (Figure 19A and B). The recombination efficiency in the liver was - 60-70% 
and, consequently, in hepatocytes was close to 100% considering that they constitute -
60% of the total number of cells present in the liver, although they occupy 80% of volume 
of parenchyma (Malarkey et aI., 2005). To further check the efficiency of recombination, 
we performed analyses of the transcription and translation products (Figure 20). RT -PCR 
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analysis of total RNA clearly showed the absence of the EDA exon both in liver and 
purified hepatocytes from EDA+/+CRE mice (Figure 20A) . In agreement with the RT-P R 
result, Western blot analysis using an anti-EDA monoclonal antibody confirmed the 
absence of the domain both in EDA+/+CRE plasma and liver FN, similarly to th wi ld-type 
condition (Figure 20B). As expected, a positive signa l was present only in th DA+/+ 
protein samples. 
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LIVER-specific eRE-mediated 1 
recombination in villo 
TG-Alf-p-CRE (EDA''' l~l) 
eRE Rtcombinase 
~A~ ______ ~r 
Albumin Enh ance r a-f~toprottl n Enhancer 
&Promoter 
c 
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lox P 
Figure 18. Generation of liver-specific EDA-null mice. 
The floxed EDA +/+ mice (Panel A) were crossed with a transgenic train expres ing 
the CRE-recombinase in hepatocytes (Panel B) in order to obtain a liv r- pecific 
deletion of the EDA exon and maintain the EDA + condition in the re t of the body 
(Panel C). chemes of the floxed and optimized EDA + and that of the DA- FN 
alleles are shown (Panels A and C). The EDA exon is indicated as a da hed box, the 
10xP sites as black triangles, -I and + 1 are the exons upstream and downstr am of 
EDA, respectively. A scheme of the Alf-P-CRE transgene is shown (Pan I B). The 
CRE recombinase (dotted box) is expressed under the control of the mouse albumin 
enhancer and promoter (da hed box) and the mouse alpha-fetoprotein enhancer (gray 
box). Correct polyadenylation was directed by the hGH fragment (empty box) . 
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Figure 19. Liver-specific deletion of the EDA exon. 
A. and B. Southern blot analysis of different ti ssues from heterozygou 
EDA wt/+CRE (Panel A) and homozygous EDA +/+CRE (Panel B) mice. peci fic 
recombination was observed only in the liver. EDA w., DA + and DA- bands ar 
indicated. Liver DNA samples from three mice are shown in Panel B. T issues ar 
as indicated: K, kidney; H, heart; L, lung; T, testis; M, skeletal mu cle; 1, intestine· 
Ta, tail ; B, brain; Li , liver. C. chematic representation of the D w., EOA + and 
ED A- FN alleles. The EDA exon is indicated as a dashed box, th lox P ites a 
black tri angles. Hind III sites (H) , the probe u ed in Panel A and B (red line below 
+ 1 exon), the fl anking exons (-1 and + 1) and the expected size of Hind lI1 -d ig sted 
fragments are indicated . 
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Figure 20. EDA exon and domain are missing from the liver FN mRNA and 
. . I f EDA+1+CRE . I protem, respective y, 0 anIma s. 
A. RT-PCR analysis howing the inclusion/excl usion of the EDA exon in total 
RNA prepared from liver and purified hepatocytes from di fferent genotypes. The 
position of the EDA + and ED A- bands are indicated. B. Plasma and liver protein 
d f ED AW1h \1 EDA+I+ d ED +I+CRE . extracts prepare rom , an A - rTIlce were analyz d for 
the presence of the EDA domain using the anti-EDA monoclonal antibody 3E2. 
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3.1.5 FN levels are restored in EDA+1+CRE mice. 
Plasma and tissues from EDA +1+ mice expressing the hepatocyte-specific eRE 
recombinase (EDA +/+CRE) were analyzed by Western blot with anti-total FN (Figure 21 and 
22) and anti-EOA antibodies (Figure 20 and 24). As expected, due to the deletion of the 
EOA exon from the liver FN gene, pFN levels were completely restored in the EDA +I+CRE 
mice (Figure 2IA). Western blot analysis of plasma using an anti-FN polyclonal antibody, 
clearly revealed in EOA +/+CRE mice normal levels of pFN comparable with those of the 
control mice (EDA wtJwt). Plasma protein loads were similar in the three genotypes 
(EOA wtJwt, EOA+1+, EDA+/+CRE) as shown by a 10% SOS-PAGE followed by Coomassie 
blue staining (Figure 2IB). Western blot analysis of the protein extracts prepared from 
EOA+/+CRE organs using an anti-FN polyclonal antibody showed normal levels of FN 
similar to those found in EDA wtJwt ones (Figure 22). These results clearly indicated that an 
important proportion of the FN present in the extracellular matrix of tissues derives from 
plasma, arriving to more than 60% in testis, and up to 40% in other tissues such as brain, 
heart and lung (Figure 22B). Therefore, the amount of FN that is synthesized and deposited 
locally in the tissues is much lower than believed. In order to rule out that the FN levels 
detected in the tissues could be contaminated by circulating plasma proteins, mice of each 
genotype were abundantly perfused with PBS before dissection of the organs. Detection of 
the levels of plasma globulins that remained in each tissue after perfusion was performed 
by Western blot and normalized with the ~-Tubulin signal. Figure 23 shows that the 
remaining globulin levels after tissue perfusion were less than 10% of the levels seen in the 
non-perfused organs. This finding indicated that the differences of FN levels among the 
different strains were not due to residual contamination of pFN, since most of plasma 
proteins were washed-out from the perfused organs. To confirm that the variation of FN 
levels detected in tissues were only due to variation of pFN and not cFN, we performed 
Western blot analysis using a monoclonal antibody to specifically detect the EDA-
containing FN isoform. As expected, we could observe no differences in EOA + cFN levels 
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DAwt/\\I EDA+I+ d EDA+1+CRE b' I d' (F' . of the E , an ram, ung an testis ; Igure 24 -C) tissues. 
Quantification of the testis FN and its normalization with ~-Tubulin is shown in the bar 
graph (Figure 24D). 
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EDA+1+CRE • Figure 21. Plasma from mice has normal FN levels. 
FN 
FN 
d fi EDAwt/wt EDA+I+ d ED +I+CRE . A. Plasma was prepare rom , an A mlC (3 month-o ld) 
and total FN levels were detected by We tern blot analysis. B. The protein load was 
controlled performing a cooma sie blue taining of a 10% D -PAG containing 
equal amounts of plasma from the three genotype. The intensity of the ignals in 
Panel A was quantified with the help of the Quantity One Software and the r suIts 
are shown in Figure 22B. The signal obtained in the EDAwt/wt amples was 
considered 100%. The Mean ± D of three independent experiments is hown. 
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Figure 22. Ti sues from EDA +/+ RE mice have norm al FN level. 
. d J:: EDAwtlwt DA+/+ d +/+ RE . A. Protem extracts were prepare lrom , an EDA mice (3 
month-old) and total FN levels were detected by We tern blot analysis. The protein 
load was controlled by detection of ~-Tubulin in the arne extracts. B. The intensity 
of the signals in Panel A was quantified with the help of the Quantity On oftware. 
The signal obtained in the EDAwtlwt samples was con idered 100%. The Mean ± SD 
of three independent experiments is hown. 
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Figure 23. Perfusion of tissues showed almost no residual plasma proteins. 
Equal amounts of proteins extracts (50 Ilg) from liver (Panel A) and brain (Panel 8) 
were loaded, run on a 12% SDS-PAGE and analyzed by Western blot for the 
presence of plasma gamma globulins. The protein load was controlled by det cti n 
of ~-Tubulin in the same extracts. Lanes 1-7 correspond to serial dilution of 
EDAwt/\\1 plasma (each lane is 1:2 of the previous one, starting fro m 0.05 III to 
0.00078 Ill). Lanes 8, 12 and 15 correspond to non-perfused samples. Lane 9- 11 , 
13-14 and 16-18 correspond to perfused sanlples. The protein load was quantified by 
detection of ~-Tubulin in the stripped membrane (lower panels). 
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Figure 24. Similar levels of EDA +FN were observed in tissues from all three 
genotypes. 
A., B. and C. The same protein extracts from brain (Panel A), lung (Panel B) and 
testis (Panel C) used in Figure 22 were analyzed by Western Blot using th anti-
EDA monoclonal antibody 3E2. D. The ratio between DA+FN and ~-Tubulin 
signals was used for normalization and results are shown in the bar graph. The ratio 
obtained in the EDA wt/wt samples was considered 100%. 
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3.1.6 Immunostaining of tissue sections confirmed the decrease of FN levels in 
EDA +/+ tissues and the recover in tissues of EDA +/+CRE mice. 
The above results were confirmed by immunohistochemical analysis of tissue 
sections. Similar levels of FN-specific signal were detected in the sinusoids of liver 
samples prepared from all three genotypes (Figure 25A-C, black arrows). FN-specific 
signal was observed in brain sections of EDA wt/wt and EDA +/+CRE samples, probably 
associated with the cell surface of glial cells (Price and Hynes, 1985; Tom et aI., 2004; 
Yang et aI., 2006) while the intensity of the signal in EDA +/+ samples was much lower 
(Figure 25E, white arrows). In the case of testis, a strong FN signal was observed in 
basement membranes of seminiferous tubules and interstitial regions of EDA wtlwt and 
EDA +/+CRE sections. On the contrary, a faint signal was observed in EDA +/+ samples 
(Figure 25H, white arrows). These results suggest that plasma is an important source of 
tissue FN. Gross histology of tissue samples from all three genotypes was similar, 
suggesting that the FN locally synthesized is sufficient to maintain the normal tissue 
architecture. 
3.1. 7 Bile fluid from EDA +/+ mice does not contain normal levels of soluble FN. 
Soluble FN is present in most body fluids including bile fluid. Hepatocytes are 
considered polarized cells (Zegers and Hoekstra, 1998) due to their ability to secrete 
soluble FN both in plasma and bile fluid. Based on the observations that EDA +/+ 
hepatocytes secreted lower amounts of soluble FN into the bloodstream we evaluated 
whether FN sectretion into the bile fluid was also diminished. A decrease in FN levels in 
the bile fluid of EDA +/+ mice was observed by Western blot analysis using and anti-FN 
polydonal antibody (Figure 26A). This result suggests both the absence of an EDA-
dependent polarization of FN secretion in hepatocytes, as postulated for airway epithelial 
cells (Wang et aI., 1991) and endothelial cells (Kowalczyk et aI., 1990), and the presence 
of a general defect in the secretory pathway of the soluble FN by EDA +/+ hepatocytes. 
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EDAwtlwt EDA+1+ EDA +I+C RE 
Liver 
Brain 
Testis 
Figure 25. Immunohistochemical analysis of liver, brain and tc ti ti sue. 
Tissue sections of liver (Panel -C), brain (Panel D-F) and testis (Panel -I) fTo m 
EDAwt/wt (panel A, D and G), EDA +/+ (Panel B E and H) and DA +/+ RE (Panel , F 
and I) mice were stained with an affinity purified anti-F polyc\onal antibody. The 
black arrows indicate FN in the extracellular matrix of o Awt/wt and DA +/+ RE fr m 
different tissues and EDA +/+ liver. White arrows indicate the decrea e in Ie el f F 
from the same areas of brain and testis only in DA +/+ mice. S, sinusoid . BM 
basement membrane; and JR, interstitial region are indicated by black arrowh ad . Th 
black bars correspond to 50 flm. 
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Figure 26. FN levels are reduced both in the bile fluid of EDA +/+ and in pia rn a of 
EDA wtJ+ mice. 
A. The same amount of bile fluid (2!l undiluted) was loaded and analyzed by W stern-
blot using an anti-FN polyc1onal antibody. The bile of EDA +/+ mice contained les F 
than control mice. A control from EOA +/+ Jlasma is shown (lane 4). B. PIa rna 
samples were prepared from EOAwtJwt, EOA' +, OA+/+ ~ OAwtl+ RE, and EOA /+ RE 
mice and total FN levels were detected by Western-blot analysi using an anti-F 
polycJonal antibody. Plasma of EOA"'II+ heterozygous mice contained intermediate 
amounts of FN levels. C. Same sample of Panel B were tained with an anti-
monoclonal antibody. D. and E. The intensity of the signals in Panel Band \ a 
quantified with the help of the Quantity One Software and the value were bar graphed 
in the Panel 0 and E, respectively. The signal obtained in the 0 wtlwt ample was 
considered 100%. Plasma of EDAwtl+ heterozygous mice contained more EOA +F 
than the EDA +/+ homozygous mice (Panel C and ). 
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3.1.8 EDA +/+ hepatocytes do not show intracellular accumulation of FN. 
The anomalous presence of the EDA domain in pFN may prevent its secretion into 
fluids by hepatocytes, similarly to that observed for the secretion of the IIICS variants 
(Schwarzbauer et aI., 1989). The "defective" EDA + IEDA + pFN dimers might be formed, 
but their transit through the pFN-secretory pathway might be slower. These dimers could 
be secreted at a much lower rate than "normal" EDA-/EDA- pFN dimers, leading to lower 
levels of soluble pFN in EDA +/+ mice and to intermediate FN levels in plasma of EDA +/wt 
and EDA +/- mice (Figure 26B and D). Moreover, the stronger signal in EDA +/wt samples 
compared to those of EDA +/+ mice could be interpreted as a less-defective secretion of 
EDA wt/EDA + dimers than EDA +/EDA + ones (Figure 26C and E). However, we have not 
seen intracellular accumulation of FN in the liver of EDA +/+ mice by immunostaining of 
tissue sections (Figure 25A and B) or by immunofluorescence of primary culture of 
hepatocytes (Figure 27 and 28). Cultured EDA wtlwt and EDA +/+ hepatocytes for 24 and 48 
hr were stained by immunofluorescence and clearly revealed normal deposition of cFN 
around the cell surfaces but no intracellular accumulation of FN. These results suggest that 
the putative "misfolded" dimers may be quickly degraded by the cells. 
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wtlwt 24 h wt/wt 24 h 
+1+ 24 h +/+ 24 h 
Figure 27. Immunofluorescence analysis of primary culture of hcpatocytes (I) . 
. fi d fi EDA\\ t/\\1 d ED +/+ . d . Hepatocytes were pun Ie rom an A mice an plated onto rat taJl 
collagen coated glas -slips for 24 hIS. Cells were fixed and stained with an affinity 
purified anti-FN polyclonal antibody. Nuclei of the same fields ar shown (Ho tscht 
staining). 
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wtlwt 48 h wt/wt 48 h 
+/+ 48 h +/+ 48 h 
Figure 28. Immunofluorescence analysi of primary culture of hepatocyte (II). 
Hepatocytes were purified from EDA \\lIwt and EDA +/+ mice and plated onto rat ta i I 
collagen coated g\a s- lips for 48 hrs. Cell were fixed and stained with an affi nit 
purified anti-FN po\yclonal antibody. Nuclei of the sam fie lds are shown (Ho t cht 
stain ing) . 
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3.2 EDA +FN AND LIVER FIBROSIS. 
3.2.1 EDA +FN mRNA is up-regulated as consequence of a liver injury. 
Since EDA + cFN expression has been observed both in vivo (in fibrobla tic foci f 
human fibrotic liver and hepatocellular carcinoma (Matsui et aI. , 1997), and rat 
regenerating liver (Caputi et aI., 1995b)) and in vitro (in cultured rat hepatic cells after 
experimental induction of liver fibrogenesis (Jarnagin et aI. , 1994)), we postulated that 
EDA + cFN may be an important contributor to liver fibrosis also in mice. In order t as e 
this possibility, we qualitatively examined the expression of the DA-containing FN 
variants in murine livers following a fibrogenic insult such as the carbon tetrachl ride 
(CCI4) intoxication. After administrating the toxin (0.5 !ll per gram of body weight) to 
EDA wtlwt mice for a period of 5 weeks, we found by RT-PCR analysis a harp up-
regulation of the EDA +FN mRNA (Figure 29). This result clearly provides an indicati n 
that an increase in the ratio of the EDA-containing FN vs the DA-Iacking FN may be 
associated to the onset of the fibrotic process in mouse liver. 
~~C~C=I:4-~t~re~a~t:e~d~~~Control 
805 bp-
535 bp-
RT -PCR analysis of WT mice 
Figure 29. EDA +FN mRNA is upregulated as a consequence of liver injury. 
RT -PCR analysis of the EDA-inclusion pattern in the FN mRNA using total RNA 
extracts from CCl4-treated WT livers. Lane 1-3, RNA samples extracted from 3 
animals treated for 5 weeks with 0.5 !ll/gr of CCI4• Lane 4, Control sample. The DA + 
and EDA- band are indicated. 
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3.2.2 Reduced aSMA levels in EDA-1- mice following liver fibrosis induced by low-
dose eeL. administration. 
We have previously shown that EDA-1- mice are incapable of adequately healing 
cutaneous wounds (Muro et aI., 2003). This is due to ulceration of the newly formed 
epidermis, abnormal re-epithelialization, and ongoing proliferation of infiltrating 
inflammatory cells. In order to explore the role of EDA + cFN in liver fibrosis, EDA-1- and 
EDA wtlwt control mice received intraperitoneal (IP) injections of the fibrogenic toxin CCI4• 
A dose of 0.5 III per gram of body weight was administrated twice a week for a period of 5 
weeks (Maher and McGuire, 1990). We observed that both the EDA/- and EDA wtlwt 
animals developed a significant degree of fibrosis in the liver. Western blot analysis of 
liver protein extracts evidenced elevated levels of one of the markers used to determine 
activated fibrotic cells (or myofibroblasts), the smooth muscle a-actin (aSMA). However, 
EDA-1- mice failed to develop significant increases in aSMA levels as it was observed in 
EDA wtlwt mice (Figure 31A). aSMA signals were quantified and normalized for (3-Tubulin 
levels and the aSMNf3-Tubulin ratios were bar graphed (Figure 31 B). As a vehicle for 
CC4 injections we used mineral oil. In order to establish that the observed response is 
provoked by the fibrotic toxin, we evaluated the aSMA level in the liver protein extracts 
from EDA-1- and EDA wtlwt animals that were treated for 5 weeks exclusively with the 
vehicle. We observed no aSMA signal in any of the mineral oil challenged samples 
(Figure 30). Equal protein load was checked by determination of (3-Tubulin levels in the 
same protein extracts. In order to confirm the data obtained by Western blot analysis, we 
next performed histological examination of liver samples from the same animals. The 
immunostaining of serial sections using the same anti-a.SMA antiboby, revealed less 
intense aSMA-positive areas in the EDA-1- sections than in the EDA wtlwt ones. This finding 
indicated that a lower number of myofibroblasts were present in the EDA-1- liver (Figure 
32). 
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Figure 30. The CCI~-vehicle mineral oil does not activate hepatic stellate cell . 
EDA"1f\\1 and EDA-1- mice were IP injected twice a week for 5 weeks with the 
vehicle. The whole liver protein was extracted and immunoblotted for a MA 
expression. /3-Tubulin was assessed as a protein loading control. Western-blot 
analysis showed that no aSMA signal was present either in the ED wt/w. or in the 
EDA-1- protein samples. Cl-2, mineral oil challenged samples; C3, unchallenged 
samples. M , protein extract from rat aorta was used as a a MA molecular weight 
marker. 
3.2.3 Quantification of the collagen content in the EDA",t/wt and EDA-1- mice 
following liver fibrosis induced by low-dose CC~ administration. 
Previous studies have shown that fibropro liferat ive di sorders are characterized by 
increased production and deposit of ECM proteins in tissues by me enchymal ce ll 
phenotypes (Bissell , 1990; Bissell , 2001). Indeed, activated tissue fibroblasts and hepatic 
stellate cells are retained responsible not only for the abnormal deposition of FN in area 
of active fibrogenesis (Jarnagin et al. 1994; Serini et aI. , 1998) but also for other important 
proteins such as collagens (Maher and McGu ire, 1990). ctually, co llagens are th 
predominant ECM proteins identified in fibrotic lesions and are the hallmark of 
fibroproliferative diseases. For this reason we evaluated the collagen cont nt in th 
EDA \\t/\\1 and EDA-1- mice following liver fibro i induced by th 14 in ult. The co ll agen 
amount was measured by an indirect method based on the determination in ti sue of a 
peculiar and rare amino acid called hydroxyproline that i higly abundant in co llagen . 
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Figure 31. Reduced aSMA levels in EDA-1- mice following liver fibro is induced 
by low-dose CCl4 administration. 
A. EDAwtlwt and EDA-1- mice were IP injected twice a week for 5 w ek with 14 
(0.5 f-ll/gr of body weight) or vehicle (Figure 30). The whol li ver pr tein a 
extracted and immunob1otted for aSMA expression. ~- ubulin wa a a a 
protein loading control. B. Densitometry of aSMA bands (normalized ~ r ~-lubu1in 
is shown in the bar graph (mean ± SD of three independent animal p r g n typ . 
The ratio obtained in the EDAwtlwt samples was consider d 10 %. Quanti'ficati n r 
the bands was done with the help of Quantity-one software. he differ n b twe n 
EDAwtlwt and EDA-1- ratios was statistically significant, according t th -te t *p < 
0.04). 
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Figure 32. Reduced a SMA and collagen levels in EDA-1- mice following liver fibrosis induced by low-dose CC~ administration. 
Serial histological sections of liver samples from EDA,,1/wt and EDA-1- mice, treated with 0.5!lVgr of CC~ and vehicle (Control) for 5 weeks, 
were analyzed for the presence of activated hepatic stellate cells. To address this issue we performed immunohistochemical staining using an 
anti-aSMA antibody (left columns). Trichrome staining was used to detect collagen-rich areas (right columns). The dotted rectangles in the 
middle panels indicate the magnified area shown in the bottom panels. Shown are photomicrographs of a representative field. The black bar in 
the right-bottom corner of the photographs corresponds to 310 11m and 100 11m for the top and middle rows, and the bottom row, respectively. 
It has been evaluated that - 14% of collagen amino acids is represented by hydroxyproline 
(Nelson, 2005). Since it is found in a reduced number of proteins other than collagens, the 
quantification of hydrox proline content gives a good estimation of the collagen present in 
a tissue. As expected, following 0.5 f,ll/gr CCl4 admirtistration, twice a week for 5 weeks, 
EDAwtlwt mice developed sigrtificant degree of liver fibrosis. The elevated level of collagen 
in the fibrotic EDAwtlwt livers was measured by both the hydroxyproline assay (Figure 
33A) and quantification of the collagen-positive areas of liver sections (Figure 33B) after 
trichrome stairting (Figure 32). On the contrary, EDA-1- mice failed to develop similar 
levels of liver fibrosis although this did not reach statistical significance. Indeed, the 
average collagen content in EDA-1- liver samples was decreased after the CCL4 insult as 
shown in Figure 33. 
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Figure 33. EDA-1- mice failed to develop high levels of liver fibrosis following 
low-dose CCI4 administration, although this did not reach statistical 
significance. 
A. Liver tissues from EDA\\ WI and EDA-1- animals fo llowing 5 weeks of (0.5 f,lllgr)-
CC~ treatment were harvested and assessed for total collagen content by 
hydroxyproline assay. EDA\\V\\\ n = 6; EDA-1-, n = 7; mean ± SD are shown in the 
bar graph. B. Quantification of the collagen-positive areas of liver sections 
(Trichrome staining in Figure 32) from EDAwtlwt and EDA -1- animals after 5 weeks 
of (0.5 f-ll/gr)-CC14 treatment. EDAwtlW\ n = 4; EDA-1-, n = 4; mean ± SD are shown 
in the bar graph. The difference between EDAwtlwt and EDA-1- ratios was not 
statisticall sigrtificant, according to the T -test (p > 0.05). NS, not significant. 
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3.2.4 Reduced aSMA levels in EDA-1- mice following liver fibrosis induced by 
middle-dose CC4 administration. 
In order to better understand the mechanisms participating in the fibrotic process, 
we evaluated the relationship between the activation rate of the hepatic stellate cells 
(HSCs) to a myofibroblast-like phenotype and the dose of the injected toxin. To address 
this issue we repeated the same intoxication experiment injecting increasing doses of CCl4 
(1.0 to 2.0 f..ll/gr). In this section If..ll ofCCl4 per gram of body weight was administrated to 
EDA-1- and EDA wtlwt mice. Both aSMA and 13-Tubulin levels were evaluated by Western 
blot (Figure 34A) and the normalized aSMA levels were bar graphed (Figure 34B). The 
reduction in aSMA levels in the EDA"/- mice in respect to the EDA wtlwt animals was 
evident and statistically significant, confirming the previous result (O.Sf..lI/gr CCI4). 
However, we noticed an increment in aSMA average levels in EDA-1- mice in respect to 
the lower dose CCl4-treated EDA-1- mice (Figure 31 B). Histological analysis of the same 
liver samples revealed less intense collagen- and aSMA-positive areas in the EDA-f-
animals. This result confirms the Western blot analysis and indicates that a lower number 
of myofibroblasts was present in the EDA-1• liver sections (Figure 35). 
3.2.5 Reduced aSMA and normal collagen levels in EDA"/- mice following liver 
fibrosis induced by high-dose CC4 administration 
We next increased both the CCl4 dose and the intoxication period administrating 
1.5 f..ll of CCl4 per gram of body weight, always twice a week but for a period of 6 weeks. 
Even though the mean value of aSMA level in EDA"/- mice was lower than that of the 
control mice, the differences between EDA wtlwt and EDA"/ samples were not statistically 
significant according to the T -test (Figure 36). However, we cannot rule out that the high 
variability in the response of the EDA wtlwt mice to the toxin may have affected the 
significance of the test. Indeed, when we performed the histological analysis we still 
noticed a reduction of the aSMA signal in all the EDA .f- sections (Figure 37) as previously 
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observed with lower CCl4 doses. On the contrary, a similar degree of liver fibrosi s wa 
observed in EDAwllwt and EDA"'- mice as shown by the elevated I ve l of co llagen 
evaluated by both trichrome co loration of the liver sections (Figure 37) and hydroxyproline 
assay (Figure 38). 
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Figure 34. Reduced aSMA levels in EDA-1- mice following liver fibro i induced 
by middle-dose CCI4 administration. 
A. EDAwllwt and EDA-1- mice were IP injected twice a week for 5 w k with 14 
(l.0 I-lI/gr of body weight) or vehicle. The whole li ver protein wa extract d and 
imrnunoblotted for aSMA expression. ~-Tubulin was assessed a a pr tein l ad ing 
control. B. Densitometry of aSMA bands (normali zed for ~-Tubulin) i hown in the 
bar graph (mean ± SD of three independent animals per genotype). Th rati btai n d 
in the EDA wll",! samples was considered 1 00%. Quantification of th band wa d 
with the help of Quantity-one software. The difference between DA \ 11\ I and 
ratios was statistically significant, according to the T -test (*p = 0.01). 
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Figure 35. Reduced a SMA and collagen levels in EDK '- mice following liver fibrosis induced by middle-dose CCI4 administration. 
Serial histological sections of liver samples from EDAwtlwt and EDA-1- mice, treated with 1.0 Ill/gr of CCl4 and vehicle (Control) for 5 weeks, 
were analyzed for the presence of activated hepatic stellate cells. To address this issue we performed immunohistochemical staining using an 
anti-aSMA antibody (left columns). Trichrome staining was used to detect collagen-rich areas (right columns). Shown are photomicrographs 
~ of a representative field. The black bar in the right-bottom comer of the photographs corresponds to 200 /lm and 100 /lm for the top and 
middle rows, and the bottom row, respectively. 
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F igure 36. Reduced aSMA levels in EDA-1- mice following liver fibrosis induced 
by high-dose CCI .. administration. 
A. EDAwtlwI and EDA-1- mice were IP injected twice a week for 6 weeks with 14 
(1.5 !!ligr of body weight) or vehicle. The whole liver protein was extracted and 
immunoblotted for uSMA expression. ~-Tubulin was assessed as a prot in loading 
control. B. Densitometry of uSMA bands (normalized fo r ~-Tubulin) is hown in 
the bar graph (mean ± SD of three independent an imals per genotyp ). The ratio 
obtained in the EDA \\~/wl samples was considered 100%. Quantification of th band 
was done with the help of Quantity-one software. The difference between ED Wl/ wl 
and EDA/- ratios was not statistically significant, accord ing to the T-te t (p > 0.05). 
NS, not significant. 
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Figure 37. Reduced a SMA and normal collagen levels in EDA-1- mice following liver fibrosis induced by high-dose CCl4 administration. 
Serial histological sections of liver samples from EDA \I'IIwt and EDkl- mice, treated with 1.5 ~Vgr of CCl4 and vehicle (Control) for 6 weeks, were 
analyzed for the presence of activated hepatic stellate cells. To address this issue we performed immunohistochemical staining using an anti-
aSMA antibody (left columns). Trichrome staining was used to detect collagen-rich areas (right columns). The dotted rectangles in the middle 
panels indicate the magnified area shown in the bottom panels. Shown are photomicrographs of a representative field. The black bar in the right-
bottom comer of the photographs corresponds to 310 11m and 100 11m for the top and middle rows, and the bottom row, respectively. 
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Figure 38. EDA-1- mice develop high levels of liver fibrosis followind high-do c 
CCl4 administration. 
Liver tissues from EDAwtlwt and EDA-1- animals following 6 weeks of 14 treatment 
were harvested and assessed for total collagen content by hydroxyproline as ay . 
EDAwtlwt, n = 4; EDA-1-, n = 4; mean ± SD are shown in the bar graph. he 
difference between EDAwtlwt and EDA-1- ratios was not statistically ignifi ant, 
according to the T-test (p > 0.50). NS, not significant. 
3.2.6 Similar aSMA levels in EDAwtlw, and EDA-1- mice following liver fibrosis 
induced by very-high-dose CCI4 administration. 
When we administrated a dose of 2.0 !J.I of CCl4 per gram of body weight for a 
period of 6 weeks the reaction to the intoxication was similar in the DA-1- and 
mice. No difference was observed in the aSMA levels between the DA-1- and ntr I 
mice as shown by the Western blot analysis and quantification of the band (Figur 39). 
Due to the high lethality of the dose, 30 animals for each genotype (15 mice for ach x) 
were used to perform the experiment. Indeed, after 3 weeks from the first injecti 11 , ab lit 
90% of the mice were dead, independently from the sex and genotype a WI1 in the 
Kaplan-Meier graphical representation (Figure 40). Since no difference wa en in th 
CC14 mortality curve between the two genotypes, we retained di spen abl p rforming n 
histological analysis of the dead mice. The survivors were instead used for the 
quantification of the aSMA levels (Figure 39). 
EDAwt/wt 
a SMA A 
~-Tub 
CCI4-dose: 2.0 J,tl/gr of body weight 
,.-. 
~ 
= 
NS B 
'-" 120 
0 
.... 
... 100 ~ 
I. 
= 80 .... 
-
= ~ 60 
= ~ 40 I 
c:a. 
........ 
~ 20 0 00 
t:S EDAwUwt EDA-1-
Figure 39. Similar aSMA levels in EDA",t/wt and EDA-1- mice following liver 
fibrosis induced by very-high-dose CCI4 administration. 
A. EDAwtlwt and EDA/- mice were IP injected twice a w ek for 6 week with 
CCl4 (2.0 f-ll/gr of body weight) or vehicle. The whole liver protein wa extracted 
and immunoblotted for aSMA expression. ~-Tubulin was assessed as a pr tein 
loading control. B. Densitometry of aSMA bands (normalized for ~-Tubulin) is 
shown in the bar graph (mean ± SD of three independent animals p r gen typ ). 
The ratio obtained in the EDAwt/wt samples was considered 100%. Quantifi ati n 
of the bands was done with the help of Quantity-one software. The diffi r n e 
between EDAwtlwt and EDA-1- ratios was not statistically significant accord ing t 
the T-test (p > 0.50). NS, not significant. 
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Figure 40. Similar mortality rate both in EDAwtlwt and EDA-/- mice following a 
very-high-dose CCI4 intoxication. 
EDAwt/wt and EDA-/- mice were IP injected twice a week with 14 (2.0 ~I/gr f 
body weight) . Within 3 weeks 90% of EDA,,1/wt and DA-/- mice w re dad. Th 
graph shows a Kaplan-Meier representation of the survivals versu time f 15 
EDA-/- and 15 EDAwtlwt male mice. The results were analyzed with the Log-rank 
test and the differences between the EDA wt/wt and EDA-/- curve w r n t 
statistically significant. San1e course was observed repeating the experim nt with 
the same number of female mice. All mice used were 314-month-old. 
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3.2.7 Similar aSMA levels in EDA wtlwt and EDA +/+ mice following liver fibrosis 
induced by CCI4 administration. 
In order to confirm that the reduction in aSMA levels observed in the EDA"/-
animals following induction of fibrosis with CCl4 was correlated to the lack of the EDA 
domain from the FN protein, aSMA levels were quantified in the EDA +/+ mice challenged 
with 0.5 and 1.0 ~l of CCl4 per gram of body weight for 5 weeks. In both the experiments, 
quantification of aSMA bands revealed similar levels of the protein in the EDA +/+ and 
EDA wtlwt liver protein extracts (data not shown). Similarly, histological evaluation of 
aSMA-positive areas, quantification of collagen-positive areas after trichrome staining and 
hydroxyproline assays showed no differences between the two genotypes (data not shown). 
3.2.8 Reduced aSMA levels in EDA-/- mice following liver fibrosis induced by short-
time bile duct ligation (BDL). 
In order to determine whether the role of EDA + cFN in the early development of 
liver fibrosis could be extended to other fibrosis models, we used the bile duct ligation 
(BDL) model (Maher and McGuire, 1990). Mice were subjected to laparatomy and ligation 
of the common bile duct as described in Material & Methods (Figure 14). We observed a 
significant increase in the levels of aSMA after 7-day-BDL in EDA wtlwt mice but not in 
EDA-1- mice (Figure 42A) confirming the Western blot results obtained with the low-dose 
CCl4 insult. Seven days after the operation, livers were excised and protein extracts were 
prepared. As for the CCl4 experiments, equal amounts of protein were loaded and run in a 
12% SDS-PAGE. The membrane was stained with an anti-aSMA monoclonal antibody 
following gel blotting. The aSMA signals were quantified and normalized according to p-
Tubulin levels. The aSMAlp-Tubulin ratios were bar graphed (Figure 42B). As a control, 
sham-operated mice were used. The sham operation consisted in the manipulation of the 
bile duct following laparatomy, without ligation and cut of the common bile duct. As 
expected, no aSMA signal was evident in any of the liver samples from the sham-operated 
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animals (Figure 41). In order to confirm the result obtained by Western blot analysis, we 
next assessed serial BDL-liver sections for the presence of aSMA within HSCs, indicating 
the presence of activated myofibroblasts. The fibrotic regions in the liver of the EDA \vtlwt 
mice contained clusters of aSMA-expressing myofibroblasts in hjgher amounts than the 
EDA /- samples (Figura 43). As expected and similarly to the low-dose CCl4-administration 
experiment, EDA\\1/\vt mice developed higher degree of fibrosis as shown by the increased 
levels of collagen, measured by quantification of the collagen-positive areas of liver 
sections (Figure 44) after trichrome staining (Figure 43). On the contrary, EDA-1- mice 
failed to develop similar levels of liver fibrosis as shown by the reduction of the collagen-
positive areas, although tills did not reach statistical significance. 
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Figure 41. The sham operation as a control for the bile duct ligation (BDL). 
Sham operation is consistent with laparotomy and manipulation but not ligation and 
cut of the common bile duct. Protein samples from sham operated EDA \vt/wt and 
EDA-1- mice were separated in 12% SDS-PAGE and immuno-blotted for aSMA 
expression. I3-Tubulin was assessed as a protein loading control. M, liver samples 
from BDL WT animals were used as marker. 
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Figure 42. Reduced aSMA levels in EDA-1- mice following liver fibro i induced 
by short-time BDL. 
A. EDA\\lIwt and EDA-1- mice were subjected to laparotomy and BDL or sham 
operation (Figure 36). The whole liver protein was extracted and immunoblotted for 
aSMA expression. (3-Tubulin was assessed as a protein loading control. B. 
Densitometry of uSMA bands (normalized for (3-tubulin) is shown in the bar graph 
(mean ± SD of three independent animals per genotype) . The ratio obtained in the 
EDAwtlwt samples was considered 100%. Quantification of the bands was done with 
the help of Quantity-one software. The difference between ED A wtlwt and DA-1-
ratios was statistically significant, according to the T -test (*p < 0.02). 
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Figure 43. Reduced aSMA and collagen levels in EDA-1- mice following liver fibrosis induced by 7-day-bile duct ligation (BDL). 
Serial histological sections of liver samples from EDA"lIM and EDA-1- mice undergoing BDL for 7 days or sham operation (Control) were analyzed for 
the presence of activated hepatic stellate cells. To address this issue we performed immunohistochemical staining using an anti-a -SMA antibody (left 
columns). Trichrome staining was used to detect collagen-rich areas (right columns). The dotted rectangles in the middle panels indicate the magnified 
area shown in the bottom panels. Shown are photomicrographs of a representative field. The black bar in the right-bottom corner of the photographs 
corresponds to 31 0 ~m and 1 00 ~m for the top and middle rows, and the bottom row, respectively. 
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Figure 44. EDA-1- mice failed to develop high levels of liver fibrosis following 
7-day-BDL, although this did not reach statistical significance. 
Quantification of collage~ositive are~~ in .the liver sect~ons (Trich~om~ staining 
in Figure 43) from EDA and EDA ammals, followmg 7-day-hgatton of the 
bile duct is represented in the chart. EDA wtlwl, n = 4; EDA"I-, n = 4; mean ± Dar 
shown in the bar graph. The difference between EDA wtlWI and EDA-1- ratio wa 
not statistically significant, according to the I-test (p > 0.05). NS, not significant. 
3.2.9 Similar aSMA levels in EDA",t/wt and EDA-1- mice following liver fibro i 
induced by long-time bile duct ligation (BDL). 
As in the case of the high doses of CCI4, the differences in aSMA levels betwe n 
EDA-1- and EDAwI/wt mice vanished after an increment in the fibrogenic insult uch a a 
longer period of ligation of the bile duct. Fourteen (Figure 45) and eighteen d y (n t 
shown) after the operation, mice were sacrificed and livers excised for a MA ignal 
evaluation. In both the experiments the reaction to the insult was simi lar in DA WI/WI and 
EDA-1- mice. 
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Figure 45. Similar aSMA levels in EDAwt/wt and EDA-1- mice following liver 
fibrosis induced by IODr--time BDL. 
A. EDAwt/wt and EDA- - mice were subjected to laparotomy and BDL or hanl 
operation. The whole liver protein was extracted and immunoblotted for a MA 
expression. ~-Tubulin was assessed as a protein loading control. B. Densitometry of 
aSMA bands (normalized for ~-Tubulin) is shown in the bar graph (mean ± SD of 
three independent animals per genotype). The ratio obtained in the EDA wt/W\ samples 
was considered 100%. Quantification of the bands was done with the h Ip of 
Quantity-one software. The difference between EDAwt/wt and DA-1- ratio wa not 
statistically significant, according to the T -test (p > 0.40). NS, not significant. 
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4. DISCUSSION 
4.1 A MAJOR FRACTION OF THE FIBRONECTIN PRESENT IN THE 
EXTRACELLULAR MATRIX OF TISSUES IS PLASMA-DERIVED. 
In multicellular organisms, the ECM provides physical support to tissues and 
organs by occupying the space between the cells. The ECM is present in all tissues, being 
particularly abundant in connective tissue and basement membranes. It is a heterogeneous 
mixture of water, saccharides, and various protein components traditionally classified into 
four categories: collagens, proteoglycans (PGs), non-collagenous glycoproteins such as 
flbronectins, and elastins. Upon deposition, the protein constituents are organized into 
three-dimensional, tissue-specific meshworks that constitute the structural environment in 
which cells are embedded. The ECM structure is highly dynamic and undergoes a constant 
remodelling controlled by a delicate balance between synthesis and degradation (Aszodi et 
al., 2006). A lot of effort has gone into showing that the ECM is not only a benign scaffold 
around cells but also a dynamic, mobile, and flexible key element in the definition of 
cellular behaviour. However, the origin of each of the components that form the ECM is 
still ill defined. The concept of a fibronectin flow from plasma into tissues or ECM has 
been acknowledged for a long time. Indeed, soluble FN added into the culture medium of 
cells or injected into the plasma of mice was incorporated into the ECM, with its 
distribution being undistinguishable from that of endogenous FN (Bae et aI., 2004; 
McKeown-Longo and Mosher, 1983; Dh et aI., 1981; Peters et aI., 1990; Sottile et aI., 
1998). These initial findings suggested that both local tissue production and transfer from 
plasma of FN contribute to form the ECM of tissues. However, the extent of this 
phenomenon has never been addressed. The reported reduction of pFN levels in mice 
heterozygous for the targeted FN allele (FNwtI-) (George et aI., 1993) and in conditional 
pFN-null mice (Sakai et aI., 2001) has given a hint to evaluate the levels of FN also in the 
mouse tissues, but neither of these authors addressed this issue. We had previously 
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reported that mice with a constitutive inclusion of the EDA domain in FN (EDA +/+) 
showed a significant decrease of FN both in plasma and in most of the tissues of adult 
animals (Chauhan et aI., 2004; Muro et aI., 2003). During the present work, pFN levels in 
young, adult and old EDA +/+ mice have been shown to be of about 20% of the pFN levels 
in control mice (EDA wtlwt) (Figure 15A). Additionally, analysis of EDA +/+ embryos 
revealed an apparent decrease of FN levels in plasma of up to 60% of control levels 
(Figure 15A). We hypothesized that the main reason for this important decrease in FN 
levels in the ECM of EOA +/+ tissues could be related to the reduction of pFN in those 
animals, which implicates that a major proportion of the FN present in the ECM is 
probably plasma derived. Moreover, we suspected that the reason for the pFN reduction in 
the EOA +/+ bloodstream was an incapability of hepatocytes to release soluble FN bearing 
the EOA domain. Not only hepatocytes are known to be the main source of the pFN 
(Tamkun and Hynes, 1983a), but we also observed that EDA +/+ hepatocytes in culture are 
unable to release as much soluble FN to the medium as those EOA wtlwt (Figure 17C and 
0). Our previous experiments had also shown that the decrease in pFN was due neither to 
lower levels of mRNA in EOA +/+ tissues, as shown by Northern blot analysis, nor to a 
reduced FN production by non-hepatic EOA +/+ tissues, since the amount of FN secreted by 
embryonic and adult heart fibroblasts was similar to that produced by EDA wtlwt fibroblasts 
(Muro et aI., 2003). Furthermore, the proteolytic degradation of FN in EDA +/+ plasma and 
tissues was also excluded. Overall, these data seem to exclude a general defect in FN 
production by EDA +/+ tissues, and show that the deficiency in FN secretion was limited to 
EOA +/+ hepatocytes. This was confirmed when we crossed our "floxed" EDA +/+ mice with 
a transgenic mouse expressing CRE recombinase in hepatocytes (Figure 8), in order to 
generate a liver-specific EDA-null mouse (EDA +/+CRE) having an EDA'/· liver inside an 
EOA+/+ body (Figure 18). We observed that the levels of FN present both in plasma and 
tissue ECM in these mice were restored to normal (Figure 21 and 22). Furthermore, the 
finding that EDA + cFN levels were similar in the same tissues of EDA +/+ and EDA +/+CRE 
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mice confirmed that the variation in total FN content was only due to a difference in pFN 
(Figure 24). Our results clearly indicated that an important proportion of the FN present in 
the extracellular matrix of tissues derives from plasma, reaching more than 60% in testis 
and up to 40% in other tissues such as brain, heart and lung. Our in vivo results confirmed 
previous evidence that plasma could behave as a sort a reservoir of FN for tissue 
maintenance, and showed for the first time that the contribution of pFN to the ECM of 
tissues is roughly equal to the FN locally produced in all major tissues. The present results 
contribute significantly to the understanding of the role of pFN, and perhaps of other 
plasma proteins, in the modulation of cellular activities and in the formation of the 
extracellular matrix of tissues. 
Sakai et al. have recently shown that pFN supports neuronal survival and reduces brain 
injury following transient focal cerebral ischemia, suggesting the incorporation of pFN into 
the injured brain (Sakai et aI., 2001 ). Our results confirmed and extended their 
observations, since we have shown that pFN is incorporated in non-injured brain. 
Additionally, we also demonstrate that this is a general mechanism occurring in most 
normal tissues, which import up to 60% of their FN from plasma. 
The observation that EDA +/+ embryos and young mice (of up to 1-2 months of age) had a 
reduced pFN (Figure 15A) but contained normal levels of tissue FN (Muro et aI., 2003) 
suggests that the ratio between tissue FN requirements and tissue FN production might be 
higher in adults than in embryos. Adults, therefore demand an important supply of FN 
from plasma, which is instead prevented in the EDA +/+ mouse. 
Here we have presented evidence that the inclusion of the EDA domain in hepatocyte FN 
affects its secretion into both the bloodstream and bile fluid. The reason why EDA +/+ 
hepatocytes are not able to secrete as much FN as EDA wtlwt hepatocytes is still unclear. 
Soluble pFN is normally a dimer, with its dimerization occurring in the lumen of the 
endoplasmic reticulum (ER) of hepatocytes, shortly after its synthesis (Choi and Hynes, 
1979). The assembly of dimers seems to occur by random assortment of monomers, but 
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only certain types of dimers are selected for secretion (Schwarzbauer et aI., 1987a). In fact, 
experiments co-expressing recombinant FN fragments (deminectins) containing or not the 
IlleS domain (VI20 and YO, respectively) in cultured fibroblasts showed that among the 
three possible types of dimers (VONO, VI20NI20 and VONI20), only those containing 
VI20 are found in the medium. This selective retention of VO homodimers within the ER 
indicates that the V region may be required for the formation and secretion of native FN 
dimers (Schwarzbauer et al., 1989). In an analogous in vivo situation, it has been shown 
that rat plasma FN also lacks VO homodimers and consists only of VON+ and V+N+ 
combinations (Schwarzbauer et aI., 1989). Similarly to VONO dimers, the EDA + IEDA + 
dimers produced by EDA +/+ hepatocytes might not be efficiently secreted into either 
plasma (Figure 15) or culture medium (Figure 17) and could therefore be selectively 
retained and degraded due to a possibly unfolded or misfolded conformation. Intracellular 
protein degradation is an important mechanism of cellular regulation not only to eliminate 
waste products due to aberrant protein folding or failed protein secretion but also to 
regulate the protein output to the needs of the cell. It could be possible that hepatocytes are 
programmed to eliminate and/or to maintain at very low levels the EDA +FN. One of the 
reasons to avoid high EDA +FN levels in plasma could be linked to its pro-thrombotic 
activity (see Introduction §1.4.4). It could also be possible that the degradation process of 
FN resembled the degradation pathway that governs the output of another huge hepatic 
glycoprotein such as apolipoprotein B (apoB). The intracellular degradation process of 
newly synthesized apoB has been shown to occur at every stage of the secretory pathway, 
from protein translation and polypeptide translocation across the membrane of the ER to 
vesicular transport (Yao et al., 1997). The proteolysis of nascent apoB can be performed by 
the ubiquitin-proteasome system in the cytosol as well as by resident ER proteases 
(Davidson and Shelness, 2000). Thus, EDA +PN proceeding along the normal secretory 
pathway may be stopped by a rapid and efficient proteolytic degradation at one or more of 
the steps of the process. In keeping with this hypothesis, we did not observe any 
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intracellular accumulation of FN in EDA +1+ hepatocytes by immunostaining of tissue 
sections (Figure 25A-C) or immunofluorescence staining of primary culture hepatocytes 
(Figure 27 and 28). 
Western blot analysis of plasma from heterozygous mice (EDA wtI+) showed intermediate 
levels of total FN in comparison with EDA wt/wt and EDA +1+ animals (Figure 268), 
supporting the idea that EDA +FN is produced less efficiently because dimers containing 
only one EDA+FN monomer (EDA wtIEDA+ heterodimers) would be secreted more 
efficiency than EDA+IEDA+ homodimers.1t is noteworthy that the "presence" of the EDA 
domain seems to negatively affect FN production by the hepatocyte. Indeed, following the 
in vivo removal of the EDA exon from the FN gene, a normal production of pFN is 
restored in EDA +1+ mice. On the contrary, in the case of III CS, the "absence" of the domain 
in both subunits of the dimer (VONO variant) affects dimer formation and/or secretion, as 
shown by Schwarzbauer et al. This finding, though, has been demonstrated only in vitro by 
expressing cDNA encoding truncated FN fragments (or deminectins) in fibroblasts 
(Schwarzbauer et aI., 1989). 
Surprisingly, analysis of the FN content of both EDA +1+ perfused liver (Figure 16A) and 
total cellular (Figure 178) extracts revealed that, unlike in other tissues, the ECM does not 
contain a reduced level of FN. Indeed, FN content was similar in EDAwttwt and EDA +1+ 
mice. The normal level of FN in the ECM of liver and purified hepatocytes from EDA +1+ 
mice raises several questions regarding FN export mechanisms in hepatocytes. The current 
model of FN assembly into the ECM or "fibrillogenesis" (Figure 46) postulates that 
soluble, inactive and compactly folded FN dimers bind a5~1 integrins through the RGD 
cell binding sequence present in the type 11110 module along with the synergy sequence 
located in the adjacent type 1119 module (Mao and Schwarzbauer, 2005; Schwarzbauer, 
1991). Other integrins can also support FN-matrix assembly but with lower efficiency 
(Geiger et aI., 2001) (Figure 46A). Although initially distributed diffusely over the cell 
surface, the IntegrinIFN complexes soon cluster. Integrin clustering recruits signaling and 
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cytoskeletal proteins into "focal complexes", stimulating a number of distinct intracellular 
responses, including reorganization of the actin cytoskeleton and changes in gene 
expression (Figure 46B). The tension exerted on FN dimers as a consequence of integrin 
translocation along the actin stress fibers and out of the focal contacts, stretches and 
unfolds the FN subunits (Wierzbicka-Patynowski and Schwarzbauer, 2003) (Figure 46C). 
Consequently, the FN-binding domains that were hidden in the compact form are now 
exposed and become involved in FN-FN interactions. Soluble FN dimers are thus 
incorporated into a network of insoluble fibrils (Choi and Hynes, 1979). However, the 
precise mechanism of the initial binding between FN and integrins is not yet clear. The 
observation that EDA +/+ hepatocytes secrete low amounts of soluble FN while the EDA +/+ 
liver has normal FN levels suggests that inclusion of the EDA domain, which is placed 
near the RGD and the synergy sequences, could facilitate the unfolding or stretching of 
dimers. Consequently, FN cell-binding sites would be more accessible to integrins 
(Manabe et aI., 1999; Manabe et aI., 1997). The conformation of the FN molecule may be 
globally altered upon insertion of the EDA segment and the possible increased exposure of 
the RGD motif in the type 11110 module, and/or other cryptic sites could render the 
EDA + IEDA + dimers stickier or less soluble. Thus, an augmented "stickiness" of the 
EDA + IEDA + dimers could not only explain the normal level of FN in the EDA +/+ liver 
ECM (Figure 16A and 17B) but also the enhanced thrombus formation in injured arterioles 
in the presence of EDA +FN (see Introduction § 1.4.4). The initial step of fibrillogenesis 
may be the intracellular binding of FN to integrin receptors. Once all the cell-surface 
receptors are fully occupied by the FN dimers, the excess of dimers could be released into 
the bloodstream, explaining the presence of 20% of EDA +FN in EDA +/+ plasma. However, 
all these hypotheses need demonstrating. 
Recently, a4fH and a9fH integrins have been shown to specifically bind to the EDA 
segment of FN. This interaction therefore provides a novel mechanism by which both cell 
adhesion and signal transduction are regulated by alternative splicing (Liao et aI., 2002). 
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Figure 46. Fibronectin matrix assembly model. 
A. Binding of soluble, compactly folded and inactive FN dimers to diffu ely di tribu t d 
integrins induces receptor clustering and co-localization of talin (whi te oval ) and G al 
adhesion lcinase (F AK, red rectangle). FAK autopho phorylation (P) r cruit r (p ink 
circle), and these two kinases regulate the very early step of as embly. B. lu t red 
integrins and co-localized syndecan (gray and black bars), a tran membrane pr teogly an 
that can bind to FN, organize the actin cyto keleton (green line) and acti ate ign ling 
molecules including Ras/MAP kinase (orange), Rho TPa e (viol t) and protein kina 
(PKC) (blue) at the "focal complexes". C. FN fibri llogenesis i driv n by c perati n r 
two distinct types of cell-surface adhe ion: "focal adhesion" and ' fibr illar ad he i n". Th e 
cooperate in a process by which integrins and dynamic ten ion force eem to unma k 
cryptic FN assembly sites t~at m~diate ~N polarization and generate network of fibri llar 
ECM. Ligand-bound a5~1 mtegnns actIvely translocate fro m the fi cal adh i n t th 
fibrillar adhesions parallel to the actin microfi lament bundl . This concerted m m nl 
could provide a mechanism by which tensile forces tretch FN and induc fibr ill g n i 
(Wierzbicka-Patynowski and chwarzbauer, 2003). 
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Thus, to assess whether the constitutive presence or absence of the EDA domain in mouse 
liver ECM could affect the expression of other ECM genes, we performed microarray 
hybridization of membranes bearing cDNA fragments corresponding to mouse 
extracellular matrix, adhesion molecules and other related genes. Preliminary results 
showed 2-fold variations (increases or decreases) in the expression of some specific genes 
(data not shown). Northern blot analysis will be necessary to confirm these variations in 
gene expression. Quantification of some of the main proteins synthesized by hepatocytes 
and secreted into the liver ECM and/or plasma of EDA wtlwt, EDA+1+ and EDA-1- animals, 
such as vitronectin, collagen and fibrinogen, revealed no differences in the protein levels 
among these genotypes (Figure 16). 
Since FN is found both in blood and bile fluids, secretion of FN by hepatocytes seems not 
to be polarized as is the case for endothelial cells (Kowalczyk et aI., 1990), where a 
polarized FN-containing matrix is assembled onto the basolateral cell surface facing the 
interstitial compartment. Since the extracellular matrix promotes platelet adhesion and 
activation (Clark, 1996), mechanisms to polarize ECM formation are essential for 
endothelial cells to maintain a non-thrombogenic apical surface. We have observed a 
decrease in the FN levels of EDA +1+ mice bile fluids (Figure 26A) that suggests an absence 
of an EDA-dependent polarization of the process of FN secretion in hepatocytes, similarly 
to airway epithelial cells (Wang et aI., 1991). These cells secrete FN from both apical and 
basal surfaces, although the EDA +FN isoform is preferentially secreted apically to the 
airway lumen. 
Overall, the present findings highlight the extraordinary structural and behavioral diversity 
between pFN and the FN present in the ECM, and attempt to explain the incapacity of 
hepatocytes to synthesize and secrete a potentially pro-thrombogenic EDA +FN isoform 
into the bloodstream. 
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4.2 THE FN-EDA DOMAIN PARTICIPATES IN THE ACTIVATION OF 
HEPATIC STELLATE CELLS. 
The pathogenesis of progressive tissue fibrosis is not completely understood, and 
has been likened to an exuberant and dysregulated wound healing response. Therefore, 
understanding why normal wound healing is triggered and tissue injury is limited is of 
critical importance. Here we present evidence in support of the important role of EOA +FN 
in tissue repair/progressive fibrosis following liver injury. Carbon tetrachloride (CCI4) 
administration and bile duct ligation (BOL) represent two well-established models to 
induce experimental liver fibrosis in rodents (Constandinou et aI., 2005; Xia et aI., 2006). 
Both models, even though differently, represent a liver insult that leads to the stimulation 
of hepatic fibrogenic cells, key elements of the fibroproliferative process typical of liver 
fibrotic diseases (Jarnagin et al., 1994; Maher and McGuire, 1990). Such cells are indeed 
responsible for an abnormal, intensive production and deposition of extracellular matrix 
proteins such as collagens and fibronectins in tissue fibrotic foci. The importance of the 
EDA-containing FN variant in the fibrotic process is shown by the upregulation of 
EDA+FN mRNA in EDA wtlwt hepatic tissue following CCl4 treatment or BOL (George et 
aI., 2000; Jarnagin et aI., 1994) (Figure 29). We found that mice unable to produce 
EDA +FN show a reduced fibrotic response to fibrogenic insults. Therefore, expression of 
EOA +FN by non-parenchymal cells is a critical early event for the liver response to injury. 
In fact, histopathologic evidences (Figure 32, 35, 37 and 43) supported by Western blot 
analysis (Figure 31, 34 and 42) have shown a significant reduction of aSMA-expressing 
myofibroblasts in EDA/- mice compared with EOA wtlwt controls. Additionally, primary 
lung fibroblasts from EDA wtlwt, EDA +1+ and EDA/- mice were able to express comparable 
uSMA levels when plated on FN matrices bearing the EOA domain, in the presence of 
TGF-~ (Eric White's personal communication, University of Michigan Medical Center, 
Chicago, USA). Interestingly, EDA wtlwt and EDA+1+ fibroblasts were also able to express 
uSMA when plated on EDA-FN matrices, implying that either exogenous (matrix-derived) 
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or endogenous (cell-derived) EDA +PN supports myofibroblast differentiation. Instead, 
EDA-1- fibroblasts were not able to express high levels of aSMA when plated on the same 
EDA-FN matrices, again confirming that the presence ofEDA+FN, regardless of its origin, 
is important for the differentiation to myofibroblasts. However, when the same experiment 
was repeated in the absence of TGF -13, no induction of aSMA was observed, indicating 
that EDA+FN is necessary, but not sufficient for myofibroblast differentiation. We also 
observed that following a stronger liver insult such as the administration of a higher dose 
of CCl4 for a longer period (Figure 36 and 39), or a longer BDL duration (Figure 45), the 
level of aSMA in EDA"/- livers paralleled that of EDA wtlwt livers. These data support the 
idea that other factors participate in myofibroblast transformation in addition to EDA +FN. 
Since the EDA +FN variant is one of the ECM components to be earlier expressed after 
injury, we speculate that the EDA domain could be one of the first elements that trigger the 
activation of HSCs after mild liver insult, at the onset of the fibrotic process. When the 
insult is greater, however, other factors such as some cytokines, growth factors and ECM 
proteins may playa role in the activation process along with the EDA domain. 
TGF -13 has been shown to be directly involved in the differentiation of both skin (BaIza et 
aI., 1988; Borsi et aI., 1990; Serini et aI., 1998) and lung (Giri et aI., 1997) fibroblasts, and 
indirectly involved in HSC differentiation (George et aI., 2000). It stimulates the inclusion 
of the EDA exon into FN mRNA. Taken together, the data available and our results seem 
to indicate a biologically active role for the EDA domain in the in vivo conversion of HSCs 
and fibroblasts into myofibroblasts, supporting the contention that EDA +FN is necessary 
for TGF-j3-mediated a-SMA expression in vivo. However, the precise mechanism by 
which TGF-j3 stimulates the production of EDA+FN mRNA is not yet well understood. In 
general, the FN-EDA splicing depends on the recognition of a splicing enhancer element 
located within the EDA exon itself by splicing factors termed SR proteins because they 
abound in serine-arginine motifs (Buratti et aI., 2004; Caputi et aI., 1994; Muro et aI., 
1999) (Figure 4). It is thought that TGF-j3-induced alterations in the intracellular levels 
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and/or the phosphorylation state of these factors might result in an increase of splicing 
activity (Blaustein et aI., 2005; Li and Sun, 1997; Maehama and Dixon, 1998). 
The fibrotic process is mainly characterized by a strong production and deposition of 
collagen into the ECM. Previous studies have shown that both HSCs (Maher and McGuire, 
1990) and skin fibroblasts (Serini et aI., 1998) produce increased amounts of collagens 
following a fibrogenic insult. Histochemical staining of EDA wtlwt mouse lung sections 
obtained after inducing fibrosis by administering bleomycin showed an abundant 
deposition of collagen in fibrotic foci. These areas were also characterized by increased 
amounts of aSMA in comparison with untreated mice (Eric White's unpublished data, 
University of Michigan Medical Center, Chicago, USA). Interestingly, the levels of 
collagen and aSMA in bleomycin-treated EDA-/· samples were reduced in comparison 
with those from EDA wtlwt mice, and similar to the basal levels of untreated mice (Eric 
White's unpublished data, University of Michigan Medical Center, Chicago, USA). These 
results suggest that: a) the EDA domain of FN plays a critical role in the development of 
fibrosis in both lung and liver; b) the mechanisms triggering lung and liver fibrosis may be 
similar, and c) the role of the EDA domain in the differentiation and activation of hepatic 
stellate cells and skin fibroblasts (Jarnagin et aI., 1994; Serini et aI., 1998; Serini and 
Gabbiani, 1999) can be extended to lung fibroblasts. However, the differences we observed 
between lung and liver fibrosis suggest the involvement of other factors and a more 
complex fibrotic process in the liver. In fact, while the levels of uSMA and collagen in the 
lung of EDA-1- animals following bleomycin injury were similar to those of untreated mice 
(Eric White's unpublished data, University of Michigan Medical Center, Chicago, USA), 
the liver from both control and EDA-1- mice showed an increase in the levels of uSMA 
(Figure 30-31 and 41-42) and collagen (Figure 33 and 44) after fibrogenic challenge. 
Although liver levels of uSMA and collagen increased significantly in mutant mice 
following both CCl4 treatment and BDL, these increases were markedly lower than in 
EDA \\<1I\\<1 mice. This suggests that the lack of the EDA domain attenuated the development 
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of a full fibrotic response to liver injury. However, even though EDA-I- mice failed to 
develop collagen levels as high as those EOA wtlwt, the difference between EOA wtlwt and 
EOA-I- livers in the levels of collagen, measured both by hydroxyproline assay or by 
quantification of the extent of collagen-positive areas in liver sections, were not 
statistically significant (Figure 33 and 44). The reason for the disparity in collagen 
production when comparing fibrotic lung and liver models is not clear, and might reflect 
the fact that other pathways could be bypassing the requirement for EOA +FN in the liver. 
At least three different cell lineages, expressing only uSMA, only collagen or both uSMA 
and collagen, contribute to the fibrogenic response in the liver while having different 
stellate cell marker gene profiles (Magness et aI., 2004). This fact raises the question of 
discrete hepatic stellate cell populations that may have different EOA +PN requirements 
and respond to separate sets of stimuli regarding differentiation and activation. 
Besides HSCs, the main fibrogenic cell type in peri central areas of the liver, other hepatic 
cell types have been recently shown to exhibit fibrogenic potential (Figure 47). 
Perivascular fibroblasts of portal and central veins and periductural fibroblasts in close 
contact with bile ducts can be additional sources of fibrogenic myofibroblasts in the 
injured liver. Thus, a complex interplay involving different hepatic cell types may take 
place during hepatic fibrogenesis (Lotersztajn et aI., 2005). Further work is needed to 
clarify the precise contribution of each of these cell types to the liver fibrotic process and 
the role of EOA +FN in their transformation to myofibroblasts. 
Although we have presented evidence here that EOA +FN is necessary for a-SMA 
expression in myofibroblasts, a previous report demonstrated that EOA-I- mice show no 
defect in a-SMA induction in vascular smooth muscle cells or pericytes during tumor 
angiogenesis (Astrof et aI., 2004). This observation, while seemingly contradicting our 
findings, is intriguing and may be explained in alternative ways. 
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Figure 47. Heterogeneity in hepatic flbrogenic cell populations. 
Matrix accumulation during chronic liver di seases originates fro m different 
fibrogenic myofibroblasts deriving from the "activation" of di stinct cell populations 
such as the hepatic stellate cells (HSCs), and the perivascular and peribiliary 
fibroblasts (hepatic myofibroblasts) . Following acute or chronic li ver injury, they 
undergo phenotypic changes switching from a quiescent, vitamin A-rich phenotype 
to a myofibroblastic phenotype. Myofibroblasts show de novo fibrogenic propertie , 
including proliferation and accumulation in areas of parenchymal ce ll necro is, 
secretion of proinflammatory cytokines and chemokines, and synthesis of a large 
panel of matrix proteins and of inhibitors of matrix degradation, lead ing to 
progressive scar formation. Phenotypic and functional properties of hepatic 
myofibroblasts are grossly similar overall to those of activated hepatic stell ate cell s. 
However, culture studies have clearly establi shed that several phenotypic markers 
distinguish both cell types (Lotersztajn et aI. , 2005). EDA +PN could be invo lved in 
the activation of the HSCs but not in the activation of the hepatic myofi brobla t. 
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First, it is possible that aSMA expression in pericytes surrounding angiogenic vessels is 
mediated by other growth factors in the absence of the EDA domain. Notably, Ball and 
colleagues recently reported the ability of platelet-derived growth factor receptor (PDGF) 
to up regulate directly mesenchymal stem cell a-SMA expression (Ball et al., 2007). 
Moreover, PDGF has been shown to be secreted by certain neoplasms as a means to 
promote pericyte recruitment (Furuhashi et aI., 2004). Alternatively, it is possible that the 
requirement for certain factors governing a-SMA expression is cell-type dependent. For 
instance, while we do not observe a-SMA expressing myofibroblasts in bleomycin-injured 
lung areas of ED A-1- mice (Eric White's unpublished data, University of Michigan Medical 
Center, Chicago, USA), airway smooth muscle cells do express a-SMA in the same 
animals. 
Our data suggest that therapeutic strategies targeting either the production or the function 
of EDA +FN may have a role in the treatment of fibroproliferative disorders. An attempt 
towards a new potential therapy for hepatic fibrosis was made by George et al. using a 
soluble antagonist of the TGF -~ receptor extracellular domain. Treatment of bile-duct 
ligated rats in vivo and HSCs ex vivo with a soluble TGF-~ receptor inhibited both aSMA 
and collagen production and hepatic fibrosis (George et aI., 1999). These same 
investigators subsequently showed that the effect of soluble TGF -~ receptor in hepatic 
fibrosis was mediated through the inhibition of EDA +FN production both in vitro and in 
vivo (George et aI., 2000). Preventing the accumulation of activated HSCs by modulating 
their activation and/or proliferation or by promoting their apoptosis may be a viable 
approach for the treatment of fibrotic disorders, and EDA+FN is a plausible target. 
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The origin of the fibronectin (FN) found in the extracellular 
matrix of tissues has not been defined experimentally. Previous 
studies suggest that there is contribution from both local tissue 
production and transfer from plasma, but the extent of this phe-
nomenon has not been addressed. \Ve have shown before that 
engineered mice constitutively expressing extra domain A-con-
taining FN (EDA + FN) have a significant decrease of FN levels in 
lasma and most tissues. \Ve showed that hepatocytes modified ~o produce EDA + FN have normal extracellular matrix-F levels 
but secrete less soluble F . \Vhen we performed a liver-specific 
EDA-exon deletion in these animals, FN levels were restored 
both in plasma and tissues. Therefore, an important fraction of 
tissue FN, approximately an equal amount of that produced by 
the tissue itself, is actually plasma-derived, suggesting that 
lasma is an important source of tissue FN. The present results ~ave potential significance for understanding the contributions 
of plasma FN, and perhaps other plasma proteins, in the modu-
lation of cellular activities and in the formation of the extracel-
lular matrix of tissues. 
Fibronectins (F )3 are a family of multifunctional glycopro-
teins known to play key roles in fundamental processes related 
to adhesive and migratory behavior of cells, such as embryogen-
esis, malignancy, homeostasis, wound healing, and mainte-
ance ofti sue integrity (1). FN generates protein diversity as a 
~onsequence of alternative processing of a si ngle primary tran-
cript at three different sites, the extra domain A (EDA), the 
s "tra domain B (EDB), and the type Jll homologies connecting 
e egment (IlICS) (2- 4). Two major forms ofFN exist, plasma FN ~pFN) and cellular F . pFN is a oluble dimeric form that is 
secreted into the bloodstream by hepatocytes (5, 6) and found 
t 300 and 580 ilog/ m1 in plasma of humans and mice, respec-a . 
. "ely (I, 7). pFN lacks both the EDA and EDB domams, 
tJ hereas cellular F i locally produced and deposited as insol-
:ble fibrils in the extracellular matrix of tissues and contains 
-
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these domains at variable proportions (1, 8, 9). Previous studies 
suggested that circulating pFN contributes to the extracellular 
matrix of tissues (10,11) but the extent ofthe phenomenon has 
not been addressed. 
The levels of FN in plasma are critical for hemostasis, tis-
sue repair, and susceptibility to infections. Depletion of pFN 
(liver-specific knockout of FN) results in increased brain 
injury after transient focal cerebral ischemia (12), a delay in 
thrombus formation and decreased thrombus stability (13), 
decreased angiogenesis (14), and increased susceptibility to 
bacterial infections (15). Heterozygous null FN mice appear 
healthy and fertil e (7) but show delayed thrombus growth in 
injured arterioles (16). Regrettably, the levels of FN present in 
the tissues of heterozygous null FN and in the pFN null mice 
have not been reported. 
We have previously shown that knock-in mice having con-
stitutive inclusion of the EDA exon of the FN gene (EDA +1+ 
strain) had up to 70 - 80% reduction in the levels of plasma and 
tissue FN (17). Taking advantage of the "floxed" EDA exon 
present in those mice, we generated liver-speci fic EDA-null 
mice (EDA +I+CRE) after crossing EDA +1+ animals with a 
transgenic strain expressing the CRE recombinase only in hepa-
tocytes (18). Consequently, hepatocytes of EDA +I+CRE mice, 
without the EDA exon, were able to produce and secrete pFN at 
normal levels. 
We show here that the levels of pFN were restored in those 
mice and also that the levels of tissue FN were similar to those 
observed in EDA WT /WT animals. These results showed a major 
flow of pFN into the extracellular matrix of tissues and suggest 
the importance of the pFN as an essential source of FN for the 
tissues. The presented results might have potential significance 
for understanding the contributions of pFN, and perhaps other 
plasma proteins, to cellular activities and in the formation of the 
extracellular matrix of tissues. 
EXPERIMENTAL PROCEDURES 
Mice-The generation and genetic background of the mice 
devoid of regulated spliCing at the EDA exon have been pre-
viously described (17). EDA +1+ mice were mated with the 
transgenic strain Tg Alf pCRE mice, which have CRE recom-
binase under the control of the albumin promoter and 
enhancer (18). EDA +/WT mice having the CRE recombinase 
were mated in order to obtain EDA +1+ mice with the CRE 
transgene (EDA +I+CRE). This strain expresses the CRE recom-
binase exclusively in hepatocytes (18). The genotype of mice 
was determined by peR from tail biopsies. 
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Bile was collected by holding the 
gallbladder with forceps. Two /J-I of 
each sample were mixed with pro-
tein loading buffer (0.125 Tris-HCl, 
pH 6.8, 4% SDS, 20% glycerol, and 
0.002% bromphenol blue) and 
boiled for 5 min. Bile FN was ana-
lyzed by Western blot as described 
above. 
• -- ~ +EDA 
. - • • .. .. CD -EDA 
B 18.S pc 1 day 6 days 14 days 2.S months 30 months 
--./'\~~x./'\~~X v:!l:!!...t +/+ wt/wt +/+ -i-'<. x , 
-i-'<.\x\ ,\ wt/wt ..:!:.L:!:.... 
...::..!.:.... 
In Vivo Labeling of Hepatocytes-
Hepatocytes were purified by the 
two-step collagenase perfusion meth-
od (21), using Liver Digest Medium 
(Invitrogen) as described by the 
manufacturers. Hepatocytes were 
plated in rat tail collagen for 1 h, 
washed, and then incubated for 
24 h with Met-Cys-free medium 
supplemented with 300 /J-Ci/ml of 
[35S]Met/Cys (ProMix; Amersham 
Biosciences) . The supernatant was 
collected, and a fraction was affin -
ity-purified with gelatin-Sepha-
rose as described (22, 23). 
c Z 12 ... 
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FIGURE 1. EDA H+ embryos have a decrease in the levels of pFN. A, radioactive RT-PCR analysis of the EDA 
eXon of total RNA extracted fro~ liver, brain, heart,lung, and testis from EDAWTlWT, EDA ~/+ , and EDA -/- mice. The posit ion of the EDA-contaimng (+EDA) and the EDA-Iacklng (-fDA) bands are indICated. B, Western blot 
nalvsis of pFN from IS.S-pc embryos, 1-, 6-, and 14-day-old babies, 2.S- and 30-month-old adult mice from 
~DA WTrwr, EDA ~I+, and EDA -/- animals. The samples corresponding to 18.S-pc and l -day-old time points are 
Southern Blot Analysis of Tis-
sues-DNA was extracted from tis-
sues, and 15 /J-g were digested with 
HindlII. The DNA was then run in 
an agarose gel and blotted onto 
Z-Probe membrane. A probe corre-
ools of 4-6 animals/genotype. Note that the EDA+FN migrates at a different size from the EDA- FN by 
~DS-PAGE. C, the intensity of the ~nals in panel B was quantified with the help of the Quantity One software. 
The signal obtained inthe EDAWT samples was conSidered 100%. Data are presented as the mean :!: S.D. of 
three independent animals/genotype. 
sponding to the exon downstream 
to the EDA exon was used as described (17). RNA Preparation and Reverse Transcription (RT)-PCR 
Analysis-Total RNA was prepared from freshly extracted tis-
sues and cells as described (19). The radioactive RT -PCR reac-
tions were performed and quantified as previously described 
(20). 
Protein Extracts and Western BlotAnalysis-Mice were anes-
thetized with 2.5% Avertin (300 /J-1 /20 g mouse). and organs 
were perfu ed with 25 ml of cold phosphate-buffered saline 
through the left ventricle of the heart. Organs were immediately 
dissected and nap-frozen in liquid nitrogen. Organs were 
homogenized. and protein content was determined by Bradford 
protein assay (Bio-Rad) . Identical amounts of protein sample 
were run on a 6% SDS-PAGE and analyzed by Western blot 
with polyclonal rabbit anti-FN antibody (50 /J-g of protein 
extract. 1:1500; Sigma), anti-EDA 3E2 monoclonal antibody 
(100 Il-g of protein extract. 1:300; Sigma). or anti {3-tubulin 
monoclonal antibody (20 /-lg of protein extract. E7, 1:3000; 
Developmental Studies Hybridoma Bank. University of Iowa) 
as described (17). Three animal per genotype were analyzed. 
To determine the efficiency of perfusion and elimination of 
lasma protein in each of the organs analyzed, a Western blot ~nalysis of 50 /J-g of protein extract was performed using an 
anti-mou e JgG antibody (1:2000; DAKO). Serial ECL exposi-
tions of the membrane were performed to determine the opti-
mum linear range to quantify the signals. Film were scanned 
with the Versadoc (Bio-Rad) and quantified with the help of the 
Quantity One oftware package (Bio-Rad). 
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Immunohistochemistry of Tissue Sections-Organs were 
fIxed in 4% formaldehyde and paraffin-embedded. 4-/J-m sec-
tions of each tissue were cut and incubated with affi nity-puri-
fIed polyclonal rabbit anti-FN antibody (1:200; Sigma). Then 
sections were incubated with biotinylated goat anti -rabbit IgG 
(5 /J-g/ml; VectaStain) followed by avidin-biotin-peroxidase mix 
(ABC Reagent; Vector Laboratories), 3,3' -diami nobenzidine 
peroxidase substrate (Vector Laboratories), and Gill's hema-
toxylin (Vector Laboratories). An AS LMD Leica microscope 
was used to visualize and photograph the sections. 
RESULTS 
Hepatocytes of EDA +1+ Mice Have Normal Levels of Extra-
cellular Matrix-FN but Do Not Secrete pFN- We have previ-
ously observed that mice having constitutive inclusion of the 
EDA exon of the FN gene (Fig. lA) had a significant decrease of 
FN in plasma and in most tissues (17. 20). Further characteriza-
tion of pFN levels (embryo. young. and adult mice) from 
EDA +/+ mice showed very low amounts compared with 
EDA WT/ WT and EDA -/- mice (Fig. 1. B and C). Embryos had 
60% of the pFN levels in the control sample. whereas young and 
adult EDA +1+ mice showed a higher decrease in pFN level . 
The decrease in pFN was due neither to lower levels in mRNA 
in tissues of EDA +/+ mice (17) nor to a reduced FN production 
by EDA +1+ tissues. as FN secreted by EDA +1+ embryonic 
fIbroblasts or adult heart fibroblasts was similar to that pro-
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FIGURE 2. Hepatocytes of EDA+/+ mice do not secrete soluble EDA+ 
b onectin A hepatocytes from EDA WTIWT, EDA +/+, and EDA -/- animals 
fi re ·Isolated 'plated and metabolically labeled with [3SSIMeVCys for 24 h. 
wer ' ' .. . . 50S d d tical aliquots of the conditioned medium were run In a 6% ~PAGE an 
I ~~radiographed . B, equal quantities of the samples prepared In panel A 
aU e affinity-purified w ith a gelatin-agarose resin, eluted, separated in an ~~~PAGE and autoradiographed. C, total cell extracts prepared from equal 
mber of hepatocytes from EDAWTIWT, EDA +/+, and EDA -/- mice cultured 
~u non-radioactive medium were collected after 24 h and analyzed by West-
I ~n blot w ith a polyclonal anti-FN antibody. D~ tota! cell ~xtracts from t~e 
e atocytes used in panel A were collected, and Identical allquots were run In ~e~% 50S-PAGE and autoradiographed. Molecular weight markers are 
indicated. 
A B H - 1 H EDA 
eRE Recombln..Je 
duced by the EDA WT /WT fib roblasts, excluding a general defect 
(17). 
T he specific degradation of FN in the EDA +1+ mice by pro-
teases was ruled out by a se ries of experiments: 1) Metallopro-
tei nase activity levels in plasma and tissues by gelatin zymogra-
phy analysis were similar among EDA WT/WT, EDA +/ ~ , and 
EDA -1- mice (supplemental Fig. Sl, A and B ); 2) [35SjMet_ 
labeled fragments of FN contai ning or not containing the EDA 
exon were not differentially degraded when incubated wi th 
EDA WT/WT or EDA +1+ tissue extracts or plasma in the absence 
of protease inhibitors (supplemental Fig. S1 , C and D); 3) no 
increase in FN degradati on rate was observed after mixi ng pro-
tein extrac ts from EDA +1+ or EDA WT/WT liver with those orig-
inating from diffe rent organs or plasma from EDA +1+ mice in 
the absence of protease inhibi tor (data not shown); 4) Western 
blot analysis of tissue extracts done with di fferent sets of 
anti -FN polyclonal antibodies, run on 5- 17% gradient gel, did 
not show any specific degradation products in EDA +1+ mice 
(data not shown). 
Because the hepatocytes are the source of pFN (5, 6), we 
perfo rmed metabolic labeling of hepatocyte primary cultures 
fro m EDA WTIWT, EDA +1+ , and EDA -I- live rs followed by FN 
affi nity purification of the conditioned medium to analyze pFN 
production. We observed a decreased secretion of pFN by the 
EDA +1+ hepatocytes, suggesting that the reduced levels in pFN 
in the EDA +1+ mice we re the consequence of a defect in hepa-
tocytes (Fig. 2, A and B). However, the FN amounts detected by 
Western blot in hepatocyte cell extracts were simi lar (Fig. 2C). 
Additio nally, the decrease of pFN in EDA +1+ embryos (Fig. IB) 
but not in embryo niC ti sues (17) confirmed that the defi ciency 
+ 1 H 
I 
-. 
2.7 kb 
in FN secretion was limited only to 
EDA +1+ hepatocytes. T hese resul ts 
showed that EDA +1+ hepatocytes 
were unable to sec rete pFN in nor-
mal amounts. We hypoth esized that 
the reduced levels of tissue FN could 
be due to the decreased supplyof FN 
from plasma to tissues. 
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GURE 3. Liver-specific delet ion of t he EDA exon. A, scheme of the Alf P-Cre t ransgene. The CRE recombi-
FI e (dotted box) is expressed under the control of the mouse albumin enhancer and promoter (dashed box) 
na~ the mouse a -fetoprotein enhancer (gray box). Correct polyadenylation was directed by the hGH fragment 
an box). B, partial map of the EDA + and EDA - FN alleles. The EDA exon is indicated as a dashed box and the (e~~~tes as black triangles. Hindll l sites (H), the probe used in panel C (black line below + 1 exon). the flanking 
10)( ns ( - 1 and + 1), and the expected size of Hindill-digested fragments are as indicated. C, EDA +/+ mice were 
e)(o sed w ith a transgenic strain expressing the CRE recombinase in hepatocytes. Southern blot analysis of the 
C~ffS rent t issues from EDA +/.CRE mice was performed, and specific recombination was observed only in the ~I e EDA + and EDA - bands are indicated. Liver DNA samples from three mice are shown. Tissues are as 
~Iv~.~ated : K kidney; H, heart; L, lung; T, testis; M, skeletal muscle; I. intesti ne; To, tail; B. brain; M. molecular 
In .1 ht markers. D, RT-PCR analysis showing the inclusion/ exclusion of the EDA exon in total RN A prepared 
welg liver and purified hepatocytes from the different genotypes. The position of the EDA + and EDA - bands is 
fronn 
indicated. 
Generation of Liver-specific EDA 
N ull Mice-To determine th e ex-
tent of FN fl ow into ti ssues we 
restored the capacity o f hepato-
cytes to produce pFN not co nta in -
ing the EDA exon by cross-breed-
ing EDA +1+ mice with a transgenic 
strain express ing th e eRE recom-
binase only in hepatocytes (18). 
T he aim was to perform a tissue-
specific deletio n of the EDA exo n 
wi th out modifying the EDA + 
allele in o ther cell types and ti sues 
(Fig. 3, A and B). Southern blo t 
analy is of differe nt ti ssues from 
th e EDA +1+ mice ca rryi ng the 
liver-specific e RE recombinase 
(EDA + I+ CRE mice) howed e RE-
mediated reco mbinat io n o nly in 
the live r (Fig. 3C). T he percentage 
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A wt/wt +/ + +/ +CRE wt/wt +/+ + /+CRE of reco mbinati on in liver was 
- 60 -70%. Because hepatocytes 
constitute 60% of the to tal number 
of cells present in the liver (24), one 
can consider that the percentage of 
recombination in hepatocytes was 
close to 100%. RT -PCR analysis 
confi rmed the absence of the EDA 
--
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FN exon in the FN m RNA both in liver 
II-tub 
and purified hepatocytes fro m 
EDA +1+ RE mice (Fig. 3D ). 
FN Levels Are Restored in 
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o Plasma l iver Brain Testis Heart lung 
o 
o 
• 
wt/wt 
+/+ 
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EDA +/+CIIE Mice-Tissues and 
plasma from EDA +1+ mice express-
ing the hepatocyte-specific CRE re-
combinase were analyzed by Western 
blot with polyclonal anti -FN and 
anti-EDA-specific antibodies. As ex-
pected, pFN levels were completely 
restored in the EDA +1+ RE mice 
(Fig. 4A ). Tissue ext rac ts prepared 
from EDA +1+ RE mice contained 
amounts of FN similar to that found 
in EDA WT/WT mice (Fig. 4A). T he 
GURE 4 Plasma and tissues from EDA +/+CRE mice have norma l FN levels. A. plasma and protei n 
FI t acts ":"ere prepared from EDA WTIWT, EDA +1+, and EDA +HCRE mice (3 month-old), an d tota l FN levels 
eX r detected by Western blot analysis. The protein load was controlled by detecting f3-tubuli n in the wer~ ext racts. B the intensity of the signals in panel A was quantified with the help of the Quantity One 
sat;ware. The ra;io between FN and f3-tubulin ~nals was used fo r normalization, and result s are shown in 
~~e ba r graph. The ratio obtained in the EDA WT sam ples was conSidered 100%. Th e mea n :!: S.D. of th ree 
independent experiments IS shown. 
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IGURE 5. A plasma from EDA +/HRE mice has no EDA-containing FN. Plasma 
F d liver pr'otein extracts prepared from EDAWTIWT, EDA+'''', and EDA+'+CRE 
a~ce were analyzed for the presence of the EDA domain with the 3E2 ant i-r~A monoclonal antibody. B, similar levels of EDA+FN were seen in tissues 
m all three genotypes. The same protein extracts from testis used in Fig. 4 
frO re analyzed by Western blot with the 3E2 anti-EDA monoclona l antibody. ~~he ratio between EDA +FN and f3-tubulin signals was used fo r normaliza-
.' n and resu lts are shown in the bar graph. The ratio obtained in the 
~gAWT/WT samples was consi?ered 100%. Data are presented as the mean :!: 
O of three independent animals/genotype. S .. 
2 8060 JOURNAL OF BIOLOGICAL CHEMISTRY 
cellular matrix 
derived from plasma was - 60% in testi s and - 40% in o ther 
tissues such as brain, heart, and lung (Fig. 4B) . T hese results 
clearly indicate that an important proportion of the FN present 
in the extracellular matrix of adult tissues derives from plas ma. 
Consequently, the amount of FN that is synthesized and depos-
ited locally in tissues is much lower than believed. 
We then used th e monoclonal antibody 3E2 to spec ifically 
detect th e EDA-containing FN isoform. As ex pec ted, no 
EDA +FN was present in the plas ma of EDA WT / WT mice. 
Additi onally, we did not detec t EDA FN in the plasma of 
EDA +I+CRE mice, indi ca tin g a hi gh effi ciency of CRE-medi -
a ted recombinati on in hepatocytes. The EDA + FN isofo rm in 
live r was clea rly visible only in the EDA +1+ samples (Fig. SA , 
la nes 4-9) , confirming again the Southern blo t and RT -PC R 
data (Fig. 3, C and D) . T he absence of EDA + FN in the plasma 
of EDA +I+ CRE mice also suggests that th e FN fl ow is mainly 
from plas ma to tiss ues and not vice ve rsa (Fig. SA , lanes 1- 3 ). 
No diffe rences were observed in the levels of EDA +FN in 
testi s (F ig. 5, B and C) and in o th er ti ssues (da ta no t shown ) 
between the EDA WT/WT and EDA +1+ RE samples, sugges t-
ing that th e obse rved differences in ti ssue FN among th'e 
d ifferent ge notypes corresponded to EDA - FN incorporated 
fro m plas ma into th e extrace llular ma trix of ti ssues. 
To ensure that the detected levels of FN in tissues were not 
due to non-complete perfusion of the organs, we performed 
Western blot analysis of the plasma globuli ns that remained in 
each tissue after perfusion and normalized th e protein load 
with the l3-tubulin Signal. Supplemental Fig. 2 shows that the 
remai ning globulin levels after tissue perfusion were - ] 0% of 
the levels seen in the non-perfused orga ns. Because most 
plas ma pro teins were washed out from the perfused organs, the 
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Liver 
EDAwtlwt 
EDA+I+ 
EDA+I+CRE 
Brain Testis modulation of cellular activities in 
tissues. The concept that there is FN 
flow from plasma into tissues or 
extracellular matrix of cells has been 
known for a long time. Addition or 
injection of soluble FN into the cul-
ture medium of cells or into the 
plas ma of mice. res pec tively. 
resulted in the inco rporation of 
FN into the extracellular matrix 
(10. 11. 28 -30). However. th e 
magnitude of the contribution of 
pFN to the extracellular matrix 
was not possible to address with 
either model. In the present report 
we have shown that in some tis-
sues up to 60% of the fibron ec tin 
present in the extracellular matrix 
could be plasma-derived. 
FIGURE 6. Immunohistochemical analysis of liver. brai n. a nd test is. Tissue sections of liver (A-C). brain (D-F), 
and testis (G-I) from EDAWTIWf (A, D, and G), E~A +1+ (8, E, and HJ, and EDA.+I+CRE mice (e. F, and f) were stained 
with an affinity-purified fe0lyclonal antl-FN antibody. The black arrows Ind icate FN In the extracellular matrix of 
EDA WTIWT and EDA +I+C E from different tissues a~d EDA ::: liver. White a,,?ws indicate the decrease in levels 
f FN from the same areas of brain and testis only In EDA mice. 5, slnusolds, 8M, basement membrane, and 
Sakai et al. (12) have recently 
shown that pFN supports neuronal 
survival and reduces brain injury 
following transient focal cerebral 
ischemia. suggesting the incorpora-
tion of pFN into the injured brain . 
Our results confirmed and extended 
~, interstitial reg ion, are indicated by black triangles. The black bars correspond to SO ,...m. 
differences of FN levels among the different strains were not 
due to residual contamination of pFN. 
Immunostaining afTissue Sections Confirmed the Decrease of 
FN Levels in EDA +/+ Tissues and the Recovery in Tissues of 
£DA +/+ CRE Mice-The above results were confirmed by 
immunohistochemical analysis of tissue sections. Similar levels 
of FN-specific signal were detected in the sinusoids of liver 
samples prepared from all three genotypes (Fig. 6. A-C. black 
arrows). In the brain sections of EDA WTf WT and EDA +I+ CRE 
mice a stronger FN-specific signal. probably associated with the 
cell surface of glial cells (25-27). was observed when compared 
with the EDA +1+ mice (Fig. 6E. white arrows). Similarly. in 
testis tissue sections. a stronger FN-specific signal was observed 
. n the basement membrane of seminiferous tubules and inter-
I . fED WT/ 'I.¥IT d EDA+1+cRE . d stitial regiOns 0 A an mice compare 
with EDA +1+ samples (Fig. 6H. white arrows), However. we did 
not observe intracellular accumulation of FN in the tissue sec-
tiOns of EDA +1+ mice by immunohistochemical analysis (Fig. 
6. B. E. and H) or in primary culture of hepatocytes either by FN 
immunofluore cence (supplemental Fig. 3) or by metabolic 
labeling (Fig. 2D). 
Gross histology of tissue samples from all three genotypes 
was similar. suggesting that the FN synthesized locally is suffi-
cient to maintain the normal tissue architecture. T hese results 
indicate that there was a flow of FN from plasma to the extra-
cellular matrix of tissues and plasma is an important source of 
tissue FN. 
DISCUSSION 
Our data demonstrate an important and novel role for 
plasma proteins. in particular that of fibronecti n. in the forma-
tio n of the extracellular matrix of tissues and. probably. in the 
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their observations to non-injured tissues as we showed pFN 
incorporation into most normal organs. including brain. In fac t. 
we are also demonstrating that this is a general mechanism that 
occurs in most normal tissues. and we suggest that other plasma 
proteins could also become incorporated into the extracellular 
matrix of tissues. modulating cellular activities. 
Because FN is found both in blood and bile fluids. secretion of 
FN by hepatocytes seems not to be polarized as proposed for 
endothelial cells (31). Furthermore. we also observed a dec rease 
in FN levels in the bile fluid of EDA + 1+ mice (data not shown). 
suggesting the absence of an EDA-dependent polarization of 
FN secretion in hepatocytes. as postulated for ai rway epithelial 
cells (32). T he low levels of soluble FN in the plasma of EDA I" 
mice and intermediate levels in EDA +/WT and EDA +1 - mice 
(data not shown) point toward the existence of a mechanism. 
analogous to that observed for the secretion of the IlleS vari-
ants (33). that detects the EDA domain during the secretory 
pathway of pFN from hepatocytes and prevents the release of 
EDA +FN into the bloodstream. The "defective" EDA + /EDA + 
pFN dimers might be formed but their transit through the pFN 
secretory pathway might be slower compared with EDA - / 
EDA - dimers. However. immunostaining of tissue sections. 
immunofluorescence of primary culture of hepatocytes. or 
metabolic labeling ofhepatocytes did not reveal any intracellu-
lar accumulation of FN in the liver of EDA 1+ mice. suggesting 
that the putative "misfolded" dimers are qui ckly deg raded. 
We observed th at the amount of pFN supplied to th e ex tra-
cellular matrix of tissues varied among the different organs 
analyzed. sugges ting that th ere might be equilibrium 
between the amount of FN locall y produced by the tissues 
and the avai lability of cellular receptors to inco rporate FN 
from the plasma pool. 
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To conclude. the presented results might have potential ig-
nificance for understanding the contributions of pFN. and per-
haps other plasma proteins. to cellular activities and in the for-
mation of the extracellular matrix of tissues. as we have shown 
that a major fraction of tissue FN i pia ma-derived. Because 
plasma provides approximately an equal amount of FN as the 
tissue itself. we suggest that plasma should be considered an 
important source of F for ti sues. Furthermore. hepatocytes 
have normal levels of F in the extracellular matrix but do not 
secrete soluble EDA +F • suggesting the existence of separate 
secretory pathways for soluble and fibrillar F . 
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SUPPLEMENTAL DATA 
Supplementary Material and Methods 
In vitro translation: cDNAs with or without the EOA exon were prepared from EDA +1+ and 
EOA/- mice by RT-PCR using the following primers: Forward 5' 
CGGGGT ACCACCATGGGCACCATCACCCTGT ATGCTGTCACT 3' and Reverse 5' 
CGCGGA TCCTI A TCAGAGTCCTGACACAA TCACCGA 3' which produce a fragment of 803 
bp and 533 bp, respectively. The PCR amplified products (EOA + and EOA) were cloned in pBS-
SKU vector. The in vitro translation was done by a single tube protein system (Novagen), based 
on a linked reaction in which transcription by a bacteriophage RNA polymerase is directly 
followed by translation with rabbit reticulocytes lysate. The translation products were analyzed 
by 10% SOS-PAGE followed by ON autoradiography. Fixed amount of the in vitro translated 
products were incubated in the absence of protease inhibitors with protein extracts (prepared in 
the absence of protease inhibitors) from tissues for 3h and 24h. 
Gelatin Zymography: A total of20 ~g of tissue protein extract or 0.2 ~I of plasma were diluted 
in 2X sample buffer (I: I) without adding any reducing agent. The samples were run on a 10% 
polyacrylamide gel polymerized in the presence of 0.2% gelatin. After electrophoresis, the gel 
was washed once for 15 minutes and then overnight in 100 ml wash buffer (2.5% Triton-XIOO, 
50 mM Tris-HCl, pH 7.5 and 5 mM CaCh) to remove the sodium dodecyl sulfate (SOS). The gel 
was rinsed three times in water, followed by a 24 h incubation at 37°C in incubation buffer (50 
mM Tris-HCI, pH 7.5 and 5 mM CaCh) and was stained for 4 hours in Coomassie Brilliant Blue. 
The absence of coloration indicates the digestion of gelatin by metalloproteinases. In a parallel 
gel, the same extracts were run and stained with Coomasie Blue. 
Immunofluorescence of primary cultures of hepatocytes: Hepatocytes were prepared as 
described in the Materials and Methods Section, plated onto rat-tail collagen coated cover slips 
and cultured for the indicated times. Cells were fixed and incubated with an affinity purified anti-
FN rabbit antibody, then with a FITC labeled secondary antibody. Nuclei were stained with 
Hoetscht. Original magnification was 200x. 
Legends to the Supplementary Figures. 
Supplementary Figure 1. A and B. MMPs activity was similar in tissues from all genotypes. 
Gelatin zymography analysis of plasma samples of EOA wt/w" EOA +1+ and EOA/- mice. The same 
amount of plasma was loaded in a gelatin-SOS gel, and the activity of metalloproteinases was 
determined. The same samples were loaded in a normal SOS-PAGE and stained with Coomassie 
Blue (Panel B) to normalize protein load. C and D. EDA + FN was not preferentially degraded. 
FN fragments containing or not containing the EOA exon were in vitro translated in the presence 
of 35S-Met/Cys and incubated for different time with tissue extracts in the absence of protein 
inhibitors. 
Supplementary Figure 2. Perfusion of tissues showed almost no residual plasma proteins. 
Equal amounts of proteins samples (50 ~g) were loaded, run on a 12% SOS-PAGE and analyzed 
by Western blot for the presence of plasma gamma globulins. The protein load was controlled by 
detecting fl-tubulin in the same extracts. Lanes 1-7 correspond to serial dilutions of EOA wtlWI 
plasma (each lane is 1:2 of the previous one, starting from 0.05 ~l to 0.00078 ~l). Lanes 8,12 and 
15 correspond to non-perfused samples. Lanes 9-11, 13-14 and 16-18 correspond to perfused 
samples. The protein load was quantified by the detection of fl-tubulin in the stripped membrane 
(lower panels). 
9-05-2007 Page 10 of 10 
Supplementary Figure 3. No intracellular FN accumulation is seen in EDA+I+ hepatocytes. 
Hepatocytes were purified from EDA wtiwt and EDA +/+ mice and plated onto rat tail collagen 
coated glass-slips for 24 or 48 h. Cells were fixed and stained with an affinity purified anti-FN 
polyclona\ antibody. Nuclei of the same fields are shown (Hoetscht staining). 
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SUPPLEMENTARY FIGURE 1 
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